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ABSTRACT 
Cerebral cavernous malformations (CCMs) are capillary-venous malformations 
located in the central nervous system that often lead to neurological deficits and cerebral 
hemorrhage. Pharmacological treatment limiting disease progression is dearly needed, as 
available therapy is limited to surgical lesion eradication or stereotactic radiosurgery. CCM 
affects up to 0.5% of the human population and can occur either in a sporadic or familial 
form. Loss-of-function mutations in any of three genes CCM1, CCM2 and CCM3 have 
been associated to familial CCM. Postnatal endothelial-specific deletion of any of the three 
Ccm genes in mice results in the development of multiple brain vascular malformations 
that faithfully resemble human CCM lesions. Here we describe that CCM malformations 
are formed by endothelial cells (ECs) undergoing endothelial-to-mesenchymal transition 
(EndMT), a phenotype that recapitulates most of the previously observed functional 
changes that are responsible for dysplasia and fragility of CCM lesions. Ccm1 deletion 
leads to activation of the MEKK3-MEK5-ERK5-MEF2 signaling cascade resulting in a 
marked upregulation of the transcription factor Krüppel-like factor 4 (KLF4) in ECs in 
vivo. KLF4 promotes an endogenous production of bone morphogenetic protein 6 (BMP6) 
in ECs that, in turn, activates the transforming growth factor-β (TGF-β) and bone 
morphogenetic protein (BMP) signalling pathway. KLF4 transcriptional activity and 
KLF4-dependent TGF-β/BMP pathway activation are responsible for the EndMT switch 
observed in the absence of Ccm1. Interestingly, using both a pharmacological treatment to 
inhibit TGF-β/BMP pathway or a genetic approach based on endothelial-specific Ccm1 
and Klf4 double knockout mice, we strongly reduce the development and progression of 
CCM lesions. Importantly loss of Klf4 almost abolishes mouse mortality due to brain 
hemorrhage in endothelial Ccm1-ablated mice. These data indicate that KLF4, TGF-
β/BMP pathway and EndMT are crucial events for CCM pathogenesis and unveil KLF4 as 
a key therapeutic target for CCM. 
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INTRODUCTION 
1. VASCULAR ENDOTHELIUM 
1.1 Endothelial cell-to-cell junctions 
Endothelial cells (ECs) line the internal surface of blood vessels and form a 
semipermeable barrier that separates blood from the tissues. The passage of fluids, 
molecules and cells across endothelial barrier can occur either through a transcellular 1 or a 
paracellular route 2. In order to regulate paracellular permeability ECs are equipped with 
highly organized intercellular structures called junctions 2. EC junctions are assembled 
during the first stages of development and are composed by transmembrane proteins bound 
to intracellular molecules that, in turn, mediate the anchorage to actin cytoskeleton thus 
stabilizing the entire structure 3. Besides to have adhesive properties necessary to maintain 
the integrity of the endothelium, EC junctions can act as signalling units able to 
communicate cell position, restrain cell migration, inhibit cell growth and apoptosis, 
control permeability and maintain apical-basal polarity to finely promote vascular 
homeostasis. ECs possess two main types of cell-to-cell junctions: adherens junctions 
(AJs) and tight junctions (TJs) 4. AJs and TJs are both intermingled and interconnected 
along the EC cleft forming a complex system with variations in depth and thickness along 
the submembrane plaque. To note, AJs can influence and control TJ organization both in 
epithelial cells 5 and ECs 6. 
AJs and TJs are also differentially expressed along the several portions of the 
vasculature tree depending on the specific functions required. AJ are usually present in all 
type of vessels while TJ expression and organization is finely modulated. The brain 
microvasculature is enriched in TJs since a strict control of permeability is required 7,8; on 
the contrary, TJs are poorly organized in post-capillary venules, where a dynamic 
trafficking between blood and tissue takes place 9. 
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1.2 Adherens junctions composition and signaling 
Endothelial AJs are composed by members of the classical cadherin family, a 
family of calcium-dependent cell adhesion transmembrane molecules (Figure 1). Vascular 
endothelial (VE)-cadherin (also called Cdh5), the main component of EC AJ 10, is an 
endothelial-specific molecule 10 expressed during development as soon as the cell is 
committed to the endothelial lineage. It is characterized by five extracellular domains 
located at the amino (N)-terminus, a transmembrane region and a cytoplasmic tail at the 
carboxyl (C)-terminus. Through extracellular domains, VE-cadherin promotes Ca2+-
dependent homophilic EC adhesion by creating a pericellular zipper-like structure along 
the cell border through lateral interaction in cis and in trans. ECs also express neuronal 
(N)-cadherin (also called Cdh2), another member of the classical cadherin family. Despite 
VE- and N-cadherin show similar structure and bind the same intracellular partners, they 
seem to play different roles in ECs. In physiological condition N-cadherin, whose 
expression is not EC-specific, is excluded from cell-to-cell contacts and localizes at the 
cell membrane to promote the anchorage of ECs to the neighbouring cells (e.g. perycites 
[PCs], smooth muscle cells [SMCs] and nerve cells). However, in the absence of VE-
cadherin, N-cadherin expression is increased and it localizes at cell-to-cell contacts 11,12 to 
mediate anti-proliferative and anti-apoptotic response to compensate for the lack of VE-
cadherin. Consistently both VE- and N-cadherin knock-out (KO) mice are embryonic 
lethal due to severe defect in vascular remodeling 13,14, thus suggesting a partial 
overlapping role of the two cadherins in the endothelium. 
VE-cadherin cytoplasmic tail binds many intracellular partners to promote vascular 
stability and control of permeability 15,16, such as the three proteins of the Armadillo family 
named plakoglobin, β-catenin and p120 are connected to the intracellular domain of VE-
cadherin (Figure 1). Plakoglobin and β-catenin can interact with α-catenin and VE-
cadherin at the same time, forming a ternary complex 17. α-catenin, in turn, can bind actin 
only when it is not hired by β-catenin, thus indicating that the cadherin-catenin complex 
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indirectly influences the actin cytoskeleton. Moreover, plakoglobin, β-catenin and p120 are 
also able to shuttle from the cell membrane to the nucleus and activate specific 
transcriptional programs. Since the transcriptional activity of β-catenin, a crucial mediator 
of Int/Wingless (WNT) canonical pathway, usually induces cell proliferation and 
differentiation, its recruitment at cell-to-cell contacts in complex with VE-cadherin and the 
consequent inhibition of its transcriptional activity generally promotes vascular quiescence. 
VE-cadherin can recruit other cytoplasmic molecules to regulate the local organization of 
the actin cytoskeleton. Among others, T-Cell lymphoma invasion and metastasis (Tiam) 18, 
a guanine nucleotide exchange factor that activates Ras-related C3 botulinum toxin 
substrate 1 (Rac1), is localized to the cell membrane through the Ras-related protein-1 
small GTPase (Rap1) to induce the organization of peripheral actin bundles. Rap1 binds to 
VE-cadherin and  it stabilizes the junctions by promoting the association of the Rapidly 
accelerated fibrosarcoma (Raf)1/Rho-associated protein kinase (ROCK) complex to VE-
cadherin to regulate the phosphorylation of Myosin light chain 2 (MLC2) and  the 
actomyosin contractility at junctions 19. 
AJ can also signal intracellularly. VE-cadherin clustering is able to directly control 
both TJ organization and stability by inhibiting the Forkhead-box protein-O1 (FoxO1) 
transcriptional activity. FoxO1 acts as repressor of the main TJ component claudin5 and, 
therefore, its inhibition via phosphorylation induced by VE-cadherin-phosphatidylinositol-
3-OH-kinase-(PI3K)-AKT axis induces claudin5 upregulation and leads to organized TJs. 
On the contrary, nuclear β-catenin is able to stabilize FoxO1 on the claudin5 promoter, 
thus sustaining its repressor activity 6. Thus, VE-cadherin-dependent β-catenin engagement 
at junctions further limits FoxO1 activity and promotes vascular stability. 
VE-cadherin can also directly modulate growth factor receptor-dependent signaling. 
The association of VE-cadherin with the vascular endothelial growth factor (VEGF) 
receptor type 2 (VEGFR2) limits its internalization and activity in the presence of the 
angiogenic growth factor VEGF-A 20. Conversely, VE-cadherin binding to either TGF-β 
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receptor complex 21, platelet derived growth factor receptor (PDGFR) 22 or fibroblast 
growth factor receptor-1 (FGFR-1) 12, controls endothelial proliferative signals to promote 
vascular quiescence.  
 
 
 
Figure 1 - Schematic representation of endothelial AJs.  
Endothelial AJs are formed by some members of the classical cadherin family such as VE-cadherin and N-
cadherin. VE- cadherin is important for the interaction between neighbouring ECs while N-cadherin mediates 
the contact between ECs and pericytes. The cytoplasmic interactore p120, α-catenin, β-catenin and 
plakoglobin promote the junction stability by inducing the anchorage of the junctions to the actin 
cytoskeleton and  they mediate the intracellular signalling. Membrane- associated phosphatases like VE-PTP, 
DEP-1 (or CD148) and RPTPµ regulate VE-cadherin turnover at junction (Adapted from Nyqvist et al., 2008) 
 
 
The phosphorylation status of VE-cadherin controls vascular permeability. 
Tyrosine phosphorylation in the VE-cadherin cytoplasmic tail (Y658 and Y685) results in 
weaker junctions and impaired barrier function 23,24,25. Permeability agents such as 
histamine 23, tumor necrosis factor-α (TNF-α) 26, platelet-activating factor (PAF) 27 and 
VEGF 24 induce tyrosine phosphorylation of VE-cadherin, β-catenin and p120 by 
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activating the Rous sarcoma proto-oncogene tyrosine-protein kinase (Src) 16 directly 
associated with VE-cadherin/catenin complex. Thus, either Src gene deletion or the use of 
Src inhibitors blocks VEGF-induced VE-cadherin phosphorylation 28. The phosphorylation 
status of VE-cadherin may also be modulated by AJ-associated phosphatases, such as the 
vascular endothelium specific protein tyrosine phosphatase (VE-PTP) 29, density-enhanced 
phosphatase-1 (DEP-1) 12,30, protein tyrosine phosphatase receptor type M (PTP-µ) 31 and 
src-homology 2 (SH2)-containing phosphotyrosine phosphatase (SHP2) 32 that bind to VE-
cadherin directly on indirectly to decrease its phosphorylation status and increase the 
strength of the vascular barrier.  
Finally, permeability can also be regulated by VE-cadherin internalization 25,33 or 
enzymatic proteolityc cleavage 34.  
 
1.3 Tight junctions composition and signaling 
TJs physically seal the plasma membrane of two adjacent cells to finely regulate the 
passage of cells and solutes through the paracellular space 35. TJs are formed by members 
of multiple families of transmembrane signalling proteins, which include claudins, 
occludins and junctional adhesion molecules (JAMs) (Figure 2). These TJ transmembrane 
components associate to the cytoplasmic proteins like Zonula Occludens ([ZO]-1, ZO-2, 
ZO-3) and cingulin 36. The high grade of junction complexity can be explained by the 
specific barrier properties that TJs must exert depending on the tissues in which they are 
located. Claudins, the major transmembrane components of TJs, are 21-28 kDa proteins 
and consist of four transmembrane domains, two extracellular loops and both N- and C- 
terminal cytoplasmic domains. The claudin family is composed by 24 members. ECs 
express claudin1, 3, 5 and 12 and among them only the expression of claudin5 is 
endothelial-specific 37. Claudins contain the conserved aa motif GLWxxC(8-10 aa)C in the 
first extracellular loop and a PDZ (Post synaptic density protein, Drosophila disc large 
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tumor suppressor and Zonula occludens-1 protein) domain-binding motif at the C- 
terminus, which is needed for the association with PDZ-containing TJ proteins ZO-1, ZO-2 
and ZO-3 35.  
Occludin, like claudins, is a four-pass transmembrane protein with both N-terminal 
and C-terminal cytoplasmic domains. The C-terminal cytoplasmic region of occludin also 
binds to ZO-1, ZO-2 and ZO-3 35.  
JAM proteins belong to the immunoglobulin (Ig) superfamily and have two 
extracellular N-terminal Ig-like domains, a transmembrane region and a short cytoplasmic 
tail harbouring a PDZ-binding domain. At least five members are known, named JAM-A 
(or JAM-1 or F11R), JAM-B, JAM-C, JAM-4 and JAM-L plus a sixth molecule called 
ESAM that shares similarities with the JAM family. Every JAM molecule displays its own 
peculiar pattern of expression. JAM-A is the most widely expressed since it can be 
detected in both endothelial and epithelial tissues of many organs as well as in platelets, 
erythrocytes and leukocytes. JAM-B is expressed exclusively by ECs, while JAM-C is 
present both in ECs and leukocytes. Much less is known about the expression pattern of 
JAM-4, JAM-L and ESAM. Of note, JAM proteins are engaged in both homophilic (i.e. 
with identical JAM molecules) and heterophilic (i.e. with different JAMs or other 
unrelated proteins) interactions. JAM-A, JAM-B, JAM-C and JAM-L contain a putative 
dimerization loop in their N-terminal region and are able to localize at cell-to-cell contacts 
in close proximity with TJ strands. JAM-A interacts with many PDZ-containing molecules 
that mediate the anchorage to actin cytoskeleton such as ZO-1, Afadin-6 (AF-6), 
partitioning defective (PAR) 3/6/atypical PKC (aPKC) complex, calcium/calmodulin- 
dependent serine protein kinase CASK/lin2 and multi-PDZ domain protein (MUPP-1) 4, 38. 
By binding PAR3/PAR6 polarity complex in association to the small GTPases Cdc42 and 
aPKC, JAM-A and JAM-C play a central role in the maintenance of apical-basal cell 
polarity 39. Cell polarity is finally required also for a correct angiogenesis and therefore, 
there are evidence showing that JAM-C is involved in tumor angiogenesis and retinal 
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neovascularization 40. 
ZOs, cytoplasmic TJ components, belong to the family of the membrane-associated 
guanylate kinase homologs (MAGUKs) 4, 41, and consist of three PDZ domains, a Src 
Homology (SH)3 domain and a guanylate kinase (GUK) domain. PDZ-binding domains at 
the C-terminus are able to mediate the anchorage of the associated transmembrane proteins 
to actin cytoskeleton. When TJs are not well developed or the cells are in sparse/migrating 
condition, both ZO-1 and ZO-2 dissociate from the cell-to-cell contacts and migrate into 
the nucleus 42, 43. ZO-1-associated nucleic acid binding protein (ZONAB), a Y-box 
transcription factor reported to localize both at TJs and in the nucleus, binds to the SH3 
domain of ZO-1 and this interaction is required for sequestering ZONAB at the plasma 
membrane and restraining its nuclear localization, thus reducing cell proliferation 44, 45. 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Schematic representation of endothelial TJs.  
Claudins play a central role in the formation of TJ strands between ECs with the cooperation of occludin and 
JAMs molecules. Many intracellular components of TJs such as ZO-1, ZO-2 and cingulin mediate junctional 
binding to actin cytoskeleton. (Adapted from Nyqvist et al, 2008) 
 26 
1.4 Endothelial heterogeneity: the example of the blood brain barrier 
The heterogeneity is an intrinsic feature of ECs. Depending on multiple factors 
such as tissues localization, vessel size and age, ECs can modify their phenotype in order 
to adapt to and support specific functions of the tissue or the organ in which they reside. 
Differences in terms of junction organization, cell morphology, gene expression or antigen 
composition and functions have been described in ECs located in different segments of the 
vascular tree. From a structural point of view the endothelium can be classified into three 
main classes: continuous non-fenestrated, continuous fenestrated and discontinuous or 
sinusoidal 4, 46. Continuous non-fenestrated endothelium is peculiar of vessels inside the 
brain, the skin and the heart. The presence of highly organized and abundant TJs in the 
vasculature of these organs allows the strong sealing of cell-to-cell contacts in order to 
strictly control the passage of several substances. The active transcytosis of molecules 
across this vessel wall is mediated by caveolae, vesiculo-vacuolar organelles and specific 
transporters 47. Conversely continuous fenestrated endothelium is characterized by the 
presence on endothelial surface of transcellular pores with a diameter of about 70 nm (the 
so called fenestrae) that allow the rapid exchange of molecules between the circulation and 
the surrounding tissue. Most of the fenestrae present a thin diaphragm that acts as a 
molecular filter and allows increased size selectivity 48,49. Fenestrated endothelium is 
permeable to water and small solutes and, therefore, it is typical of organs involved in 
filtration or secretion such as exocrine and endocrine glands, renal glomeruli and the 
gastric-intestinal mucosa. Finally, discontinuous endothelium is similar to the fenestrated 
one with the exception that fenestrae are larger in diameter (100-200 nm) and lack an 
internal diaphragm 49.This poor restrictive endothelium is typical of certain sinusoidal 
vascular beds in the bone marrow and in the liver that need to allow continuous cellular 
trafficking 47. 
Beyond structural differences, ECs express distinct patterns of cell surface markers, 
solute transporters and intracellular enzymes in different tissues. For instance, 
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ultrastructural features such as the secretory organelles Weibel-Palade bodies are not found 
in all ECs 46, while the expression of Glucose transporter 1 (Glut1) is limited to brain 
vascular ECs 50. 
The molecular mechanisms involved in EC heterogeneity are driven by the 
exposure of ECs to tissue specific environmental stimuli including mechanical forces, 
cytokines, the contact with tissue-specific cell types, circulating immune cells, 
extracellular matrix (ECM) and soluble growth factors 51. All these stimuli can activate 
specific receptor-mediated signalling pathways in ECs that further induce post-
translational modification of proteins or modify the transcription factors-dependent gene 
expression. This fine regulation of the endothelial heterogeneity through the 
microenvironment is a biological process termed trans-differentiation 52. In agreement with 
this theory, ECs cultured in vitro undergo a phenotypic drift because they are uncoupled 
from critical extracellular signals deriving from their native environment. Conversely, 
certain specific properties of ECs are determined by epigenetic modification (e.g. DNA 
methylation, histone methylation and acetylation) and can be maintained also upon EC 
isolation and culture since they are mitotically stable 51.  
A clear example of EC heterogeneity is represented by the highly specialized 
endothelium of the brain microvasculature. This endothelium has to tightly control the 
exchange of molecules, ions and cells between the central nervous system (CNS) and the 
peripheral blood circulation, thus allowing proper neuronal function and the protection of 
the CNS from toxins and pathogens 53. From an anatomical point of view brain ECs are 
supported by a basement membrane and enwrapped by PCs and astrocytic end feet 
processes to create a multicellular vascular structure called blood brain barrier (BBB) 
(Figure 3) 54, 55. All this elements together with the contribution of neurons, microglial 
cells and immune cells, constitute a peculiar microenvironment known as neurovascular 
unit (NVU) 56.  The proper interaction between these multiple cellular components is 
necessary for correct formation and function of BBB 56.  
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Figure 3 – Schematic representation of the cellular organization of the BBB. 
ECs, covered by a basement membrane in their abluminal side, are the main components of the BBB. 
Pericytes partially envelope ECs and astrocytes extend their foot processes thus providing a link with the 
neurons. A correct crosstalk between these multiple components is required for proper barrier induction and 
maintenance. (Adapted from Quaegebeur et al., 2011)  
 
High-throughput genomic and proteomic analyses of the molecular differences 
between ECs of different origins have revealed that ECs of the brain microvasculature 
possess unique properties. CNS ECs have highly organized TJs since claudin5 and 
occludin expression are very enriched in the brain endothelium 57. The importance of these 
TJ components is underlined by the phenotype of both claudin5 and occludin KO mice. 
Claudin5 deficient mice die within 10 hours after birth due to a size selective loosening of 
BBB against molecules smaller than 800 Da 58. Occludin null mice develop calcifications 
in the CNS, thus suggesting a critical role for occludin in the regulation of calcium flux 
across the BBB 59. Efflux transporters and nutrient transporters are particularly abundant in 
brain ECs 57. The first are localized on the luminal cellular side and they use the hydrolysis 
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of adenosine triphosphate (ATP) to transport small lipophilic molecules into the 
bloodstream 60. In this regard is important to note that ECs of the CNS are equipped with a 
high amount of mitochondria in order to meet the ATP needs required by this 
transportation system 61. By contrast, nutrient transporters allow the passive movement of 
important nutrients from the blood to CNS as well as the removal of waste products from 
the brain. Many of these transporters belong to the solute carrier family such as GLUT1, a 
transporter that allows the entry of circulating glucose into the brain 62, 63. The transcytosis 
in a healthy BBB is very low as compared to peripheral ECs. In agreement, a strong 
upregulation of the plasmalemma vesicle-associated protein (PLVAP) is observed during 
BBB injury and disease 64, 65. Finally, ECs express a very low amount of leucocyte 
adhesion molecules such as selectins (P-selectin and E-selectin) that are required for 
leukocyte adhesion and extravasation 46, 66, thus strongly limiting immune cell entry into 
the brain parenchyma. 
Vascular heterogeneity acquires even more importance considering that some 
vascular diseases such as atherosclerosis 67 and rare genetic diseases including Cerebral 
Cavernous Malformations (CCM) 68 develop in specific types of vessels. 
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2. CEREBRAL CAVERNOUS MALFORMATIONS 
Cerebral cavernous malformations (CCMs), also known as cavernous angioma or 
cavernoma, are vascular lesions that occur predominantly in the CNS, even if they can also 
be found in other anatomical districts such as liver, retina and skin in a lower percentage of 
the cases 69. CCM lesions consist of mulberry-like structures composed by dilated and 
enlarged vessels lined by a thin layer of ECs surrounded by a thick, discontinuous basal 
membrane with no intervening parenchyma 70 (Figure 4). CCMs arise from the venous-
capillary vascular bed and are characterized by low blood flow eventually associated with 
thrombosis and calcifications 69. Ultrastructural analysis revealed that the BBB is severely 
compromised at the level of these lesions. Thus, TJs and AJs are strongly altered and 
several gaps develop between individual cells. EC surrounding PCs are reduced in number 
and no astrocytic foot processes are present within the lesions 70. CCMs are often 
neurologically silent and it has been estimated that only approximately 60% of patients are 
symptomatic 71.  
 
 
 
 
 
 
 
 
 
Figure 4 – The morphology of CCM vascular lesions 
A) Cerebral MRI showing multiple CCM lesions. B) Surgical view of a CCM lesion. C) Schematic 
representation of the normal vasculature (left panel) and the typical mulberry-like structure of CCM lesions 
(right panel). (Adapted from Dejana et al., 2009 and Storkebaum et al., 2011)  
C  
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Clinical symptoms strongly reflect a compromised BBB and include strokes, 
intracranial hemorrhage, seizures and focal neurological deficits depending on the site of 
lesion 72. 
 
2.1 CCM genetics 
CCM is a rather frequent disease with a prevalence of 0.5 % in the population. It 
can occur both in a sporadic (80 % of cases) or familial form (20 % of cases). Sporadic 
patients usually develop a single lesion from the second decade of the life while familial 
forms are characterized by the formation of multiple lesions whose number and size 
usually increase with the age 71, 73. Moreover, while sporadic cases are not inherited, 
familial forms are transmitted in an autosomal dominant manner with variable penetrance. 
95 % of familial CCM patients harbor a heterozygous germ line mutations in one of the 
three different CCM genes known as CCM1/KRIT1, CCM2/MGC4607/OSM/Malcavernin 
and CCM3/PDCD10/TFAR15 71, 73. Different types of CCM gene germline mutations have 
been reported (e.g. nonsense, splice-site and frameshift mutations as well as large genomic 
rearrangements and few missense mutations), mostly resulting in loss-of-function of the 
relative protein 74. Mutations in CCM1 gene are the most common accounting for about 
56 % of familial CCM, whereas the CCM2 and CCM3 mutations occur in 33 % and 6 % of 
the familial cases respectively 74, 75. A CCM1 founder mutation (Q455X stop codon 
mutation in CCM1) has been identified in Hispanic Americans of Mexican descent, a 
population with a higher incidence for CCM 72.  Of note, no mutation in CCM genes has 
been detected in 5% of familial CCM, thus suggesting the existence of unknown additional 
genes implicated in CCM disease 75. To this regard a potentially new CCM gene named 
zona pellucida-like domain containing 1 (ZPLD1) has been recently identified even if its 
functional role in CCM pathology remains to be determined 76. The average age of the 
disease onset is between the 2nd and 5th decades of life, but symptoms can start in early 
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infancy or in older age. In comparison to CCM1 and CCM2 patients, CCM3 mutations are 
associated with an earlier disease onset and more severe phenotype characterized by a 
higher risk for cerebral hemorrhage during childhood 77. The standard strategy to identify 
mutations in CCM patients and to confirm their clinical diagnosis is the full sequencing of 
both the coding regions and the exonic-intronic junctions in the three CCM genes. If 
sequencing gives negative results, other approaches are currently applied in clinics 
including the multiplex ligation-dependent probe amplification (MLPA) analysis or the 
combination of microsatellite marker analysis together with quantitative real-time 
polymerase chain reaction (qRT-PCR) 78.  
It has been hypothesized that CCM pathogenesis occur following the Knudson’s 
two-hit mechanism. Loss of one allele in all cells (germ line mutation) might be followed 
by a somatic mutation in the other allele (second hit) in some ECs that, subsequently, 
would lead to the formation of a vascular lesion 79. Since the detection of homozygous 
mutations in individual ECs inside a lesion is quite challenging, the possible cause of this 
“second hit” is still an open issue.  
 
2.2 Animal models used to study CCM disease 
Since CCM proteins are well conserved across different species 80, numerous 
experimental animal models have been used to study CCM pathology. Due to the 
availability of transgenic reporter lines expressing fluorescent proteins within the 
vasculature together with its transparency and amenability to genetic manipulation, the 
zebrafish model has been extensively used to unveil the functions of Ccm genes in the 
vascular system. Zebrafish mutants KO for either santa (the zebrafish orthologue of 
CCM1), valentine (the zebrafish orthologue of CCM2) or pdcd10 (ccm3, which is 
duplicated in the zebrafish genome) show the so called “big heart phenotype”, a severe 
dilation of the cardiac chambers in which the endocardium is covered by a single thin layer 
of myocardial cells 81-83. The absence of heart looping and the endocardial cushion 
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formation in these zebrafish mutants has been also reported 82. Beyond a cardiac phenotype 
these mutants develop dilated thin-walled vessels without lumen 84, that are reminescent of 
the microvasculature observed in human CCM patients. Interestingly, the big heart 
phenotype of santa, valentine and pdcd10 KO zebrafish is very similar to what observed in 
fish lacking heart of glass (heg) 85. HEG1 is a transmembrane receptor expressed almost 
exclusively by vascular ECs that interacts with CCM1 and CCM2 85. However, since loss 
of HEG1 does not alter CCM lesion formation in mice and no mutations in the human 
orthologue HEG1 have been identified in CCM patients 86, 87, HEG1 seems to not be 
directly involved in the pathogenesis of CCM disease.  
Several murine models have been also developed by several groups in order to 
study the in vivo functions of CCM proteins during the vascular development. Constitutive 
and global deletion of any of the three Ccm genes in mice results in embryonic lethality 
due to generalized vascular defects in embryonic and extra-embryonic tissues 69, 88, 89. Of 
note, mice with a systemic Ccm3 deletion die earlier (E8.0 to E8.5) in respect to Ccm1 and 
Ccm2 KO mice (E9.5). Although CCMs expression is not endothelial-specific, they seem 
to play a specific role in the brain endothelium. Endothelial-specific deletion of either 
Ccm2 or Ccm3 strongly impairs angiogenesis and results in embryo death at mid-gestation 
68, 88, 89 while conversely, neuronal-specific and smooth muscle cell-specific Ccm2 or Ccm3 
KO mice do not show any vascular defects and survive to adulthood 88. In order to study 
the role of CCM genes during brain angiogenesis and to clarify CCM pathophysiology, 
several genetic strategies have been applied to avoid the embryonic lethality of  both 
constitutive and endothelial-specific Ccm KO mice. Based on the two-hits hypothesis, Ccm 
heterozygous mice, that usually do not develop cavernomas, have been crossed with error 
prone genetic background mice 90, 91(e.g. p53 KO and Msh2 KO animals). These CCM 
animal models, while developing lesions similar to patients, are characterized by 
incomplete penetrance, an increased risk of developing neoplasms and the impossibility to 
control the tissue specificity of the second mutation. In order to overcome these limitations 
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endothelial specific gene ablation has been induced after birth. Postnatal day 1 (P1) 
deletion of any of the three Ccm genes in the endothelium results in the development of 
vascular lesions specifically in the CNS 69,92. Interestingly postnatal Ccm gene ablation in 
other CNS cell types fails to give a pathological phenotype with the exception of the 
neural-specific deletion of Ccm3, which is characterized by diffuse enlargement of brain 
blood vessels and the formation of vascular lesions that recapitulate human CCM 93.  
In conclusion it remains unclear the reason why Ccm genes ablation specifically 
affects the brain microvasculature and whether the role of CCMs in other cellular 
components of the BBB could contribute to CCM pathogenesis.  
 
2.3 CCM protein function and pathological implications 
CCM proteins do not share any similarity in term of sequence or structure, but they 
can form a cytosolic multiprotein complex, in which CCM2 is the bridge between CCM1 
and CCM3 94, 95, necessary for their proper localization at cell-to-cell contacts in ECs 96. 
The existence of a unique CCM complex explains the strong similarity of the clinical 
manifestations observed in CCM patients and animal models upon loss-of-functions of any 
of the three Ccm genes. However, single CCM proteins can have also specific intracellular 
localization and they can interact with different unique partners 97.  CCMs, either as part of 
the same complex or as single molecular entities, exert a critical role in several 
ECprocesses such as cell-to-cell junctions organization, cell polarity, cytoskeletal 
remodeling, lumen formation and angiogenesis 97. 
Enhanced vascular permeability is a hallmark of CCM lesions in vivo. CCM 
proteins control endothelial barrier function by regulating both actin cytoskeleton 
remodeling and endothelial junction formation and maintenance. In this regard CCMs have 
been described to restrain the activity of small GTPase RhoA and its kinase ROCK 88, 96. 
Ccm gene deletion leads to RhoA activation and the following phosphorylation, mediated 
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by ROCK, of a series of target proteins involved in stress fiber formation, motility, cell 
polarization and permeability.  RhoA activation in response to the absence of CCM is due 
to reduced RhoA degradation 98 as well as to altered Striatin-interacting phosphatase and 
kinase (STRIPAK)-mediated activation of the RhoA inhibitor moesin 99.  
CCM proteins fulfill also a crucial role in the formation and maintenance of EC 
junctions. Rap1 is a binding partner of CCM1, which act as a scaffold protein for a 
membrane-tethered complex containing VE-cadherin and β-catenin 100,101. In the absence 
of Ccm1, Rap1 is mislocalized leading to junctional weakening and increased permeability. 
Lack of Ccm2 or Ccm3 also increases EC permeability due to AJ and TJ alterations 69, 88. 
Disruption of AJs in the absence of Ccm1 is accompanied by the loss of apical 
basal polarity and improper lumen formation. VE-cadherin and CCM1 form a complex that 
is required for the correct junctional localization and function of the members of the Par 
polarity complex (consisting of PAR3, PAR6 and the effector component protein kinase 
Cζ, PKCf) 102, 103. Dismantling AJs by inactivation of CCM1 leads to the altered PKCζ 
activity and consequent abrogation of endothelial cell polarity, which might explain why 
CCM-mediated lesions are abnormally enlarged and present multiple lumens 103. 
Consistently, also CCM3 seems to play a pivotal role in lumen formation through its 
interaction with GCKIII kinases 104 while for CCM2 null ECs no polarization defects were 
reported.   
AJ dismantling results in increased β-catenin nuclear localization and β-catenin -
dependent transcription in CCM1 101 and CCM3 null ECs 92. Most importantly, β-catenin 
signaling activation is responsible for the development and progression of vascular lesions 
in vivo in the absence of Ccm3 92.   
In vivo deletion of Ccm genes has already revealed that CCM proteins are essential 
for the angiogenic phase of the cardiovascular development 69, 88, 89. In vitro loss of either 
Ccm1 or its interactor Integrin Cytoplasmic Domain-Associated Protein 1 (Icap1) results 
in an excessive angiogenesis due, at least in part, to a deregulation of both the Notch 
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pathway 105 and the integrin β1-mediated signaling 106,107. Viceversa CCM3, that has 
independent and different roles in comparison to both CCM1 and CCM2 108, has been 
reported to induce VEGFA-dependent signaling by stabilizing and activating VEGFR2 89. 
Thus the absence of Ccm3 results in altered vessel growth.  
Since it is evident that CCM proteins are implicated in a number of signalling 
pathways that seem to be crucial for EC homeostasis, it is conceivable to hypothesize that 
loss of Ccm genes could lead to a hyper-activation of specific angiogenic programs 
occuring in the CNS endothelium that eventually result in the formation of abnormal, 
fragile and irregular vascular structures. In this regards it is interesting to note that while 
the endothelial-specific ablation of Ccm2 at P1 results in the formation of multiple vascular 
lesions in the cerebellum, gene deletion performed in adult mice rarely leads to CCM 
development 69. Thus, additional stimuli such as the presence of an active angiogenesis 
program in the neonatal cerebellum or other context-specific factors could be necessary to 
promote the formation of the cavernoma. In the same line of thought, it is still unclear why 
CCM lesions arise predominantly in the CNS endothelium. One possible explanation is 
that CCM proteins could restrain improper vessel growth by promoting a correct crosstalk 
of ECs with other cellular components of the neurovascular unit.  
 
 
2.4 Future pharmacological therapies for the treatment of CCM patients 
The diagnosis of CCM lesions is particularly challenging since CCM lesions are 
not detectable by angiography 109. Other imaging techniques are used currently for CCM 
diagnosis in clinics such as conventional T1- and T2- weighted MRI that allows the 
detection of cavernomas in a very sensitive way. The natural history of these vascular 
lesions is still not yet clearly understood 78. CCM lesions are highly dynamic and they may 
undergo enlargement or even de novo formation. Moreover, depending on their location in 
the cerebral microvasculature, the symptoms and hemorrhage risk can be very different. 
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Even if a clear correlation between lesions development/growth and their relative 
localization within CNS has not been identified, most of the CCM lesion are supratentorial 
while other are more deeply located in the brainstem 110. Once a CCM lesion is diagnosed 
by MRI, all these factors have to be taken in account during the clinical management of the 
CCM patient. To date neurosurgery is the only therapeutic approach offered in clinics and 
the risks associated with the microsurgical resection of the lesions are strictly related to 
their location. Due to this reason most of the efforts in this research field are now 
concentrated to identify a new pharmacological therapy able to prevent or arrest CCM 
lesion development. The pharmaceutical treatments proposed so far target the signaling 
pathways recently identified as altered in CCM. Initially Statins, well-known inhibitors of 
RhoA activation, have been proposed as a promising pharmacological tool to reduce the 
increased vascular permeability associated to CCM, but it was unable to reduce the number 
and the size of CCM lesions in mice 88, 111, 112. Conversely Fasudil, a direct inhibitor of 
ROCK, has been reported to decrease lesion burden in CCM mouse models 113. Recently 
sulindac sulfide and sulindac sulfone, two non-steroidal anti-inflammatory 
drugs previously used in clinics as inhibitors of β-catenin-dependent signalling, have been 
shown to significantly reduce the number and the size of CCM lesions in vivo at least in 
the absence of Ccm3 92. Finally, by using an unbiased screening platform to repurpose 
previously developed drugs, Gibson and coworkers have shown that vitamin D3 and 
TEMPOL, a scavenger of superoxide, are very effective in reducing CCM lesions at least 
in mouse models 112. However the molecular mechanisms through which they act remains 
undefined. For this reason the major goal of this research project is the better 
understanding of which signalling pathways are relevant for CCM pathogenesis in order to 
identify new candidate targets for pharmaceutical intervention.  
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3. ENDOTHELIAL TO MESENCHYMAL TRANSITION 
3.1 Definition of endothelial-to-mesenchymal transition 
 
ECs are characterized by a marked plasticity and may acquire a mesenchymal 
phenotype through a complex biological process called EndMT (Figure 5). During this 
transition ECs reduce the expression of specific endothelial markers (such as VE-cadherin, 
claudin5 and CD31 [PECAM1]) and strongly increase the expression of mesenchymal 
markers such as α-Smooth Muscle Actin (αSMA) or Fibroblast Specific Protein 1 (FSP1 or 
S100A4) and stem cell markers like CD44, stem cell antigen 1 (SCA1) and inhibitor of 
differentiation1 (ID1). This process is associated with altered junction organization, loss of 
cell polarity, increased cell proliferation and migratory capacity 114. EndMT has been 
implicated in fundamental physiological processes during embryogenesis 115-117 but, also, 
in pathological conditions including organ fibrosis and cancer 118-122. EndMT has often 
been considered a specialized form of epithelial to mesenchymal transition (EMT), a 
fundamental process during embryonic development, tissue repair, and disease 123 during 
which a polarized epithelial cell, that normally interacts with basement membrane, 
acquires a mesenchymal cell phenotype with an increased invasiveness and resistance to 
apoptosis 124. Both EMT and EndMT are induced by similar signaling pathways such as 
those mediated by transforming growth factor β (TGF-β), bone morphogenetic proteins 
(BMP), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived 
growth factor (PDGF), WNT, Sonic Hedgehog (Shh), Notch, and the integrin signaling, 
that, in turn, induce a number of transcription factors able activate the expression of 
EMT/EndMT-associated genes  125.  
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Figure 5 - Phenotypic changes that occur during the EndMT.  
During EndMT ECs loose the expression of endothelial markers VE-cadherin, CD31, TIE1, TIE2, and vWF, 
and acquire/increase the expression of several mesenchymal markers. Distinct changes in cell polarity, 
cytoskeleton and ECM composition, cell-to-cell junctions and increased motility accompany the switch of 
the phenotype (from Medici & Kalluri, 2012). 
 
3.2 The TGF-β signalling pathway 
 
TGF-β signalling pathway is implicated in a large number of biological processes 
including cell proliferation, differentiation, migration, ECM production and apoptosis. 
TGF-β signaling cascade involves a family of 33 ligands, two serine/threonine kinase 
receptors (type I and II) and the signal transducers mother against decapentaplegic 
(SMADs) 126. The ligands, which share a dimeric structure and a cysteine knot structural 
motif 127, include three distinct TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3), more 
than twenty Bone Morphogenetic Proteins (BMPs), Growth Differentiation Factors 
(GDFs), Mullerian Inhibitory Factors (MIFs) and Activins or Inhibins. TGF-β signalling is 
mediated by the binding of active ligands to an heterodimeric receptor complex composed 
by type I and type II serine/threonine kinase receptors 128. A total of seven TβRI receptors, 
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called activin receptor-like kinase (ALK1-ALK7) and five TβRII receptors, among which 
TGF-β type II receptor (TBRII), BMP type II receptor (BMPRII), activin receptor type IIA 
(ActRIIA), activin receptor type IIB (ActRIIB) and AMH type II receptor (AMHRII), have 
been identified. Type I (TβRI) and type II (TβRII) receptors are all composed by a 
cytoplasmic tail that retains kinase activity, a single transmembrane spanning region and a 
cysteine-rich extracellular domain. Each ligand belonging to the TGF-β superfamily can 
bind to different combinations of type I and type II receptors, thus mediating different 
signalling pathways.  Commonly, BMPs and TGF-β subfamilies are synthetized as inactive 
monomeric pro-peptides, composed by a short N-terminal sequence, a latent-associated 
peptide (LAP) and a C-terminal mature domain retained in the ECM. After the synthesis, 
two monomeric precursors dimerize and are then processed by endoproteases of the 
convertase family and proteolytic enzymes, responsible for the cleavage between LAP and 
the release and secretion of the mature homodimer protein. This fine regulation of the 
protease activity is of fundamental importance since it allows the control of active TGF-β 
bioavailability 129. 
The binding of the ligands induces the formation of the receptor complex and 
mediates phosphorylation of TβRI by TβRII, required to TGF-β downstream signalling. In 
this way TβRI can then recruit and phosphorylate the cytoplasmic mediators SMADs that, 
in turn, bind the common mediator SMAD4 (Co-SMAD) and translocate into the nucleus 
acting as TFs of specific target genes 130
 
(Figure 6). The TGF- β family of SMAD proteins 
is classified in three main groups: Receptor-associated SMADs (R-SMADs), Co-operating 
SMADs (Co-SMADs) and Inhibitory SMADs (I-SMADs) 131. R-SMADs are the SMADs 
recruited and phosphorylated by the TβR complex. Five different R-SMADs have been 
identified in humans, namely SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8; their 
structure contains two conserved Mad Homology Domains, MH1 and MH2 that are 
respectively responsible for the binding to DNA and for the R-SMADs oligomerization 132. 
Interaction of R-SMADs with the TβRI is also promoted by the presence of auxiliary 
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proteins, such as the SMAD Anchor for Receptor Activation (SARA), favouring the 
association of the TβR complex with SMAD2/3 and subsequently their phosphorylation. 
ALK4, ALK5 and ALK7 mediate SMAD2 and SMAD3 phosphorylation and are 
usually downstream of TGF-β, activins, inhibins and nodal 133. On the contrary, ALK1, 
ALK2, ALK3 and ALK6 induce pSMAD1, pSMAD5 and pSMAD8 and their activation is 
usually mediated by BMPs and AMH, even if it has been demonstrated in ECs that TGF-β 
can also interact and signal through ALK1 134. 
SMAD4 is the Co-SMAD required for the association with phospho-R-SMADs and 
their translocation into the nucleus, while I-SMADs, that include SMAD6 and SMAD7, 
mediate a negative regulation of TGF−β signaling 135. Among the I-SMADs, SMAD7 is 
the main involved into the switching off of the TGF-β signalling. Indeed SMAD7 binds to 
activated TβRs and compete with SMAD2 and SMAD3 for the binding to ALK5, 
repressing its activation 136. Moreover SMAD7 recruits the E3-ubiquitin ligases SMAD 
ubiquitination regulatory factor (Smurf)-1 and Smurf-2 to mediate ALK5 ubiquitination 
and degradation 137. SMAD7 is also a direct target gene of TGF-β/ALK5 dependent 
pathway and acts in a negative feedback loop limiting the intensity and the duration of the 
signal 136. In addition, SMAD6 was shown to bind BMPR-1B inhibiting SMAD1 
phosphorylation, thus suggesting that also BMP signalling can be impaired by I-SMADs. 
In the nucleus, SMAD complex binds specific sequences on the DNA called SMAD- 
binding element (SBE) that contains the repeated 5’ AGCA 3’motif 138, 139. Since the 
binding to SBE is relatively weak plus the fact that one of the R-SMAD (SMAD2) is not 
able to bind to DNA, the interaction with other TFs is strictly required to cooperate in 
order to mediate gene transcription. Among these, the best known are components of the 
FoxO family 140, members of the activating proteins-1 (Ap-1) family 141, run-related 
transcription factor 2 (RUNX2) 142 
 
and nuclear factor-kappa B (NF-kB) 143. 
While ALK5-induced pSMAD2/3 bind to DNA through SBE motif, ALK1-
regulated SMADs preferentially bind to BMP-responsive element (BRE), a sequence 
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enriched in guanine and cytosine (5’ GCCGNC 3’ or 5’ GRCGNC 3’). The term BRE is 
due to the fact that pSMAD1/5/8 are also the major downstream mediators of BMPs 
signaling 144, 145. 
A further level of complexity in TGF-β signalling is added by the presence of the 
TGF-β co-receptors (TβRIII) betaglycan and endoglin, characterized by a large 
extracellular and a short intracellular domain lacking catalytic activity. Betaglycan 
interacts with TβRII playing a key role in the presentation of the TGF-β ligands to the 
receptor complex 146
 
since it is strictly required for the binding of TGF-β2 that has low 
affinity for TβRII 147. 
Endoglin instead is a key modulator of the complex interplay between ALK1- and 
ALK5-dependent signalling; its inhibition in vitro decreases TGF-β/ALK1 pathway and 
indirectly enhances TGF-β/ALK5 148, indicating that endoglin may be required for optimal 
TGF-β/ALK1 signalling pathway. In addition, endoglin and betaglycan were also reported 
to potentiate BMP signaling 149. 
 TGF-β superfamily can also exert its functions through a so-called non canonical 
non-SMAD-dependent pathway, where TGF-β/TβR complex is able to directly activate 
different signalling pathways including MAPK, Rho-like GTPase and PI3K/AKT thus 
modulating a multitude of various downstream cellular responses 150. 
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Figure 6 – Schematic representation of TGF-b signalling pathway  
Upon ligand binding, type II receptor can phosphorylate type I receptor that in turn phosphorylates 
SMAD2/3. These leads to the recruitment of Smad4 that subsequently binds to SMAD2/3 and the complex 
can translocate into the nucleus where it recognized specific DNA binding site to mediate the transcription of 
target genes. SMAD7 competes with Smad2/3 for the binding to type I receptor, attenuating the signalling. 
The TGF-β co-receptor endoglin assists type I and type II receptors in mediating TGF-β downstream 
cascade. 
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3.2.1 TGF-β and BMP signalling pathway in ECs  
Mouse models and human syndromes showing either inactivation or aberrant 
expression of any of the components of TGF-β signalling pathway, like ligands, receptors 
and SMADs, all undergo embryonic lethality mainly due to cardiovascular defects 129, 151, 
152, thus suggesting a critical role for TGF-β signalling during vascular morphogenesis and 
angiogenesis. 
Moreover, in the adult, TGF-β exerts different and often divergent effects on EC 
homeostasis, the so-called “TGF-β paradox”, and any perturbation occurring to this tuned 
system can lead to the onset of pathological conditions. 
The effects of TGF-β signalling in ECs can be indeed finely mediated and even 
opposite, depending on the type I receptor involved, specifically ALK1 or ALK5 134, 153-155. 
While ALK5 is broadly expressed, ALK1 is almoust endothelium restricted. When TGF-β 
activates the ALK5/pSMAD2/3 axis the final outcome is the inhibition of EC migration 
and proliferation. The use of a specific ALK5 inhibitor, named SB-431542, has been 
demonstrated to facilitate EC proliferation and sheet formation in mouse embryonic stem 
cell-derived ECs. Furthemore SB-431542 is able to up-regulate the TJ component claudin5, 
thus suggesting a role for ALK5 also in the regulation of vascular permeability 156. One of 
the best-known TGF-β/ALK5 molecular targets is plasminogen activator inhibitor-1 (PAI-
1), an important regulator of the plasminogen activation system 134. PAI-1 is a proteinase 
inhibitor that is involved in the BM formation preventing degradation of the ECM around 
the emerging new vessels 157. On the contrary, the activation of ALK1/pSMAD1/5/8-
endoglin axis leads to EC migration and proliferation 158. Indeed the activation of this 
pathway mediates the induction of the Inhibitor of Differentiation-1 (ID1), a negative 
regulator of basic-helix- loop-helix (bHLH) TF, controlling multiple TGF-β-induced 
biological responses. In general, ID proteins are positive regulators of cell proliferation and 
negative regulators of cell differentiation 159 (Figure 7). 
Even if ALK1 and ALK5 induce divergent outcomes in ECs, they can also interact 
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and modulate each other. It has been shown that ECs defective for ALK5 are not able to 
activate ALK1 signalling cascade because its absence does not allow the correct 
recruitment of ALK1 to form TβR complex 158. Conversely, ALK1 can antagonize ALK5 
signalling at the level of SMADs 134, 153. Taken together, the regulation of ALK1 and 
ALK5 signalling and their reciprocal interaction provide a fine regulation of EC 
homeostasis and function. 
Evidence showed that in ECs VE-cadherin can associate with TβR complexes 21. 
The proper clustering of VE-cadherin at junctions is necessary for optimal TGF-β 
signalling to exert anti-proliferative and anti-migratory responses. Furthemore, VE-
cadherin physically interacts with all the components of the TGF-β receptor complex, 
including TβRII, ALK1, ALK5 and endoglin, thus enhancing TβRII/ALK1 and 
TβRII/ALK5 complex formation and TGF-β-dependent signaling 21. 
As well as TGF-β, also BMP subfamily has a prominent role in vascular 
development and angiogenesis, since genetic ablation or alteration in the expression of 
different BMP components are embryonically lethal due to cardiovascular malformations 
and failure in vascular remodelling. BMP2, BMP4 and BMP6 were all reported to be able 
to induce angiogenesis and EC proliferation and migration 160,161; the over-expression of 
these BMPs and of their target ID1 increases the ability of EC to mediate the in vitro assay 
of capillary tube formation while inhibition of ID1 expression blocks the BMP-induced 
migration 162. On the contrary, BMP9 blocks either VEGF-induced angiogenesis either 
proliferation and migration of bovine aortic ECs (BAECs) induced by bFGF. Morevoer, 
BMP9 was shown to inhibit growth and migration of human dermal microvascular ECs 
(HDMECs). Of note, BMP9 shows different effects depending on the cellular contex and 
its concentration since, at low doses, BMP9 can also promote EC proliferation and 
promote angiogenesis in in vitro matrigel plug assays and in vivo in human pancreatic 
xenografts 163. 
Furthermore, BMP signalling can interct with Notch signalling pathway, that 
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fosters EC to become stalk ECs, promoting proliferation and subsequently elongation of 
the sprouting vessels. Data showed that inhibition of BMP downstream effector SMAD1/5 
in ECs both in vivo and in vitro resulted in a decrease of Notch signalling and in reduced 
expression of Notch target genes, overall resulting in decreasing stalk EC activity 164, 165. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7- TGF-β  signalling pathway in ECs 
In ECs TGF-β can either activate ALK5/SMAD2/3 resulting in the induction of the plasminogen activator 
inhibitor-1 (PAI-1) or ALK1/SMAD1/5/8 that mediates ID1 expression. This latter pathway can also be 
initiated by BMPs that are recognized and interact with specific with type II BMP receptors (BMPRII). 
Smad7 and Smad6 compete respectively with SMAD2/3 and SMAD1/5/8 for the binding to ALK5 and 
ALK1 in order to switch off the signal, acting as negative TGF-β regulators 
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3.3 EndMT in heart cushion formation and cardiac fibrosis 
EndMT was discovered in 1977 during embryonic heart development by Markwald 
and colleagues 115. During heart development, the heart tube is composed by two different 
layers, an inner endocardium and an outer myocardium. In between the two layers there is 
a coat made by ECM called cardiac jelly. The endocardium is composed by ECs 
expressing VE-cadherin and CD31 that, during the formation of the heart cushion, receives 
stimuli from the outflow tract and the atrioventricular (AV) myocardium to acquire 
mesenchymal characteristics in order to give rise to primordial valves and membranous 
septa 115-117. BMP2 released from the myocardium has been suggested to be the first 
initiator to induce cardiac EndMT 166
 
because its expression triggers an autocrine 
production of TGFβ from endocardial cells feeding the transition of ECs to mesenchymal 
ones. Also TGF-β2 plays a central role during cushion formation because it has been 
reported that its expression is required for the endocardial EndMT in the mouse 167
 
and 
TGF-β2 deficient mice show multiple defects in AV cushion formation 168. Interestingly, 
during embryonic EndMT, TGF-β2 cooperates with β-catenin in the endocardial cells that 
mediate heart cushion formation. The transcriptional activity of β-catenin seems strictly 
required as TGF-β mediated EndMT is strongly inhibited in mice conditionally KO for β-
catenin 169. Moreover, in ECs KO for β-catenin TGF-β2-induced expression of αSMA is 
abolished, thus suggesting a possible interaction between TGF-β and Wnt signalling in 
mediating EndMT 169. 
The proof of concept that EndMT mechanism was taking place during heart valve 
formation and could also have a causative role in cardiac fibrosis was only demonstrated 
many years later taking advantage from the use of Tie1Cre;R26stoplacZ double transgenic 
mice that allow to follow lineage identity of the ECs 119. Thanks to this strategy, it has been 
demonstrated that fibroblasts associated to the emergence of cardiac fibrosis in a mouse 
model of aortic banding had an endothelial origin, as well as the cells of the AV cushion in 
primordial heart 119. The key regulator of the endothelial transition during cardiac fibrosis 
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was proven to be TGF-β1 that induced EndMT in adult coronary ECs via SMAD3 
signalling pathway. On the contrary, administration of BMP7 reduced the overall fibrosis 
in the heart due to a reduction in the number of fibroblasts of endothelial origin, 
demonstrating its essential role in inhibiting EndMT-mediated cardiac fibrosis 119. 
Moreover, the TFs Slug and Snail are described to be specifically required for the initiation 
of cardiac EndMT 170. Slug is directly activated by Notch to mediate VE-cadherin 
repression to allow endocardial cells to initiate invasion in the cardiac jelly. Furthermore, 
Slug deficient mice showed an up-regulation of Snail expression and double KO for Snail 
and Slug mice reduced heart valve development, underlying the compensatory role of the 
Snail family members in EndMT-mediated cardiac formation. 
 
 
3.4 EndMT in cancer, FOP and atherosclerosis 
Tumors are composed by a plethora of different cell types where the malignant 
cancer cell clone requires a permissive environment to grow and colonize the surrounding 
tissues. Cells that compose the tumor stroma create this favourable condition and among 
them fibroblasts are key modifiers in mediating cancer progression. In particular a 
subpopulation of fibroblasts, the so called cancer-associated-fibroblasts (CAFs), are now 
recognized among the most important promoters of tumor growth and progression 171. 
CAFs are defined as activated and reactive fibroblasts acquiring a modified phenotype in 
order to provide oncogenic signals to the transformed epithelia within the tumor 172. CAFs 
form a heterogeneous population with different origins: activation and proliferation of 
resident tissue fibroblasts mainly contribute to CAF accumulation in tumour 
microenvironment, but also BM and periadventitial cells are thought to be a possible 
origins of activated fibroblasts 172. 
Evidence showed that ECs undergoing EndMT could represent one of the CAF 
most important source 118. Qualitative analysis of the fibroblasts within the tumour in a 
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mouse model of melanoma revealed them to be double positive for the endothelial marker 
CD31 and the mesenchymal markers FSP1 and αSMA. Approximately 40% of FSP1 
positive and 10% of αSMA positive fibroblasts were co-expressing CD31, suggesting that 
these CAFs were of endothelial origin. In order to prove these data and to recognize 
possible ECs originating CAFs that had completely lost their endothelial phenotype in 
favour of a mesenchymal one, Zeisberg and colleagues took advantage from the 
Tie1Cre;R26stoplacZ double transgenic mice (a similar a model already described in the 
previous paragraphs) where the melanoma cells were implanted to trace fate lineage of 
ECs. As expected, a big portion of CAFs retained the endothelial lineage tracer β-gal, 
proving that EndMT leading to EC transdifferentiation could be an important source of 
CAFs. Moreover, it was also finally demonstrated that EndMT-mediated CAF origin was 
strongly induced by exposure of ECs to TGF-β1, supposed to act both in an autocrine and 
paracrine way to promote the accumulation of activated and promoting-cancer fibroblasts 
in the tumor stroma 118. 
Fibrodysplasia Ossificans Progressiva (FOP) is a genetic disorder causing extreme 
heterotopic ossification (HO) mostly in muscles and ligaments, leading to paralysis. FOP 
patients carry an autosomal dominant germline mutation in the ALK2 gene that results in 
constitutive phosphorylation of ALK2 receptor and downstream SMAD proteins 173. 
Different studies were aimed at identifying the cellular lineage responsible of the ectopic 
bone formation that was recently suggested to be of endothelial origin. Indeed mouse 
model for HO induced by transgenic expression of mutant ALK2 demonstrated that 
ectopic bone cells expressed endothelial markers VE-cadherin, Tie1, Tie2 and vWF 174. 
Comparable results were obtained in pathological samples of FOP patients 173. Lineage 
tracing in reporter mice further demonstrated that most of the mesenchymal cells involved 
in the first phases of ectopic ossification were ECs that underwent EndMT switch. 
Atherosclerosis is a multifactorial disease responsible for myocardial infarction and 
stroke, the largest causes of morbidity and mortality in Western Countries 175. It occurs in 
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large and medium-sized arteries 176 and it is characterized by the accumulation of 
cholesterol, a strong inflammatory reaction, increased proliferation of SMCs and fibrosis 
175,177. ECs together with leukocytes and intimal SMCs are the major players of 
atherosclerosis and an EndMT process in the inflamed endothelium seems to be involved 
in the pathogenesis of this disease 178. Both an oscillatory blood flow and the vessel wall 
inflammation, two well known atherogenic stimuli, lead to the loss of FGF signaling in 
ECs that, in turn, results in the activation of the TGF-β signaling and in the induction of 
EndMT 178,179. During atherogenesis EndMT is able to promote plaque growth by: i) 
increasing the deposition of fibronectin, a known proatherogenic ECM protein 180, 181; ii) 
increasing endothelial expression of adhesion molecules (i.e. ICAM-1 and VCAM-1) that 
further recruit the circulating immune cells; iii) inducing the formation of new SMCs and 
fibroblasts that lead to neointima expansion and plaque growth. In line with these data, 
endothelial-specific disruption of FGF-dependent signaling leads to EndMT and 
concomintant early and increased development of atherosclerotic plaques in mice with a 
Apoe
–/– background 178, thus suggesting that blocking EndMT could be a therapeutic 
strategy to halt the progression of atherosclerosis. 
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4. THE KRÜPPEL LIKE FACTOR FAMILY OF 
TRANSCRIPTION FACTORS  
 
4.1 The classification and the structure of KLFs 
 
Krüppel like factors (KLFs) are a family of transcriptional factors involved in a 
multitude of cellular processes such as proliferation, differentiation, migration and 
pluripotency in different cell type 182. The name “Krüppel-like” is due to the homology 
with the Drosophila protein Krüppel. Drosophila Krüppel KO embryos show a lethal 
phenotype characterized by an altered anterior abdominal and thoracic body segmentation 
183. Due to the peculiarity of this phenotype, the protein was named “Krüppel”, that is the 
german word for “cripple”.  Since the discovery of the first mammalian Klf gene (Klf1) in 
1993 184, a total amount of 18 family members have been identified and classified. The 
nomenclature of KLFs has been modified over the years. At the beginning, KLFs were 
initially named according to their expression among different tissues. Some family 
members are expressed ubiquitously (e.g. KLF6, 10, and 11), while other KLFs are found 
only in specific cell types or organs. For example Klf1, also named Erythroid Krppel-like 
factor (Eklf), is expressed predominantly in red blood cells while Klf2, also known as lung 
Krüppel-like factor (Lklf) is abundantly expressed in the lung. Oher KLF family members 
were, instead, either named depending on the element they bound, such as basic 
transcription element-binding protein (Bteb1 or Klf9), or depending on the physiological 
responses they modulated, such as the transforming growth factor-β-inducible early genes 
1 and 2 (Tieg1 and Tieg2 or Klf10 and Klf11, respectively) 185. To avoid misleading 
connotations due to partial description of their expression and/or function, the use of a 
numerical nomenclature (1 to 18) based on the chronological order of discovery has been 
adopted 186.  
KLF proteins are highly conserved across the species reflecting their ancient 
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evolutionary history 187. 18 genes encoding different 18 KLFs are present both in human 
and in mouse and are scattered all over the genome. Many of them have homologs in 
Gallus gallus (chicken), Danio rerio (zebrafish), and Xenopus laevis (frog) 182.  
From a structural point of view, all members of the KLF family are characterized 
by three zinc-finger DNA-binding domains at the C-terminus of the protein 186, 188 that 
show more than 65 % of aminoacidic sequence identity among the family members 189. 
Each zinc finger chelates a single zinc ion supported by two cysteine and two histidine 
residues. The first and second zinc fingers are composed by 25 aa, while the third contains 
23 aa. The pattern of aminoacidic arrangement in a classical zinc finger is #-X-C-X(1-5)-
C-X3-#-X5-#-X2-H-X(3-6)-[H/C], where C is cysteine, H is histidine and X corresponds 
to any aa. The symbol # marks the aa that are critical for the stable folding of the zinc 
finger 189. These fingers are connected each other by the so called “Krüppel-link”, a seven 
aa spacer TGEKP(Y/F)X highly conserved among the family members 190. Each zinc 
finger recognizes three base pairs in the DNA sequence and interacts with nine base pairs 
in total 189. Since the critical residues that determine the sequence specificity for the 
binding are largely conserved across the family, all KLF family members recognize very 
similar DNA sequences 186, 188. In detail they bind to related GC- and CACCC-boxes of 
DNA. As nuclear localization signals (NLS) have been identified in the zinc finger 
domains of several KLFs 182, the C-terminal portion of these proteins is not only important 
for the DNA binding but it is also critical for nuclear import. The N-terminal portion of 
KLFs is highly divergent among the family members and typically contains either an 
activation or a repression domain. In addition, alternative splicing in some Klfs can lead to 
further diversification of the protein structure 191. The divergence at the N-terminus allows 
the binding of different co-activators, co-repressors or other cofactors that, through specific 
post-translation modification (acetylation, phosphorylation, ubiquitination, and 
sumoylation), refine the transcriptional activity adding functional specificity to each KLF 
182.  
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Figure 7  - Schematic representation of the structure of KLF family members. 
KLFs are composed by a highly homologous C-terminal DNA-binding domain which contains three C
2
H
2 
zinc finger motifs connected by the “TGERP”-like spacer. Each zinc finger chelates a single zinc ion. 
Conversely, the N-terminus portion of the proteins is different between the family members and contains the 
activation and repression domains. (Adapted from Pearson et., al, 2008) 
 
 
Taking into consideration that N-terminal sequence homology correlates with the 
functional similarity, it is possible to divide the KLF family members in three different 
groups 182:  
• Group 1 includes KLF 3, 8, and 12. These KLFs interact with the 
carboxy-terminal binding proteins (CtBPs) 192, 193 and act as transcriptional 
repressor. CtBPs repress gene transcription through the recruitment of histone 
deacetylases (HDACs) and histone methyltransferases to the transcriptional 
complexes 194. CtBPs show also HDAC-independent mechanisms of action by 
inhibiting the activity of histone acetyltransferase (HAT) coactivators such as 
p300/CBP-associated factor (P/CAF) 194 or recruiting members of the polycomb 
complex 195 that promote chromatin silencing 
• Group 2 comprises KLF 1, 2, 4, 5, 6, and 7. They behave 
predominantly as transcriptional activators since they interact with HATs, such as 
cAMP response element binding protein (CBP), p300 and P/CAF 182. 
• Group 3 includes KLF9, 10, 11, 13, 14, and 16. These KLFs have 
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repressor activity since they interact at the N-terminus with the common 
transcriptional corepressor Sin3A 182. Mammalian Sin3 proteins (Sin3A and Sin3B) 
are large multidomain proteins that bind HDAC1 and HDAC2 as well as other 
proteins and provide a scaffold for the assembly of multiunit complexes that 
modify chromatin conformation 196. 
Finally, KLF15 and KLF17 are not included in this classification because they 
are phylogenetically distant 182 and they do not contain any defined protein interaction 
motifs, while KLF18 is still not properly characterized due to its recent discovery 204. 
KLFs, by virtue of their ability to activate and/or repress the expression of a 
plethora of genes, have a key role during the development, the maintenance of 
homeostasis and the adaptive responses to physiological or pathobiological stimuli in 
mammalian tissues. The functions of the different KLF family members in any of these 
biological responses are in some cases overlapping and in others widely divergent 198. 
Besides the homology/divergence in the structural composition, other important factors, 
such as differences in tissue expression, could contribute to the specificity of their 
relative function. Some members of the family are ubiquitously expressed, whereas 
others are tissue restricted. Moreover, KLF expression pattern can change dramatically 
during the development and thus the expression of certain KLFs may overlap at some 
developmental stages but not in others depending on the specific cell-context. KLF4 
expression is for example altered in several types of human neoplasm and depending 
on tissue affected, tumor type or cancer stage, it has been reported to act either as a 
tumor suppressor or an oncogene 198-200. Thus, individual KLFs show context-
dependent functions that can be either exclusive or redundant. 
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4.2 The characteristic of KLF4 gene and protein and its mechanisms of action 
 
In 1996 two different research groups cloned and characterized the murine Klf4 
gene 201, 202. Two years later, in 1998, the human KLF4 gene was cloned from human 
umbilical vein endothelial cell (HUVEC) cDNA library 202. Since it is abundant in the 
intestine and in the skin, it has been initially named either gut enriched kruppel like factor 
(GKLF) 201 or epithelial zinc finger (EZF) 202. Later on, as its expression has been detected 
also in other organs such as in lung, testis, thymus, cornea, cardiac myocytes and 
lymphocytes 201-205, this gene was definitely renamed as KLF4.  
The human KLF4 gene locus is located on chromosome 9q31, whereas mouse Klf4 
is located on chromosome 4B3. Both human and mouse KLF4 contain five exons 
transcribed in a mRNA of about 3.5 kilobase (KB). Several splice variants were reported 
both in human and in mouse 201, 206. The human KLF4 gene encodes for a protein with a 
predicted molecular mass of 50 kDa containing 470 aa, whereas murine Klf4 encodes for a 
polypeptide of 483 aa with a predicted molecular weight of 53 kDa. The human and mouse 
KLF4 sequences revealed a 91 % aminoacidic sequence identity. KLF4 protein can be 
divided in several functional domains:  
• a N-terminal transcriptional activation domain (1-157 aa) rich in 
proline, serine, threonine and acidic aminoacid residues. Acidic residues enhance 
the binding of coactivators such as p300/CBP 207, HAT proteins that increase 
hystone acetylation at the promoter region facilitating the recruitment of other 
transcription factors as well as the basal transcriptional machinery.  
• a repressor domain close to the N-terminal transcriptional activation 
domain (158-385 aa) that allows the interaction with repressors such as HDAC1 
and HDAC2 182. Two lysine residues (K225, K229), which are acetylated by 
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p300/CBP, are also contained in the repressor domain 208. The mutation of these 
two lysines to arginine significantly decreases the ability of KLF4 to transactivate 
its target genes 207, suggesting that acetylation of KLF4 is important for its 
function.  
• a C-terminus highly conserved triple zinc finger DNA binding 
domain (402-483 aa).  The consensus DNA binding elements for KLF4 determined 
by both chromatin immunoprecipitation sequencing (ChIP-seq) and base-specific 
mutagenesis are the following ones: [5’-GGG(C/T)G(T/G)GG-3’] 209 and  [5’-
(A/G)(G/A)GG(C/T)G(C/T)-3’] 210. Notably both sequences are enriched in CpG 
and can be methylated. The ability to bind either unmethylated or modified DNA 
elements may contribute to the different KLF-mediated regulation of several 
biological processes via selectively recruiting different chromatin cofactors 211.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8 - Schematic representation of KLF4 structure. 
 KLF4 is composed by three domains: an activation domain, a repression domain and a DNA binding domain. 
The coactivators like p300/CBP proteins are able both to interact with the activation domain and to acetylate 
the lysines 225 and 229 located in the repressor domain. The DNA binding domain of KLF4 located at the C-
terminus is composed by three zinc fingers that bind to the GC/CACCC sequence in the promoter regions of 
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its target genes. The transport into the nucleus is facilitated by the presence of a NLS both in the DNA 
binding and repression domains. (Adapted from Vangapandu et al., 2009)  
 
In addition to these domains, a PEST sequence (proline [P], glutamine [G], serine 
[S] and threonine [T]) is reported to be located between the activation and the inhibitory 
domains (113-132 aa) 212, suggesting that KLF4 protein may be degraded via the ubiquitin-
proteosome pathway and explaining the relative short half life of KLF4 protein (about 2 
hours). Finally, KLF4 contains two discrete NLS: the first is a basic hexapeptide sequence 
having PKRGRR repeats just N-terminal to the three C-terminal zinc fingers, whereas the 
second is contained within the first two zinc fingers themselves 213.  
KLF4 can function as a transcriptional repressor either by competing for the DNA 
binding with an activator (known as passive repression) or by the recruitment of 
corepressors such as HDAC to the promoter region of target genes. For instance while 
KLF4 inhibits SMAD3-mediated activation of PAI-1 as well as β-catenin/TCF4- 
dependent transcription by directly competing for p300 binding 215, in KLF4-mediated 
repression of the CD11d gene, KLF4 directly interacts with HDAC1 and HDAC2 216.  
The presence of both activation and repressor domains might allow KLF4 to switch 
between its positive and negative transcriptional effects in a cell-context specific manner 
212. KLF4 is expressed in the mesenchymal cells, in the endothelium and in the epithelium 
by E10.5 217. Klf4 KO mice were born at the expected mendelian ratio but died within 15 
hours after birth secondary to dehydration due to the loss of skin barrier function 218, thus 
suggesting the essential role of KLF4 for skin barrier function during the development. Of 
note, vascular abnormalities had not been reported during the early embryonic 
development of Klf4 KO mice 218. To overcome the limitation of the peri-natal lethality, 
several research groups developed mice expressing Cre-recombinase under the control of 
specific promoters in order to study the KLF4 activity in a tissue-specific manner. Specific 
Klf4 deletion in murine stomach results in increased proliferation and altered 
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differentiation of gastric epithelial cells 219 while loss of Klf4 in the eye leads to an 
abnormal corneal epithelium and the lack of goblet cells in the conjunctiva 220. In 2006 
KLF4 has been used together with Oct4, Sox2 and c-Myc to reprogramm somatic cells into 
pluripotent stem cells, thus being instrumental in stem cell renewal and generation of 
induced pluripotent stem cells (iPS cells) 221. 
Since KLF4 controls multiple cellular processes in a context-dependent manner, we 
will focus our attention on its role in the endothelium.  
 
 
4.3 The Role of KLF4 in endothelial cell biology 
KLF2, KLF4, and KLF6 are the three members of the KLF family expressed by 
ECs 222. KLF4 regulates several vascular functions such as permeability and vascular tone 
223, 224, angiogenesis 225, 226, coagulation and inflammatory reactions 234, 235 thereby playing 
a protective role in several pathological conditions.  
Limited in vivo studies in mice demonstrate that KLF4 depletion in lung vascular 
endothelium resulted in a most severe edema as well as greater lung polymorphonuclear 
neutrophil (PMN) sequestration in response to lipopolysaccharide (LPS) challenge thus 
suggesting a potential role of KLF4 in the regulation of vascular permeability 227. In 
agreement with these data KLF4 has been found to regulated endothelial barrier by directly 
inducing the expression of both AJ and TJ components such as VE-cadherin, ZO1, 
occludin and claudin5 228, 229, 230. However further in vivo experiments need to be 
performed in order to validate and extend these observations in other patho-physiological 
conditions. 
Endothelial KLF4 controls also the vascular tone by inducing the expression of 
nitric oxide synthase 3 (Nos3) and prostaglandin I2 synthase (PTGIS), two enzymes that 
catalize crucial reactions for the production of important vasodilatators such as nitric oxide 
(NO) and prostacyclin respectively. It also represses the expression and activity of the 
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potent vasoconstrictor endothelin1 (Edn1) and its receptor endothelin receptor b (Ednrb) 
224. By finely regulating the vascular tone KLF4 plays a beneficial role in pulmonary 
hypertension (PH), a disease characterized by an increased blood pressure in the 
pulmonary arteries due to the abnormal muscularization of distal pulmonary arterioles 239.  
KLF4 has recently emerged as an important pro-angiogenic factor induced by 
hypoxia that is one of the most powerful angiogenic stimuli in physiological and 
pathological conditions 225, 233. KLF4 promotes angiogenesis by inducing the expression of 
critical components of the VEGF signaling pathway (i.e. VEGFA and VEGFR2) 225, 234 and 
by inhibiting the Notch signalling pathway that usually costrains the tip cell formation 225. 
In line with these data endothelial specific KLF4 overexpressing mice subcutaneously 
inoculated with B16F0 melanoma cells develop tumors characterized by an increase 
number of vessels with poor perfusion that result in reduced tumor growth, a vascular 
phenothype very similar to the one obtained upon Notch inhibition through DLL4 
blockade 225. Since a minor study has conversely reported that KLF4 has been able to 
inhibit angiogenesis in HUVECs by activating miR-15a through a transcriptional 
regulation 235, future studies have to be performed to clarify the role of KLF4 during 
different physio/pathological conditions of angiogenesis.   
Finally, one of the most characterized functions of KLF4 in the endothelium is the 
regulation of EC responses to inflammation and shear stress. Several cytokines such as 
TNF-α, interleukin-β (ILβ) and interferon-γ (IFNγ) as well as fluid shear stress, defined as 
the frictional force per unit area to which ECs are subjected when exposed to blood flow 
176, strongly induce Klf4 expression 227, 228. KLF4 upregulation, in turn, promotes multiple 
endothelial vasoprotective transcriptional programs in these conditions. KLF4 
overexpression leads to the acquisition of a quiescient anti-inflammatory EC phenotype by 
both by inhibiting the expression of a diverse set of pro-inflammatory factors (including 
among the others the Vascular Cell Adhesion Molecule 1 (VCAM-1) and the prothrombotic 
gene PAI-1, and by inducing the expression of important protective genes such as eNOS 
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and thrombomodulin (THBD). Mechanistically, KLF4 switches off inflammatory gene 
expression by inhibiting, both alone and in combination with p300, the activity of the NF-
kB subunit p65 227-229.  
In line with these roles KLF4 has been reported as a protective molecule in 
atherosclerosis 228. Endothelial-specific deletion of Klf4 in Apoe–/– mice, a genetic 
background prone to develop atherosclerosis when challenged with high fat diet, results in 
a bigger atherosclerotic burden characterized by an increased inflammatory reaction. 
Conversely, sustained expression of Klf4 in the endothelium strongly reduces the area of 
the atherosclerotic plaque as well as the immune cell infiltration. Interestingly, the laminar 
flow in straights region of the arteries induces KLF expression to protect these vessel tracts 
from atherosclerosis 228. ECs align in the direction of flow, express anti-inflammatory 
genes and show low levels of oxidative stress. Conversely when arteries divide or curve 
sharply, the flow becomes oscillatory, endothelial KLF4 expression is not increased and 
ECs acquire an activated and pro-inflammatory state characterized by increased oxidative 
stress and higher expression of inflammatory genes. These arterial portions exposed to 
oscillatory flow show a higher susceptibility to develop atherosclerosis 176. Various 
signaling molecuels are involved in the perception and mediation of shear stress responses. 
These include the extracellular-signal-regulated kinase (ERK5), a mitogen-activated 
protein kinase (MAPK) able to induce KLF4 expression 226, 236. 
 
4.4 The ERK5 signalling axis 
The human ERK5 gene locus (also termed MAPK7) has been cloned in 1995 by two 
different research groups independently 237, 238. It is located on chromosome 17p11.2 and 
encodes for a protein of 816 aa with a predicted molecular mass of 102 kDa. Due to its 
large size in comparison to other MAPKs, ERK5 was also termed big MAPK (BMK1). 
The N-terminal portion of the protein contains the kinase domain and it is required for 
cytoplasmic targeting, oligomerisation and the interaction with the ERK5 upstream 
 61 
regulator MAPK/ERK kinase 5 (MEK5, also termed mitogen-activated protein kinase 
kinase 5  [MAP2K5]) 239, 240. The big C-terminal region of ERK5 contains both a NLS and 
a nuclear export signal (NES) necessary for nuclear shuttling as well as a potent 
transcriptional regulation domain. The ERK5 C-terminal tail contains also two proline rich 
domains for the binding of proteins with a Src-homology 3 (SH3) domain and a myocyte 
enhancer factor 2 (MEF2)-interacting region 241-243. Several growth factor including VEGF, 
EGF, FGF and PDGF as well as stress conditions (i.e. hypoxia, laminar flow or osmotic 
stress) are known to activate ERK5 241-243. Tipically these extracellular stimuli initiate the 
signalling cascade by activating the MAPK kinase kinases (MAPKKK) MEK kinase 2 
(MEKK2) and 3 (MEKK3) that, in turn, phosphorylate MEK5 on Ser311/Thr315 241-245. As 
a consequence, phosphorylated MEK5 induce ERK5 activation by catalizing a dual 
phosphorylation at specific residues (Thr218/Tyr220) located in the activation loop of 
ERK5. In resting condition ERK5 acquires a folded conformation to mask the NLS and to 
expose a nuclear export signal (NES) and thereby ERK5 is retained in the cytoplasm. Upon 
MEK5-dependent phosphorylation, ERK5 undergoes autophosphorylation that determines 
a conformational change allowing ERK5 to translocate into the nucleus to regulate target 
gene expression 245. Nuclear ERK5 promotes gene transcription either directly via a poorly 
defined transcriptional activation domain present in the C-terminal tail of the protein 246 or 
by increasing the activity of several transcription factors including the myocyte enhancer 
factors (MEF), C-myc, the cAMP response element-binding protein (CREB) and serum-
response factor accessory protein 1a (Sap1a) 247, 248. MEF2A, MEF2C and MEF2D, 
members of MEF family, mediate most of the ERK-5-dependent transcriptional responses. 
ERK5 interacts with MEF2s at the C-terminal region and it can increase their 
transcriptional activity by catalizing their phosphorylation 248-250.   
ERK5 controls a large number of biological processes such as proliferation, 
migration, apoptosis and angiogenesis. In the endothelium ERK5 has a key role in the 
regulation of cell survival, angiogenesis and cell response to shear stress 248-250. 
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Figure 9 – The ERK5 structure and signalling axis 
Upon stress conditions (i.e. osmotic stress or laminar flow) or exposure to mitogens (growth factors and 
cytokines) a typical three-tiered hierarchical MAPK module is activated: the MAPKKK MEKK2/MEKK3 
phosphorylate the MAPKK MEK5, which in turn activates the MAPK ERK5 by inducing the 
phosphorylation on Thr218 and Tyr220 residues within the kinase domain located in the C-terminus of 
ERK5. The kinase domain of ERK5 mediates the phosphorylation of several TF such as MEF2C, c-Myc and 
Sap-1. The ERK5 protein structure contains also a NLS, two proline-rich domains (PR1 and PR2) and a large 
C-terminal tail. (Adopted from Nithianandarajah-Jones et. al., 2014) 
 
Erk5 KO mice are lethal at embryonic day 10.5 (E10.5) due to severe 
cardiovascular defects. Vascular defects are due to the formation of immature and leaky 
blood vessels that resulted in diffuse heamorrage 249, 250. Interestingly endothelial-specific 
loss of Erk5 resulted in an altered vascular phenotype comparable to global ERK5 deletion 
251, thus suggesting that ERK5 activity is essential in ECs during the vascular development. 
Notably, mice deficient for the two upstream activators of ERK5 such as MEKK3 and 
MEK5 show a similar vascular phenotype 252, 253. Beyond its role during the development, 
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ERK5 is important in the maintenance of vascular integrity since its deletion in adult mice 
is lethal within 2–3 weeks after gene ablation due to leaky blood vessels 251. This 
phenotype might be attributed to the important anti-apoptotic role of ERK5 in ECs. ERK5 
promotes EC survival by inducing the expression of the pro-survival protein B-Cell 
CLL/Lymphoma 2 (BCL-2) and by inhibiting, through phosphorylation, the activity of the 
pro-apoptotic protein BCL2-Associated Agonist Of Cell Death (BAD) 254.  
Fluid shear stress induces MEK5-dependent ERK5 activation that results in the 
MEF2-dependent expression of the transcription factors KLF2 and KLF4 that, in turn, 
have a protective since they confer anti-thrombotic and anti-inflammatory properties to the 
vascular endothelium 226, 236, 255, 256. Interestingly vasoprotective drugs such as statins have 
been shown to potently activate the MEK5/ERK5/KLF4 dependent gene expression in ECs, 
thus suggesting that some of the pleiotropic vasoprotective effects of these drugs may be 
elicited through activation of ERK5 226.  
ERK5 has been implicated also in the regulation of tumor angiogenesis. ERK5 is 
activated by the pro-angiogenic growth factors VEGF and FGF-2 in ECs 251 and its in vivo 
deletion results in a regression of tumor vasculature and concomitant growth inhibition of 
xenografted human tumors 257. These evidences lead to the recent development of small-
molecule inhibitors of the ERK5 signalling axis. BIX02188 and BIX02189 are two 
indolinone-6-carboxamides that selectively inhibit MEK5 activity 258 while XMD8-92, 
which derives from chemical modifications of the polo kinase inhibitor BI-2536 259, is a 
highly-selective inhibitor of ERK5 activity. Notably, in contrast to the lethal phenotype 
due to the endothelial-specific ablation of Erk5 in adult mice, no side effects in the 
vasculature were observed after XMD8-92 administration in mouse xenograft models 259, 
thus suggesting XMD89-2 as useful drug to target ERK5-mediated tumor growth and 
angiogenesis.  
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5. MATERIALS AND METHODS  
 
5.1 Antibodies 
For Western blotting (WB) and immunostainings the following antibodies were 
used: VE-CADHERIN rat (550548, BD Biosciences); VE-CADHERIN goat (sc-6458, 
Santa Cruz); N-CADHERIN mouse (610920, BD Biosciences); PECAM1 hamster 
(MAB1398Z, Millipore); PECAM1 rat (553370, BD); PECAM1 rabbit (ab28364, Abcam); 
mKLF4 goat (AF3158, R&D); hKLF4 goat (AF3640, R&D); FSP1 rabbit (07-2274, 
Millipore); ID1 rabbit (BCH-1/37-2, BIOCHECK); SCA1 rat (ab51317, Abcam); Cleaved 
Caspase-3 (5A1E, Cell Signaling); GFP rabbit (A-6455, Invitrogen); hCLAUDIN5 rabbit 
(ab53765, Abcam); pSMAD1/5 rabbit (9516, Cell Signaling); SMAD1 rabbit (9644, Cell 
Signaling); pSMAD3 rabbit (1880-1, Epitomics); SMAD3 rabbit (9523, Cell Signaling); 
Glucose transporter type 1 (GLUT1) rabbit (RB9052P1, Thermo Scientific); ERK5 rabbit 
(07-039, Upstate); VE-PTP rabbit (produced and purified by New England Peptide); 
MEKK3 rabbit (5727, Cell Signaling); MEK5 mouse (610957, BD); BMP6 sheep (LS-
C150156, LS-BIO); GAPDH mouse (SC-32233, Santa Cruz); tubulin mouse (T9026, 
Sigma); vinculin mouse (V9264, Sigma); horseradish peroxidase (HRP)-linked anti-
mouse, anti-rat and anti-rabbit (Cell Signaling); HRP-linked anti-goat (Promega). Biotin-
conjugated isolectin B4 (Vector Lab) was used to identify retinal vasculature. ALEXA 
FLUOR 488, 555 and 647 donkey secondary antibodies were from Life Technologies.  
 
5.2 Mouse lines 
Ccm1 floxed/floxed, Ccm2 floxed/floxed and Ccm3 floxed/floxed mouse strains 
were previously described 69, 92. The Cdh5(PAC)-CreERT2 mouse line 260 were kindly 
provided by R.H. Adams. Klf4 floxed/floxed mice  219  were kindly donated by G.K. 
Owens. These mice were received on a mixed background (C57BL6J/129SvJ) and 
subjected to MAX-BAX® Program in Charles River to perform accelerated backcross. 
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Mice were all bred on a C57BL/6 pure background. To obtain the EC-CCM1 KO mice, 
Cdh5(PAC)-CreERT2 animals were bred with the Ccm1 floxed/floxed mouse strain to 
obtain tamoxifen-inducible endothelial-specific expression of Cre-recombinase and Ccm1 
gene recombination. To generate double EC-CCM1 KO KLF4 KO mice, Cdh5(PAC)-
CreERT2; Ccm1 floxed/floxed mice were crossed with Klf4 floxed/floxed animals. 
Deletion of floxed exons by Cre-recombinase produces loss-of-function. Both EC-CCM2 
KO and EC-CCM3 KO mice were derived as described for EC-CCM1 KO animals. EC-
KLF4 KO mice were generated by crossing Cdh5(PAC)-CreERT2 mice with Klf4 
floxed/floxed animals. For tamoxifen-induced gene ablation, tamoxifen (T5648, Sigma) 
was dissolved in corn oil-10 % ethanol at 10 mg/ml and then further diluted at 2 mg/ml in 
corn oil. Pups were injected at P1 with an intragastric injection of 100 µg.  
 
5.3 Endothelial cell isolation and culture 
The cultured cell lines used in this study for in vitro experimental approaches were:  
• WT, CCM1 KO, CCM2 KO, CCM3 KO and KLF4 KO lung derived ECs: these 
cells were isolated from the lung of two month old floxed mice.  Lungs were 
removed under sterile conditions, washed two times with PBS and minced finely 
with scalpels. Organ disaggregation was carried out by incubating them with 
collagenase A (1.5 mg/ml; Roche) and DNAse (25 µg/ml; Roche) in DMEM (37 
°C for 3 hours). After filtering through nylon screen, cells were collected, 
centrifuged at 1,200 rpm for 10 minutes and then seeded in gelatin 0.1 % coated 24 
wells. Upon 48 hours ECs were washed and immortalyzed with polyoma middle T 
antigen supernatant. The purity of EC lines was analyzed by performing extensive 
stainings for endothelial specific molecules. Ccm1, Ccm2 and Klf4 floxed alleles 
were deleted by treating pure ECs in vitro with TAT-Cre recombinase using 
Hyclone ADCF-Mab medium (ThermoScientific) 261. Recombination of the floxed 
Ccm3 gene was induced by treating the cells at culture day 1 with the AdenoCre 
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viral vector, as previously described 262. All these cell lines were cultured in 
MCD131 (Lonza) with 20 % North American (NA) fetal bovine serum (FBS) 
(HyClone), glutamine (2 mM; Sigma), sodium pyruvate (1 mM; Sigma), heparin 
(100 µg/ml, from porcine intestinal mucosa; Sigma), and EC growth supplement 
(ECGS) (5 µg/ml, made in our laboratory from calf brain). 
• WT, CCM1 KO and CCM1-KLF4 KO primary brain derived ECs (BMECs). 
Mouse brain microvascular fragments were recovered by brains of two month old 
mice either WT, Ccm1 floxed/floxed or Ccm1-Klf4 floxed/floxed mice. Brain were 
rolled on Whatman 3MM chromatography blotting paper to remove the meninges, 
triturated and digested with 0.75 % type 2 collagenase (Worthington Biochemical 
Corp.) 1 hour at 37 °C. The pellet was resuspended in a 25 % w/v BSA solution 
and centrifuged for 20 minutes at 2,600 rpm at 4 °C to obtain a microvessel 
enriched cell pellet. Then, further digestion was performed in 10 mg/mL 
collagenase/dispase (Roche) and 1 µg/ml Dnase I (Roche) for 15 minutes at 37 °C. 
Capillary fragments were seeded in culture medium and selected for puromycin (4 
µg/ml) resistance for 2 days. Recombination of the floxed alleles was achieved by 
treating selected ECs with TAT-Cre recombinase in vitro. Culture medium was 
DMEM (GIBCO) with 10 % North American (NA) fetal bovine serum (FBS) 
(HyClone), glutamine (2 mM; Sigma), penicillin/streptomycin (100 units/l; Sigma), 
sodium pyruvate (1 mM; Sigma), heparin (100 µg/ml, from porcine intestinal 
mucosa; Sigma), and EC growth supplement (ECGS) (5 µg/ml, made in our 
laboratory from calf brain). 
• Immortalized cerebral microvascular EC of human origin ECs (hCMEC/D3). 
hCMEC/D3 were provided by P.O. Couraud 263  and cultured in Rat Collagen I 
(Cultrex) treated plates in a complete medium composed by EBM-2 medium 
(Lonza) supplemented with 5 % of Fetal Bovine Serum, 1 % 
Penicillin/Streptomycin, 1.4 µm Hydrocortisone, 5 µg/ml Acid Ascorbic, 10 mM 
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HEPES, chemically defined Lipid concentrate (1/100) and FGF-2 (1 ng/ml).  
• 293T packaging cells provided by IFOM Cell Culture facility and cultured in 
DMEM medium (GIBCO) supplemented with 10 % South American (SA) FBS 
(Hyclone), glutamine (2 mM) and sodium pyruvate (1 mM). 
• HEK293 used to perform luciferase assay were provided by IFOM Cell Culture 
facility and cultured as described for 293T. 
All cells were grown at 37 °C in a humidified atmosphere with 5 % CO2. 
For ex-vivo experiments, to obtain freshly isolated PECAM1+ brain derived ECs 
from EC-CCM1 KO, EC-CCM1 KO KLF4 KO mice and matched controls (P12), brain 
microvascular fragments were processed as described for BMECs. EC pellets obtained 
were finally resuspended in 0.1 % BSA and 2 mM EDTA in PBS pH 7.4 and incubated for 
45 minutes at 4 °C with Dynabeads (Invitrogen) previously coated with rat anti-mouse 
PECAM1 antibody (BD). ECs were then separated using a magnet and processed without 
to be exposed to any culture condition. In order to obtain both lung- and spleen-derived 
PECAM1+ ECs from EC-CCM1 KO and matched controls, the organs were disaggregated 
with collagenase A plus DNAse (1.5 mg/ml and 25 µg/ml, respectively; Roche) for 2 hours 
at 37 °C and passed through a 70 µm cell strainer before to be incubated for 45 minutes at 
4 °C with anti-mouse PECAM1 covered dynabeads. Heart-derived PECAM1+ ECs from 
the same animals were recovered by incubating minced hearts with type I collagenase (2 
mg/ml, Sigma) for 45 minutes at 37 °C. A trituration of the heart suspension using a 30 cc 
syringe is required before pipetting the cell suspention through a 70 µm cell strainer and 
loading it on anti-mouse PECAM1 covered dynabeads. 
 
5.4 Cell treatments  
LY-364947 (Calbiochem), XMD8-92 (SelleckBio) and BIX-02189 (SelleckBio) 
were dissolved in dimethylsulphoxide (DMSO). For LY-364947 treatment, cells were 
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grown to confluence in MCDB with 5 % FBS and daily stimulated with 40 µM LY-
364947 for 1 week. For XMD8-92 and BIX-02189 treatment, confluent ECs monolayers 
were grown in complete media (MCDB-131 with 20 % FBS) and treated daily with either 
5 µM XMD8-92 (for 72 hours), 10 µM BIX-02189 (for 48 hours) or vehicle only. For 
BMP6 (R&D) treatment, ECs were grown in MCDB-131 with 5 % FBS and stimulated 
(100  ng/ml) either for 4 hours in order to analyse SMAD1 phosphorylation or for 96 hours 
for EndMT marker evaluation.  
 
5.5 Treatment with TGFb/BMP inhibitor in vivo 
10 mg/kg of LY-364947 (Sigma) or 10 mg/kg of LY-364947 plus 10 mg/kg SB-
431542 (SelleckBio) were intraperitoneally injected daily starting 2 days after the Ccm1 
recombination (P1). Control mice were treated with vehicle only. The animals were 
sacrified at P13. 
 
5.6 Production of Lentiviruses 
Both shRNAs against murine Klf4 and Bmp6 as well as control non-targeting 
shRNA cloned into pLKO.1 puro-based lentiviral vector were purchased from Sigma-
Aldrich (St Louis, MO, USA, TRCN0000238250 and TRCN0000065652). The cDNA 
coding for the wild-type mouse Klf4 was obtained by GeneCopoeia (Rockville, USA) and 
subcloned into the lentiviral expression vector pLenti-III-HA (provided by abm, 
Richmond, BC, CANADA) using XhoI and EcoRI restriction sites (Promega, Fitchburg, 
WI, USA). The lentiviral particles were produced in 293T cells using a four-plasmid 
transfection system mediated by calcium phosphate, as previously described 271. Briefly, 
24 hours before transfection 4x106 cells were plated in a 158 cm2 petri dish. The day after, 
cells were transfected with a solution composed by: 7 µg of ENV (envelop plasmid), 12.5 
µg of pMDL (packaging plasmid), 6.25 µg of REV (REV-expression plasmid), 32 µg gene 
transfer (shCTRL, shKLF4, shBMP6, pLenti-III-HA or pLenti-III-KLF4), 156 µl CaCl2  
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plus 0.1 X TE to a final volume of 1094 µl. 1250 µl of 2 X HBS were added to the 
transfection mix that then was bubbled vigorously and transferred dropwise on the cell 
monolayer. Lentivirus-containing supernatants were collected 48 and 72 hours after the 
cell transfection, passed through a 0.45 µm filter and concentrated using PEG ON at +4 °C. 
Two consecutive cycles of lentiviral infection were carried out in the presence of 
polybrene followed by a selection with 3 µg/ml puromycin for 72 hours and maintenance 
with 1.5 µg/ml puromycin. 
 
5.7 Cell transfection and RNA interference 
To perform RNA interference the following siRNA were used: Stealth RNAi 
directed to mouse Bmp6 (MSS-236054, MSS-236055 and MSS-236056, Life 
Technologies), Stealth RNAi directed to mouse Ccm1 (MSS294386, Life Technologies), 
Stealth RNAi directed to human CCM1 (MSS234455, Life Technologies), ON-TARGET 
plus SMART pool directed to mouse Ccm2 (L-057315-00-0005, Dharmacon), Stealth 
RNAi directed to mouse Ccm3 (MSS249998, Life Technologies), Stealth RNAi directed to 
mouse Erk5 (siERK5#1 MSS215825 and siERK5#2 MSS215827, Life Technologies), 
Stealth RNAi directed to mouse Mek5 (MSS215820), Stealth RNAi directed to mouse 
Mekk3 (siMEKK3#1 MSS218528 and siMEKK3#2 MSS218529), Stealth RNAi directed 
to mouse Mef2A (MSS206607), Stealth RNAi directed to mouse Mef2C (MSS206611), 
Stealth RNAi directed to mouse Mef2D (MSS247431), negative control siRNA Medium 
GC content (12935-300, Life Technologies) ON-TARGET plus siControl (D-001810-10, 
Dharmacon). Cells were transfected with 40 nM siRNA oligonucleotides for 5  h in 
Optimem using Lipofectamine 2000 (Life Technologies) in accordance with the 
manufacturer’s instructions and as previously described 103.  
 
5.8 Western blotting 
For WB analysis, cells were lysed using a boiling modified Laemmli sample buffer 
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(2 % SDS, 20 % glycerol, and 125 mM Tris-HCl, pH 6.8). After 10 minutes incubation at 
100 °C, lysates were spinned for 1 minute at 13,000 rpm to discard cell debris.  Protein 
concentration of the collected supernatant was estimated using the BCA Protein Assay Kit 
(Pierce). Equal amounts of proteins were separated by SDS–PAGE on acrylamide/bis-
acrylamide gels at different concentrations and transferred to a Protran nitrocellulose 
membrane 0.2 µm pores (Whatman). The membranes were then blocked for 1 hour at room 
temperature (RT) and, then, incubated with primary antibody (overnight [ON] at 4 °C) and 
HRP-linked secondary antibodies (1 hour at RT) in Tris-Buffered Saline-Tween (TBST) 
containing 5 % BSA. After three washing steps, membranes were incubated with 
Amersham ECL WB detection reagents (GE Healthcare) for 1 minute and specific signals 
were detected by chemi-luminescence system (GE Healthcare) using ChemiDoc™ MP 
System (Biorad). 
 
5.9 qRT-PCR analysis 
Total RNA was isolated by extraction with the RNeasy mini kit (Qiagen). Isolation 
of RNA from freshly isolated PECAM1+ brain derived ECs was performed using RNeasy 
micro kit (Qiagen). 1 µg RNA was reverse transcribed with random hexamers (High 
Capacity cDNA Archive kit; Applied Biosystems).  cDNA (5 ng) was amplified in 
triplicate with the TaqMan Gene Expression assay (Applied Biosystems) and an 
ABI/Prism 7900 HT thermocycler. For any sample the expression level normalized to the 
housekeeping genes encoding 18S, hypoxanthine phosphoribosyltransferase 1 (Hprt1) or 
Glucuronidase beta (Gusb) was determined by the comparative threshold cycle (Ct) 
method as described previously 265. mRNA levels of the several transcripts of interest 
obtained by freshly isolated tissue derived ECs were normalized for endothelial cell 
content using Pecam1 amount. 
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5.10 Affymetrix 
RNA was extracted from WT and CCM1 KO BMECs upon 7 days of culture and 
analyzed using Affymetrix GeneChip arrays Gene ST 1.0 containing probes for 29,000 
murine genes. For each condition, total RNA from three distinct preparations was used to 
measure biological variability. In order to identify the modulated genes, an initial filter was 
applied to select transcripts regulated with a statistical p-value below 0.05. 
 
5.11 Cell migration assay 
Wound healing assay was used to measure cell migration. Confluent EC 
monolayers were starved ON and then manually wounded with a pipette tip. Cells were 
then washed with Phosphate-Buffered Saline (PBS) and incubated at 37 °C for the 6 hours 
in complete media. Cell migration was examined by crystal violet staining (0.5 % crystal 
violet in 20 % methanol) and phase contrast microscopy. Quantification of migration was 
performed by ImageJ software.  
 
5.12 Cell proliferation assay 
Cell proliferation assay was performed as previously described 12. Briefly, cells 
were plated at density of 4,000 cells/well in 96 well plates and analyzed at the indicated 
time points by crystal violet staining (0.1 % crystal violet in 20 % methanol). The optical 
density of the dye was measured using a Victor Microplate reader at the wavelenght of 590 
nm. Where indicated, cell proliferation were evaluated by measuring the percentage of Ki-
67 positive cells. 
 
5.13 Generation of 3-D endothelial spheroid assay 
EC spheroids were generated by seeding in non adherent round-bottom 96 well 
plates (Greiner) a number of 500 WT and CCM1 KO ECs in culture medium containing 
0.25 % (w/v) carboxymethylcellulose. Suspended cells formed single EC spheroid within 
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24 hours. Then, cell spheroids were embedded into collagen gels as described 266 in a cell 
culture medium containing both 10 ng/ml VEGF-A (PeproTech) and 10 ng/ml FGF-2 
(PeproTech) was added. After 24 hours of incubation EC spheroids were fixed in 4 % 
paraformaldehyde (PAF). Actin staining (TRITC-Phalloidin, Sigma) was performed in 
order to evaluate cell sprouting and migration. The cumulative length of sprouts that 
originate was from quantified with ImageJ software. At least 10 spheroids per 
experimental group were analysed in each experiment.  
 
5.14 Transcription factor binding site analysis  
The identification of putative KLF4 binding sequences on genomic DNA was 
performed using the software MatInspector 267, which predicts the transcription factor 
binding sites (TFBS) by using a large library of weight matrices. Using the RSAT software 
(http://rsat.sb-roscoff.fr/) we retrieved a sequence spanning from 5000 bp upstream and 
1000 bp downstream the transcription start site (tss) of  Fsp1, Sca1, Id1, Bmp6 genes.  
 
5.15 Transcriptional reporter assay  
Genomic DNA isolated from lung derived murine WT ECs  was used to amplify promoter 
regions, identifed as enriched in KLF4 binding sites by chromatin immunoprecipitation 
(ChIP), of either Fsp1 (1.8 KB), Sca1 (2.1 KB) or Bmp6 (2.3 KB). As depicted in Table 2, 
we designed for each promoter sequence both forward and reverse primers modified at 
their estremity in order to contain restriction sites for specific restriction enzymes (XhoI 
and KpnI for both Fsp1 and Sca1 promoters; XhoI and BglII for Bmp6). The three 
promoter sequences were amplified using 200 ng of DNA, 10 mM dNTPs, 10 µM forward 
and revers primers, 1µl DMSO, 10µl  Phusion HF buffer 5X and 0.5 µl high fidelity DNA 
polymerase Phusion (NEB). The following thermal cycle programs were applied: 
Fsp1-  98 °C 30 sec, 98 °C 10 sec, 65 °C   25 sec, 72 °C 54 sec, 72 °C 10 min 
Sca1- 98 °C 30 sec, 98 °C 10 sec, 65 °C   25 sec, 72 °C 70 sec, 72 °C 10 min 
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Bmp6- 98 °C 30 sec, 98 °C 10 sec, 67 °C   25 sec, 72 °C 70 sec, 72 °C 10 min 
Upon the enzimatic restiction we cloned these DNA fragments into the polinker of PGL3-
basic vector (Promega) upstream the luciferase cDNA.  
 
  
 
 
 
 
Figure 10 - Representation of PGL3 basic vector backbone 
  
 
 
 
 
 
Table 1 – List of primers used for promoter cloning 
 
 
To perform the transcriptional reporter assay, HEK-293 cells were plated in 24 well 
plates and transfected for 5  hours in Optimem using Lipofectamine 2000 (Life 
Technologies) with the reporter plasmids expressing the luciferase cDNA under the control 
of a promoter portion of either Fsp1, Sca1 or Bmp6. pCDNA3 expression vectors 
containing either full length KLF4 or a mutant KLF4 lacking the DNA-binding zinc finger 
domain (KLF4 ΔZnF) (kind gifts of Mukesh Jain) 214 were co-transfected where indicated. 
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Renilla expressing plasmid was used as an internal control to correct for transfection 
efficiency. DualLuciferase® Reporter Assay System (Promega) was used to measure 
firefly and renilla luciferase activities 30 hours upon transfection with a GloMax® 
luminometer (Promega).  
 
5.16 Chromatin Immunoprecipitation  
ChIP assays were performed as described elsewhere 268. Briefly, cells were starved 
ON and cross-linked with 1 % formaldehyde for 10 minutes at RT. 125 mM glycine for 5 
minutes at RT was then added in order to inactivate formaldehyde. After two washes with 
ice-cold PBS ECs were lysed by scraping in ice-cold SDS buffer (NaCl 100 mM, Tris HCl 
pH 8.1 50 mM, EDTA 5mM, NaN3 0.2 %, SDS 0.5 %). The lysate was collected and then 
centrifuged at 1,300 rpm for 5 minutes at 4 °C. After removal of the supernatant, the pellet 
was resuspended in Immunoprecipitation buffer (1 volume of SDS Buffer + 0.5 volume of 
Triton Dilution Buffer [NaCl 100 mM, Tris HCl pH 8.6 100 mM, EDTA 5 mM, NaN3 0.2 
%, Triton X-100 5 %]). Sample sonication in microTUBE (COVARIS) was performed 
after 10 minutes of incubation using a COVARIS S220 according to the following 
conditions: Peak Incident Power 175.0 Watt, Duty Factor 10 %, 200 Cycles/Burst. An 
aliquot of chromatin was then digested with Proteinase K (1 ug/ul) for 30 minutes at 55 °C, 
incubated at 65 °C for 3 hours to revert the cross-linking and then purified using the 
QIAquick Gel extraction Kit (QIAGEN). The purified chromatin was loaded on 1 % 
agarose gel to evaluate the size of the sonicated chromatin fragments. 1 mg of DNA 
fragments with an average size of 500 base pairs (bp) were incubated with either 10 µg of 
KLF4 directed antibody or IgG control ON at 4 °C in the presence of protein G covered 
magnetic beads (Life Technologies). The following day, beads were recovered and washed 
twice with Mixed Micelle Washing Buffer (NaCl 150 mM, TrisHCl pH 8.1 20 mM, EDTA 
5 mM, Sucrose 5.2 % w/v, NaN3 0.02%, Triton X-100 1 %, 0.2 % SDS), 500 Buffer 
(Deoxycholic acid 0.1 % w/v, NaCl 500 mM, HEPES pH 7.5 25 mM, EDTA 1 mM, NaN3 
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0.02 %, Triton X-100 1 %), LiCl Detergent Washing Buffer (Deoxycholic acid 0.5 % w/v, 
LiCl 250 mM, EDTA 1 mM, NP-40 0.5 % v/v, NaN3 0.02 %, Tris HCl pH 8.0 10 mM). 
Proteins/DNA complexes were detached from beads by heating the samples at 65 °C for 10 
minutes. De-crosslinking was performed at 65 °C ON. DNA was purified using Wizard SV 
Gel and PCR Clean-Up System (Promega) and amplified by qRT-PCR using 
oligonucleotides flanking the assayed promoter regions (listed below). Primers were 
always tested to avoid "auto- amplification" due to self-complementarity.  qRT-PCR 
reactions were carried out by diluting DNA in the presence of specific primers (0.4 µM 
each) to a final volume of 25 µl in SYBR Green Reaction Mix (Perkin Elmer). S.D.S 2.2.1 
software was used to convert qRT-PCR curves in Ct values. For each region the mean of 
the Cts of the inputs was calculated and subtracted to the Ct values of the immune samples 
(ΔCt). Then, the % of enrichment of input for the immune samples was obtained as 2^-ΔCt 
and multiplied by the % of input taken during the experiment. The same calculation was 
performed for the non-immune (IgG control) immunoprecipitated samples. To remove 
unspecific signal, the non-immune values were subtracted from the immune samples.  
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Table 2 – List of primers used in ChiP 
 
 
 
5. 17 Immunofluorescence and hystology 
For immunofluorescence stainings perfomed in vitro, ECs were plated in 15 µ- 
slides (Ibidi) and, at confluency, fixed for 10 minutes in 4 % PAF at RT or for 3 minutes in 
ice-cold Methanol. Cells fixed in PAF were subjected to a permeabilization step with PBS 
plus 0.05 % TritonX-100 for 5 minutes. A PBS solution containing 5 % Donkey Serum 
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and 2 % BSA was used to perform the blocking the samples for 1 hour at RT. After the 
blocking ECs were incubated for 1 hour at RT with primary antibodies diluted in blocking 
solution. Appropriate fluorofore-conjugated secondary antibodies (Molecular Probes) were 
used on cells for 2 hours at RT. After several washing steps, sections were post-fixed with 
2 % PAF for 5 minutes and then mounted with Vectashield containing DAPI (Vector 
Laboratories).  
For tissue immunostaining, mouse brains were dissected, embedded in Tissue-Tek 
OCT (Sakura) and snap frozen. 10 µm-thick sections were fixed either  in 4 % PAF for 20 
minutes or ice-cold methanol for 5 minutes. PAF-fixed samples were permeabilized with 
PBS containing 0.5 % Triton X-100 for 5 minutes at RT. Slides were then blocked for 3 
hours at RT with PBS containing 2 % BSA, 5 % Donkey Serum and 0.05 % TritonX-100 
(blocking solution). Incubation with primary antibodies (ON at 4 °C) and secondary 
(3 hours at RT) antibodies was carried out in blocking solution. After several washing 
steps, section were counterstained with DAPI, post-fixed with 2 % PAF for 5 minutes and 
then mounted with Vectashield (Vector Laboratories). Analysis of the staining was 
performed with a Leica TCS AOBS confocal microscope using several objectives: 20x 
(HC PL FLUOTAR NA=0.5, dry), 40x (HCX PL APO NA=1.25, oil) or 63x (HCX PL 
APO lbd.BL NA=1.4, oil). Images were acquired with Leica Confocal Software and then 
adjusted with Adobe Photoshop. The adjustments used in the preparation of the figures 
were for brightness, contrast and background noise (blur filter).  
For lesion quantifications brains were fixed in 4 % PAF ON at 4 °C and then 
embedded in 4 % low-melting-point agarose. Serial sagittal sections (150 µm) of the 
cerebellum were obtained using a vibratome (1000 Plus, The Vibratome Company, St. 
Louis, MO, US). Each section was stained for Glucose transporter 1 (Glut1) for vessel 
detection and examined under confocal microscopy (10× and 20× objectives). Analysis of 
the number/size of the CCM cavernae was performed using Image J software. Three 
different groups of caverns were defined according to their size (area in µm2) 69.  
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For immunochemistry on human samples, 3 µm paraffin sections were stained with 
hematoxylin and eosin (H&E) to assess the histological features. Immunohistochemical 
analysis for CLAUDIN5 and KLF4 was performed on serial sections. Paraffin was 
removed with xylene and the sections were rehydrated in graded alcohol. Antigen retrieval 
was carried out using preheated sodium citrate solution for 50 minutes. Tissue sections 
were blocked with 5 % FBS in PBS for 60 minutes and incubated ON with primary 
antibodies. HRP-Polymer Kit (Biocare Medical, Pike Lane Concord, CA, USA) was used 
for the detection of antigens followed by a diaminobenzidine chromogen reaction 
(Peroxidase substrate kit, DAB, SK-4100; Vector Lab). All sections were counterstained 
with Mayer's hematoxylin. Images were acquired using an upright microscope (Olimpus 
BX51) using a 20x objective (UPlanFL N 20x NA=0.5). NIS-elements software was used 
for image analysis. BMP6 and PECAM1 immunohistochemistry on murine brain samples 
were performed as described above for CLAUDIN5 and KLF4. Antigen retrieval was 
carried out using sodium citrate for BMP6 and EDTA for PECAM1.  
 
5.18 Immunofluorescence analysis of the retina 
Retina immunostaining was carried out with littermates processed simultaneously 
under the same conditions. The retinas were dissected from fixed eyes in 2 % PFA for 2 
hours at 4 °C. After blocking/permeabilization in 1 % BSA, 5 % donkey serum and 0.5 % 
Triton-X100 in PBS ON, the retinas were washed in Pblec Buffer (1 % Triton X-100, 1 
mM CaCl2, 1 mM MgCl2 and 0.1 mM MnCl2 in PBS, pH 6.8) and incubated ON at 4 °C in 
Pblec buffer containing biotinylated isolectin B4 (IB4) and the primary antibodies. Then, 
the retinas were incubated with both fluorophore-conjugated secondary antibodies and 
with Alexa Fluor 488/555/647 streptavidin (Life Technologies) and mounted with ProLong 
Gold (Life Technologies). Confocal analysis was performed using a Leica TCS AOBS or a 
Leica TCS SP5 confocal microscope using the following objectives: 40x (HCX PL APO 
NA=1.25, oil) or 10x (HC PL FLUOTAR NA=0.3, dry). Leica Confocal Software was 
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used for the acquisition. The figures were prepared as described in “Immunofluorescence 
and histology” section. The vessel front density and vascular progression in the retinae 
were measured as previously described 269. All image analyses were carried out using the 
ImageJ software. Quantification of the nuclear pixel intensity was obtained by using the 
co-localization highlighter plug-in of ImageJ software. Mean intensity of co-localizing 
pixel per field has been calculated through ImageJ and normalized on the number of 
endothelial nuclei.  
 
 
5. 19 Intravenous injection of tracer and tracer detection  
Cadaverine conjugated to Alexa Fluor-555 (Invitrogen) was injected IP at the dose 
of 12.5 µg/g 2 hours before mice sacrifice (P13). Animals were then anesthezitazed with an 
intraperitoneal injection of Avertin (20 µl/g) in order to perform a 5 minutes perfusion with 
PBS. Brains were dissected and fixed in 4 % PAF ON at 4 °C. Cadaverine leakage in the 
brain was measured by evaluating mean fluorescence of brain images acquired under a 
stereomicroscope equipped with HBO 100 lamp and a Filter Set Lumar 43 HE. ImageJ 
software was used to calculate cadaverine mean fluorescence. 
 
5.20 Statistics 
Data are expressed as mean ± standard deviation (SD). Student’s two-tailed non-
paired t-tests were used to determine the statistical significance of the in vitro, ex-vivo and 
in vivo analyses. The significance level was set at P<0.05. For survival experiment, 
Kaplan-Meier curves were analyzed with the Mantel-Cox test. 
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6. RESULTS 
 
6.1 Establishment of a mouse model of CCM disease 
Over the past years numerous studies have provided new insights into CCM protein 
functions in vitro. However, a clear understanding of which signalling pathways are 
relevant in vivo to the etiology of the CCM disease is still lacking.  
To investigate the role of CCM1 in vivo in mice and circumvent the embryonic 
lethality of ubiquitous inactivation of the gene 270 we generated endothelial specific and 
inducible Ccm1 loss-of-function mice (EC-CCM1 KO mice) by crossing tamoxifen-
inducible Cdh5(PAC)-CreERT2 and Ccm1 floxed/floxed transgenic mice 260. Cdh5(PAC)-
CreERT2-Ccm1-floxed/floxed mice were then bred with Rosa 26-Enhanced Green 
Fluorescent Protein (EYFP) mice 271 to monitor tamoxifen-induced Cre/Lox recombination 
through the expression of EYFP. Animals were tamoxifen-injected at P1 and analyzed 
between P3 and P15. High gene recombination efficiency was verified by qRT-PCR in 
freshly isolated PECAM+ brain derived ECs, since Ccm1 transcript was reduced by more 
than 80% in EC-CCM1 KO pups analyzed at P12 in comparison to vehicle treated WT 
mice (Figure 11). Ccm1 deletion resulted in the development of several vascular lesions 
within the central nervous system and in the retina in all Ccm1-ablated mice (Figure 12 A 
and Figure 13). Cavernomas started to develop three days after treatment with tamoxifen 
and they progressively increased in number and size with time. The lesions were mostly 
concentrated in the cerebellum and presented comparable features to human CCM lesions. 
Indeed histology and immunofluorescence analysis showed that lesions were composed of 
dilated vessels (Figure 12 A, B) that, with time, formed multiple caverns with signs of 
vascular leakage and chronic accumulation of haemosiderin (Figure 12 B). At late stages 
of lesion development (>P12) we also observed a marked inflammatory and immune 
reaction around the vascular lesions previously reported in CCM patients 272, characterized 
by infiltration of macrophages Cd11b positive (Figure 12 C) and lymphocytes CD3 
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positive (Figure 12 D) that increased with lesion size (Figure 12 E). 5% of familial CCM 
patients present vascular lesions also in the retina 273. Consistenlty we observed that EC-
CCM1 KO animals presented CCM vascular malformations of retinal vascular plexus  in 
 
 
 
 
 
 
 
 
Figure 11 - High Ccm1 recombination mediated by tamoxifen-induced Cre-recombinase activity in 
EC-CCM1 KO brains.  
qRT-PCR analysis of Ccm1 in freshly isolated brain PECAM+ ECs from wild-type and EC-CCM1 KO mice. 
Data are mean ± SD from three independent observations. ***P< 0.001. 
 
in both eyes (Figure 13 A, B). EYFP staining of the retina of EC-CCM1 KO mice 
confirmed also in this context the high recombination efficiency after tamoxifen treatment 
69, 274, 275  (Figure 13 B). Consistent with what was observed in human retinal CCM lesion by 
angiography 73, CCM lesions were restricted to the venous-capillary bed that can be easily 
distinguished by morphological analysis of EC-CCM1 KO retinas (Figure 13 A). 
Furthermore, using the same gene targeting strategy (Ccm2 or Ccm3 floxed/floxed animals 
crossed with Cdh5(PAC)-CreERT2 mice), tamoxifen-induced endothelial specific deletion 
of either Ccm2 or Ccm3 at P1 resulted in CCM malformations in the CNS and in the retina 
69, 92. As in patients, the morphology of the cavernomas was indistinguishable in the 
absence of any of the three Ccm genes, with Ccm3 endothelial deficiency showing the 
most severe phenotype 69. 
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Overall these data demonstrate that this mouse model reproduced to a large extent 
human CCM features with a complete penetrance and high reproducibility, thus being 
suitable both for deciphering the molecular mechanisms involved in the different phases of 
development and progression of the disease and for the evaluation of future therapeutic 
agents.  
 
Figure 12 - Endothelial Ccm1 deletion at P1 in the mouse results in brain vascular malformations 
comparable to human CCM lesions.  
A) Representative images of WT and EC-CCM1 KO mouse brains after dissection at P12. EC-CCM1 KO 
mice show cerebellar vascular lesions (black arrows). Right panel: cavernomas visualised by H&E staining. 
B) Left and middle panels: mulberry–shaped lesions (white arrows); PECAM1 (red) is used to identify blood 
vessels. Right panel: histology showing accumulation of haemosiderin (black arrowheads) in CCM. C-D) 
Immune cells infiltration in CCM lesions: immunofluorescence showing accumulation of CD11b-positive 
macrophages (green) and CD3-positive T-lymphocytes (green) in cavernomas of EC-CCM1 KO mice. 
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PECAM1 marks ECs. Cell nuclei are visualised with DAPI. E) Quantification of leukocyte infiltration in 
CCM lesions (classified in three groups based on their size) in a total of 8 EC-CCM1 KO mice. Scale bar: 
500 µm (A, left and middle panels), 100 µm (A, right panel), 60 µm (B-D). 
 
 
 
 
Figure 13 - Endothelial Ccm1 deletion at P1 in the mouse results in retinal vascular malformations 
comparable to human CCM lesions.  
A) Upper panels: representative images of WT and EC-CCM1 KO mouse retinas upon dissection at P15; 
Lower panels: PECAM1 staining of WT and EC-CCM1 KO mouse retinas. V= vein. B) Analysis and 
quantification of Ccm1 recombination in retinal endothelium of WT and EC-CCM1 KO mice at P15 by 
EYFP staining (red). Isolectin B4 (IB4) (green) marks the endothelium. Dotted line indicates the lesion area. 
Data are representative of 3 independent observations (n = 5 for genotype from 2 different litters). Scale bars: 
500 µm (A, left and middle); 200 µm (I, upper panels); 100 µm (A, right; I, lower panels; J); 60 µm (B-G);  
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6.2 CCM vascular lesions are lined by endothelial cells with a mesenchymal and stem-
like phenotype 
Since CCM proteins interact with critical components of adherens junction (AJ), to 
investigate the phenotype of ECs lining the vascular lesions we first analyzed the 
expression and the organization of junctional proteins. The key AJ protein VE-cadherin 
expressed presented a disorganized distribution outside cell-to-cell contacts in the ECs 
forming the lesion (Figure 14 A, left and middle panels) as compared with ECs lining the 
pseudo-normal vessels surrounding the lesion where it appeared to be perfectly localized at 
intercellular cleft (Figure 14 A, right panel). Conversely N-cadherin, a pro-migratory 
cadherin that was previously reported to be weakly expressed at cell-to-cell junctions in 
normal quiescent vessels 12, was remarkably upregulated in the CCM lesion (Figure 14 B). 
Cadherin switch (downregulation of VE- and upregulation of N-cadherin) has been 
previously associated to EndMT 276, 277. During this transition ECs lose progressively the 
expression and proper localization of endothelial specific molecules and acquire the 
expression of mesenchymal and stem-like markers as well as a higher proliferative and 
migratory capability. To further prove the hypothesis that EndMT occurred in Ccm1 null 
ECs, we evaluated the expression of a number of mesenchymal markers, such as SLUG 
(also known as SNAI2), ID1 and αSMA 122, 278, 279. Interestingly we found that these 
proteins were absent in pseudo-normal peri-lesion vessels, whereas they were strongly 
upregulated in the ECs forming the vascular malformation (Figure 14 C-E). In addition, 
SCA1 and CD44, which are widely accepted stem cell-markers in normal and tumor 
tissues 280, 281 were also highly expressed in ECs lining the lesions in comparison to ECs of 
the surrounding normal vessels (Figure 14 F, G). Importantly, KLF4, a zinc finger 
transcription factor involved in the regulation of many endothelial biological processes 
such as proliferation, differentiation, development, inflammation and apoptosis 222-228, was 
the only EndMT related marker analyzed whose expression was increased both in the 
lesion and the normal vasculature of EC-CCM1 KO mice (Figure 14 H), while it was 
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poorly expressed in brain vessels of WT mice (Figure 14 I). Interestingly, the upregulation 
of mesenchymal and stem-cell markers in the absence of Ccm1 was confirmed in freshly 
isolated PECAM+ brain EC isolated by EC-CCM1 KO mice (Figure 15). 
Thus, our results showed that Ccm1-ablation in vivo causes a general modification 
of the endothelial phenotype conferring mesenchymal and stem-like traits to these cells. 
 
Figure 14 - Ccm1 deletion causes EndMT in vivo.  
A) VE-cadherin expression (green) in normal vessels and vascular lesions (indicated by dotted area) of EC-
CCM1 KO mouse brains. DAPI visualizes cell nuclei. Red arrowheads denote VE-cadherin out of the 
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junctions. Central and right panels show higher magnification. B) N-cadherin staining (green) in lesion and 
in normal peri-lesion vessels (PECAM1, red) of EC-CCM1 mouse brains. PECAM1 staining identifies ECs. 
C-H) Mesenchymal and stem-cell markers (green) in the vascular lesions (PECAM1, red) of EC-CCM1 KO 
mouse brains. PECAM1 marks ECs. DAPI visualizes cell nuclei.  I) KLF4 expression (green) in WT mouse 
brain. Data are representative of three independent observations (n= 5 for each genotype from two different 
litters). White arrowheads highlight normal peri-lesion vessels; dotted areas denote vascular lesions. Scale 
bars: 50 µm (A, left); 60 µm (B-I); 8 µm (A, middle and right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 - Ccm1 deletion causes EndMT marker mRNA upregulation in vivo.   
qRT-PCR of EndMT markers in freshly isolated PECAM+ brain ECs (fold difference in gene expression in 
EC-CCM1 KO- versus WT-derived ECs). Data are mean ± SD from three independent observations. 
*P<0.05; **P<0.01; ***P<0.001.  
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6.3 Loss of Ccm1 expression induces EndMT transition in a cell-autonomous way 
To directly investigate whether EndMT induction in EC-CCM1 KO mouse lesions 
is a cell-autonomous process, ECs were isolated from lungs of Ccm1 floxed/floxed mice, 
immortalized with PmT antigen and then treated with TAT-Cre to induce gene 
recombination. TAT-Cre treatment resulted in the complete loss of Ccm1 at both mRNA 
and protein level in vitro (Figure 16 A). The absence of CCM1 caused a switch in 
phenotype of cultured ECs, which recapitulated, to a large extent, the phenotype observed 
in vivo in EC-CCM1 KO mice. In Ccm1 null ECs both VE-CADHERIN and the tight 
junctions protein CLAUDIN-5 were significantly reduced while a large number of 
representative mesenchymal markers such as ID1, FSP1, VIMENTIN, FIBROBECTIN, L1, 
MMP14 were strongly increased 114, 282 (Figure 16 B, C). Interestingly, we also observed an 
increased expression of stem cell markers CD44, SCA1, KLF4 in CCM1 KO ECs (Figure 
16 B, C). 
To exclude the contribution of any culture contaminant to the increased expression 
of EndMT markers observed in the absence of Ccm1, we performed a co-staining analysis 
of a representative set of EndMT markers together with a specific endothelial molecule in 
WT and CCM1 KO ECs. As depicted in Figure 17 (A-C), endothelial cultures were 100% 
pure and the increased expression of either FSP1 (Figure 17 A), SCA1 (Figure 17 B) or 
KLF4 (Figure 17 C) was always observed in VE-CADHERIN positive CCM1 KO ECs, 
thus proving that cells that acquired a mesenchymal phenotype had an endothelial origin.  
Since CCM is a disease that affects specifically brain microvasculature, we moved 
to confirm our findings in a more physiological cellular model such as cultured primary 
brain derived ECs (BMECs). ECs isolated from the brain of both WT or Ccm1 
floxed/floxed mice were seeded in culture and then treated with TAT-cre recombinase to 
induce recombination of floxed alleles in vitro. As depicted in Figure 18 A, a good but not 
complete reduction of CCM1 protein levels was obtained. Inhibition of CCM1 expression 
in BMECs recapitulated the data observed in lung derived CCM1 KO ECs since several  
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mesenchymal and stem-cell markers were strongly increased (Figure 18 A, B) while VE-
CADHERIN organization at cell-to-cell junctions was dismantled in CCM1 KO compared 
to WT BMECs (Figure 19). However, due to limitations in both the supply of primary ECs 
from the brain and their extremely limited mitotic index, most of the analyses were 
performed in lung derived cell lines to understand the molecular alteration occurring in 
Ccm1 null ECs and finally validated in BMECs. 
 
 
 
Figure 16 - In vitro endothelial Ccm1 gene ablation in lung derived ECs induces a mesenchymal and 
stem cell-like phenotype.  
A) qRT-PCR of Ccm1 in lung derived WT and CCM1 KO ECs recombinated in vitro. B-C) qRT-PCR (B) 
and WB (C) analysis of EndMT-realted marker expression in WT and CCM1 KO ECs. qRT-PCR data are 
means ± SD from three independent experiments.*P<0.05; **P<0.01; ***P<0.001. WB results are 
representative of three independent observation. 
 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 - Co-expression of VE-CADHERIN and representative EndMT markers in CCM1 KO ECs.   
A) Confocal analysis of VE-CADHERIN (red) and FSP1 (green) in cultured lung derived WT and CCM1 
KO ECs. B) Confocal microscopy of VE-CADHERIN (red) and SCA1 (green) in the cell lines reported in 
A.  C) Immunofluorescence of VE-CADHERIN (red) and KLF4 (green) in the cell lines reported in A. These 
data are representative of three independent observations. Scale bar: 30 µm 
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Figure 18 - Endothelial Ccm1 gene ablation induces a mesenchymal and stem cell-like phenotype in 
vitro in brain derived ECs (BMECs).  
A) WB of CCM1 and mesenchymal/stem cell markers in WT and CCM1 KD BMECs. Tubulin was the 
loading control. B) qRT-PCR analysis of several mesenchymal and stem cell expression in WT and CCM1 
knocked-down (KD) BMECs. Means ± SD from three independent experiments. Fold changes are relative to 
WT BMECs *P<0.05; **P<0.01; ***P <0.001. 
 
 
 
 
 
 
 
 
 
Figure 19 - Alteration of VE-CADHERIN localization in CCM1 KO BMECs. 
Confocal microscopy analysis of VE-CADHERIN in WT and CCM1 KD BMECs. Arrows: normal VE- 
CADHERIN localisation at cell-to-cell junctions. Arrowheads: altered VE-cadherin distribution. DAPI 
visualizes nuclei. Scale bar: 10 µm.  
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Cell-transition to a mesenchymal phenotype is usually accompanied by increased 
proliferation, enhanced migratory capacity and invasiveness 114. Consistently we found that 
the Ccm1 gene ablation caused a significant enhancement of EC proliferation both in vitro 
and in vivo at the level of vascular lesion, as determined by the staining of the 
proliferation-associated nuclear protein Ki-67 283 (Figure 20 A-C). In addition, to test 
migratory capacity of WT and CCM1 KO ECs, we performed a spheroid assay. A certain 
number of ECs seeded in a methylcellulose-based medium collagen matrix were allowed 
to form a 3D spheroid. These spheroids were then transferred in a collagen matrix and 
stimulated with pro-angiogenic factors such as VEGFA and FGF-2. In line with previous 
observations obtained in different experimental settings 105, CCM1 KO ECs showed a 
greater invasive/sprouting capacity in response to VEGF-A/FGF-2 (Figure 21). 
 
 
Figure 20 - Ccm1 gene ablation increases cell proliferation in vitro and in vivo.  
A) Proliferation of WT and CCM1 KD BMECs was evaluated using Ki-67 staining (green). A representative 
image was shown. The number of Ki-67 positive cells for each analysed field was indicated in the chart (n=8 
fields were analyzed for each cell type). Means ± SD from three independent experiments. ***P<0.001. B-C) 
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EC proliferation in brain sections (B) and retinas (C) of WT and EC-CCM1 KO mice (P13) analysed by Ki-
67 staining. The dotted area showed a vascular lesion formed by proliferating ECs, while arrowheads 
indicated very limited mitosis in normal brain vessels (PECAM1 staining marks ECs, red; Ki-67, green). 
Scale bars: 50 µm 
 
 
 
 
 
 
 
 
 
Figure 21 - Ccm1 null ECs shows increased cell migration in vitro.  
WT and CCM1 KO lung EC migration in a 3D collagen-based matrix system visualized by actin staining 
(red). Quantification of the covered migration distance has been represented as fold difference relative wo 
WT ECs. Data represent the means ± SD from three independent experiments. ***P<0.001. Scale bars: 100 
µm. 
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6.4 Activation of the TGF-β signalling contributes to EndMT in CCM1 null ECs 
TGF-β/BMP signalling pathway has been suggested as major inducer of EndMT in 
several physiological and pathological conditions 284. We therefore investigated whether 
the EndMT switch observed in CCM1 deficient endothelium was due to an alteration of 
this signalling pathway. Upon ligand binding, a heterotetrameric complex of type I and II 
receptors phosphorylates the cytosolic mediator SMADs that, in turn, translocate into the 
nucleus to regulate the transcription of specific target genes in complex with several 
transcription factors 126. As shown in Figure 22 A, both SMAD1/5/8 and SMAD3 
phosphorylation was enhanced in CCM1 null ECs. Moreover, in agreement with a possible 
increased transcriptional activity, immuno-staining revealed a stronger nuclear localization 
of both pSMAD1 and pSMAD3 in CCM1 KO compared to WT ECs (Figure 22 B). 
To investigate the involvement of the activated TGF-β/BMP pathway in the 
EndMT occurring in CCM1 null ECs, we treated WT and CCM1 KO ECs for 4 days with 
LY-364947, a selective ATP-competitive of Transforming Growth Factor-β Type I 
receptor kinase (TβRI ALK5) 285. The inhibitor abrogated the increased SMAD1 and 3 
phosphorylation observed in CCM1-null ECs (Figure 23 A). Most importantly, LY-364947 
treatment of CCM1 KO ECs restored in part the normal EC phenotype by significantly 
decreasing the expression of thr EndMT related transcripts Fsp1, Klf4, Cd44, Id1 while up-
regulating Claudin5 (Figure 24). Furthermore, we found that LY-364947 inhibited the 
abnormal proliferation of CCM1 KO ECs (Figure 25).  
Overall these results showed that in vitro loss of Ccm1 led to a hyperactivation of 
TGF-β/BMP signalling that, in turn, was responsible for the EndMT phenotype observed 
in CCM1 KO ECs. 
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Figure 22 - Loss of Ccm1 induces TGF-b/BMP signalling activation in ECs.  
A) WB analysis of SMAD1/5/8 and SMAD3 phosphorylation and total amount in WT and CCM1 KO ECs. 
Tubulin was used as loading control. WB results are representative of three independent observations. B) 
Immunofluorescence analysis of pSMAD1 and pSMAD3 in WT and CCM1 KO lung derived ECs. Images 
are representative of three independent experiments. Scale bar: 50 µm. 
 
 
 
 
 
 
 
 
 
 
Figure 23 - The ALK5 inhibitor LY-364947 effectively inhibits SMAD signalling activation in CCM1 
KO ECs.  
WB analysis of pSMADs after LY-364947-mediated TGF-β pathway inhibition. Vinculin was used as 
loading control. Images are representative of three independent experiments. 
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Figure 24 - Ccm1 deletion induces EndMT via TGF-b/BMP signalling activation.  
qRT-PCR analysis of the effect of the treatment of LY-364947 on the expression of Klf4, Claudin-5, Cd44, 
Id1 and Fsp1 in WT and CCM1 KO ECs. Data represent the means ± SD from three independent 
experiments. *P<0.05; **P<0.01; ***P<0.001. 
 
 
 
 
 
 
 
 
 
 
Figure 25 - Inhibition of TGFβ /BMP signalling decreases the proliferation rate of CCM1 KO ECs.  
Proliferation of vehicle- or LY-364947-treated CCM1 KO ECs  quantified by counting Ki-67-positive cells 
(n=8 fields for each treatment). Data are mean ± SD from three independent experiments. *P<0.05; **P<0.01. 
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6.5 TGF-β/BMP signalling and EndMT are critical events for development and 
progression of CCM lesions 
To investigate the role of the activation of TGF-β/BMP signalling in the 
appearance and progression of CCM pathology, we tried to inhibit this pathway in vivo. To 
this purpose WT and EC-CCM1 KO pups were treated daily with LY-364947 two days 
after tamoxifen injection (performed at P1) and then sacrified at P13 to evaluate the 
number/size of vascular lesions together with the inhibition of pSMAD-depedent 
signalling. Pilot experiments using doses of this inhibitor reported in literature to be active 
in vivo (5mg/kg or 10 mg/kg) revealed only a partial inhibition of the TGF-β/BMP 
signalling that was accompanied by a mild reduction in lesion burden of EC-CCM1 KO 
mice (Figure 26 A, right panel). Therefore in order to achieve a more robust inhibition of 
TGF-β/BMP signalling we decided to combine the treatment of LY-364947 with SB-
431542, another inhibitor of pSMAD signalling reported to be very effective in vivo 293. 
The animals were subjected to a daily treatment with 10mg/Kg of LY-364947 plus 
10mg/kg of SB-431542 two days after tamoxifen injection (performed at P1). As expected, 
vehicle-treated mice presented at P13 large and frequent cerebellar lesions, with associated 
diffuse hemorrhagic zones. In contrast, LY-364947/SB-431542-treated pups showed a 
macroscopic reduction in the number and extension of the lesions and associated 
hemorrhage (Figure 26 A). Since CCM lesions are higly permeable 286, we tested also the 
effect of TGF-β/BMP pathway inhibition on vascular permeability by injecting IP 
fluorescent cadaverine two hours before mouse sacrifice at P13 287. As reported in Figure 
26 B, Ccm1 depletion resulted in marked cadaverine extravasation that was almost 
abrogated by LY-364947/SB-431542 treatment, thus suggesting that inhibition of the TGF-
β/BMP pathway not only reduced number and size of lesions, but also restored a normal 
BBB function by strongly decreasing the marked brain vascular leakage observed in EC-
CCM1 KO mice. To test whether LY-364947/SB-431542 treatment was able to effectively 
inhibit TGF-β/BMP signalling dependent EndMT in vivo, we analyzed the phosphorylation 
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state of SMAD proteins and the expression of some representative EndMT/stem cell 
markers by immuno-staining. As shown in Figure 27 (A-C), SMAD3 phosphorylation was 
markedly downregulated in LY-364947/SB-431542-treated EC-CCM1 KO pups as well as 
KLF4 and ID1 expression.  
Taken together these data showed that pharmacological inhibition of TGF-β/BMP 
signalling pathway was able to reduce lesion burden and EndMT in vivo in Ccm1 null mice. 
 
 
Figure 26 - TGF-b/BMP signalling inhibition reduces number and size of lesions and vessel leakage in 
CCM1 null mice.  
A) Representative images of either WT or EC-CCM1 KO vehicle-treated and LY-364947/SB-431542-treated 
mouse brains after dissection (left panels) and quantification of number and size of lesions (right panel) (n = 
5 in each group from three different litters). B) Whole brains photographed after fluorescent cadaverine 
injection of mice treated ad reported in A (left panels) and quantification of the recovered fluorescence 
(right). Data are mean ± SD from three independent experiments. *P<0.05; **P<0.01; ***P<0.001. Scale 
bar: 500 µm. 
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Figure 27 - TGF-β/BMP signalling inhibition reduces the mesenchymal phenotype of ECs lining CCM 
lesions in vivo.  
(A-C) Confocal analysis of pSMAD3, KLF4 and ID1 in the cavernomas of vehicle- and LY-364947/SB-
431542-treated EC-CCM1 KO mice. (PECAM1 identifies ECs, green; KLF4, ID1, pSmad3 red; DAPI 
visualized nuclei, blue). Images are representative of three independent experiments. Scale bars: 50 µm (A) 
30 µm (B, C). 
 
 
 
 
 
 
A 
B C 
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6.6 Autocrine production of BMP6 in CCM1 null ECs induces pSMAD signalling 
activation and EndMT 
In order to understand the molecular mechanism through which loss of CCM1 
induced TGF-β/BMP signalling and EndMT, we investigated whether ablation of 
CCM1 could modulate the expression of TGF-β/BMP superfamily ligands, receptors 
and other critical components of this signalling pathway (such as the common partner 
SMAD4 or the known negative regulators such as SMURFs). Among all the genes 
examined only Bmp6 ligand was significantly increased after CCM1 ablation in 
cultured ECs (Figure 28 A, B). Interestingly Bmp6 upregulation was confirmed also in 
vivo in EC-CCM1 KO mice in comparison to WT animals as verified by qRT-PCR 
analysis performed on RNA extracts of PECAM1 positive freshly isolated brain ECs 
(Figure 28 C). BMPs are secreted proteins that, upon binding to their receptors, signal 
through both autocrine and paracrine mechanisms by phosphorylating SMADs 289. 
Since BMPs have been associated with EMT 290, we hypothesized that the increased 
amount Bmp6 could be responsible of TGF-β/BMP signalling activation and EndMT in 
CCM1 null ECs. In agreement with this hypothesis the treatment of WT ECs with 
recombinant BMP6 resulted in an increased SMADs phosphorylation (Figure 29) 
together with a significant induction of mesenchymal and stem cell markers and a 
reduction of claudin5 expression (Figure 30). In order to prove that increased SMAD 
phosphorylation and EndMT marker upregulation in CCM1 KO ECs were BMP6-
dependent, we performed siRNA mediated knockdown of Bmp6 in vitro. Interestigly, 
Bmp6 silencing resulted in decreased phosphorylation state of both SMAD1 and 
SMAD3 proteins, with a concomitant reduction of the mesenchymal/stem cell markers 
upregulated in the absence of CCM1 (Figure 31).  
Altogether our data suggested that loss of CCM1 increased Bmp6 expression that, 
in turn, strongly contributed to the observed EndMT. 
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Figure 28 - Bmp6 expression is upregulated upon loss of Ccm1 in vitro and in vivo  
A) TGFb/BMP superfamily ligand gene expression profile in WT and CCM1 KO ECs (fold changes in 
CCM1 KO versus WT). Data are mean ± SD from three independent experiments. B) qRT-PCR analysis of 
Alk1, Alk5 and Tgf-brII in WT and CCM1 KO ECs. Means ± SD from three independent experiments. C) 
qRT–PCR analysis of Bmp6 in freshly isolated brain ECs from WT and EC-CCM1 KO mice. Data are mean 
± SD from three independent observations. *P< 0.05;**P< 0.01; ***P< 0.001.  
 
 
 
 
 
 
 
 
 
 
Figure 29 - BMP6 stimulation induces SMAD phosphorylation in WT ECs.  
WB analysis of SMAD1 and SMAD3 phosphorylation upon 4 hours of treatment of WT ECs with 100ng/ml 
of recombinant BMP6. Vinculin was the loading control. Images are representative of three independent 
observations.  
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Figure 30- BMP6-mediated upregulation of mesenchymal and stem-cell makers in WT ECs.   
qRT-PCR analysis of mesenchymal and stem-cell markers upon 96 hours of recombinant BMP6 stimulation. 
Fold changes in gene expression in BMP6-treated versus control. Data are mean ± SD from three 
independent experiments. *P <0.05;**P<0.01; ***P<0.001.  
 
 
Figure 31 - Ccm1 deletion induces TGFb/BMP signalling activation and EndMT via BMP6 
upregulation.  
A) Bmp6 relative mRNA levels in both Bmp6 and control (ctrl) short interfering RNA siRNA-treated CCM1 
KO ECs. Data are mean ± SD from three independent experiments. B) WB analysis of SMAD 
phosphorylation in Bmp6 and control (ctrl) short interfering RNA (siRNA)-treated CCM1 KO ECs. Vinculin 
was the loading control. WB data are representative of three experiments. C) qRT-PCR of EndMT markers in 
Bmp6 and control siRNA-treated CCM1 KO ECs. Fold change in Bmp6 siRNA versus control. Data are 
mean ± SD from three independent experiments. *P <0.05;**P<0.01; ***P<0.001. 
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6.7 KLF4 expression is increased in murine models of CCM disease and in CCM 
patients 
In order to identify upstream regulators of Bmp6 expression and TGFβ/BMP 
signalling activation we performed a global gene expression analysis of CCM1 KO 
BMECs in comparison to WT using the Affymetrix chip platform. When ranked according 
to fold change, the transcription factor KLF4 emerged as one of the most significantly 
upregulated gene upon Ccm1 gene recombination (Appendix Table 1). As reported above 
KLF4 was the only analyzed EndMT marker poorly expressed in brain vessels of WT mice 
(Figure 15 I), while strongly upregulated not only in ECs lining the cavernae of any size 
but also in peri-lesion vessels that still did not show any abnormal phenotype at the time of 
the analysis (Figure 15 H). This preliminary observation led us to hypothesize KLF4 up-
regulation upon loss of Ccm1 as an event preceding the formation of vascular lesions, thus 
suggesting KLF4 as a good candidate for the induction of both TGFβ/BMP activation and 
EndMT. Further characterization of KLF4 expression in vivo revealed that KLF4 was 
poorly expressed in the retinal vessels of WT mice, while its expression was strongly 
increased in lesion and peri-lesion vessels located both at the centre and at the periphery of 
the retina vasculature in EC-CCM1 KO mice (Figure 32). Klf4 upregulation was an early 
event during CCM pathogenesis since it appeared at P3, soon after Ccm1 gene 
recombination, in freshly isolated ECs from EC-CCM1 KO brains compared to WT brain 
ECs and it remained high during the disease progression (Figure 33). The increase in KLF4 
and its pattern of expression in vivo in ECs lining the lesions as well as in pseudonormal 
peri-lesion vessels were further confirmed in tamoxifen-inducible endothelial-specific 
Ccm2 (EC-CCM2 KO) and Ccm3 (EC-CCM3 KO) loss-of-function mice 69, 92 (Figure 34). 
Consistently, in vitro siRNA mediated knockdown of any one of the three Ccm genes in 
cultured ECs resulted in Klf4 upregulation (Figure 35). Interestingly, the increase in KLF4 
was observed also in cultured human brain ECs (hCMEC/D3) upon Ccm1 silencing 
(Figure 36) and, most importantly, immunohistochemical analysis of tissue biopsies of 
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CCM1 familial and sporadic patients confirmed the increase of KLF4 nuclear signal in 
ECs lining the cavernomas in comparison to normal peri-lesion vessels used as internal 
control (Figure 37). 
Taken together, these data showed that KLF4 upregulation is an hallmark of murine 
models of CCM disease as well as of the human pathology. KLF4 expression was already 
increased at early stages during the development and progression of the disease and is 
detectable also in pseudo-normal peri lesion vessels, thus prompting us to investigate a 
possible causal role of KLF4 during CCM pathogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 - KLF4 expression is increased in the retina of EC-CCM1 KO mice.  
KLF4 staining (magenta) in WT and EC-CCM1 KO mouse retinas at P7. ECs are marked by IB4 (green). 
Data are representative of three independent observations (n = 4 for each genotype from 2 different litters). 
Scale bars: 50 µm. 
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Figure 33 - Klf4 is upregulated at an early stage of CCM disease progression in vivo. 
qRT-PCR analysis of Klf4 at different times (P3, P5 and P9) during disease progression after tamoxifen-
induced Ccm1 recombination in freshly isolated brain ECs derived from WT and EC-CCM1 KO pups. Data 
are mean ± SD (n=3 in each group). Fold changes are relative to WT animals. * P<0.05, **P<0.01 
 
 
Figure 34 - Endothelial-specific ablation of either Ccm2 or Ccm3 induces KLF4 upregulation in the 
brain vasculature.  
Representative immunostaining of KLF4 (red) in combination with PECAM1 (green, to identify ECs) in 
brain sections of EC-CCM2 KO, EC-CCM3 KO mice and their relative WT controls (one out of three 
performed). Cell nuclei are visualized with DAPI; dotted area highlights lesion area. Scale bars: 50µm. 
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Figure 35 - Silencing of any of the three Ccm genes leads to Klf4 upregulation in vitro.  
qRT-PCR analysis of Klf4 in lung derived WT ECs transfected with either siRNA directed to anyone of the 
three Ccm genes or control siRNA (siCTRL). Data are presented as mean ± SD (n=3). Results are shown as 
fold changes relative to control siRNA treated ECs. **P<0.01; ***P<0.001. 
 
 
 
 
 
 
 
 
Figure 36 - KLF4 upregulation upon Ccm1 silencing is conserved in brain ECs of human origin.  
Left panel: Ccm1 and Klf4 relative mRNA levels in Ccm1 (siCCM1) and control (siCTRL) siRNA-treated 
hCMEC/D3. The result was shown as fold changes in gene expression in siCCM1-treated versus control. 
Data are presented as mean ± SD (n=3). ***P<0.001. Right panel: WB analysis of KLF4 amount in both 
siCCM1- and siCTRL-treated hCMEC/D3. Tubulin was used as loading control. KLF4 normalized over 
tubulin was quantified by densitometry scan. These data are representative of three independent observations.  
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Figure 37 - The increase of KLF4 in ECs lining the cavernomas is observed in familial and sporadic 
CCM patients.  
A) Immunohistochemical analysis performed on serial sections of brain tissue derived from a familial CCM1 
patient. Hematoxilin and Eosin (left panels), CLAUDIN5 (central panels) and KLF4 (right panels) stainings 
were performed in brain lesion and normal peri-lesion vessels as control brain tissue. Higher magnification 
images of KLF4 staining of the boxed regions are shown. CLAUDIN5 identifies ECs and arrowheads mark 
endothelial KLF4 positive nuclei. Scale bar: 100 µm. These data are representative of three independent 
observations. B) Immunofluorescence analysis of KLF4 expression (red) on sections of brain tissue derived 
from a sporadic CCM patient. Arrowheads indicate KLF4 positive EC nuclei; arrows highlight KLF4-
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negative EC nuclei. Images are representantive of three independent observations. Single staining for KLF4 
of boxed areas is shown on the right. PECAM1 (green) marks endothelial cells. DAPI visualises cell nuclei. 
Arrows identify peri-lesion pseudo-normal vessels. Scale bar: 30 µm.  
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6.8 KLF4 is a causative factor for the development and progression of CCM lesions 
In order to study the role of KLF4 in the development of CCM malformations, we 
generated both endothelial-specific tamoxifen-inducible Ccm1 and Klf4 double loss of 
function mice (EC-CCM1 KO KLF4 KO) and Ccm1 loss of function mice heterozygous 
for Klf4 (EC-CCM1 KO KLF4 HET) 219, 260, 291. As previously described, the newborn mice 
were tamoxifen-injected at P1 to induce expression of Cre-recombinase and endothelial-
specific gene ablation. The pups were analyzed within two weeks upon gene 
recombination. Ccm1 deletion was comparable in freshly isolated brain ECs derived from 
EC-CCM1 KO, EC-CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 KO animals at P12 
(Figure 38). Klf4 expression was almost completely abrogated in the double KO pups as 
verified by qRT-PCR (Figure 38) and immunofluorescence (Figure 39 B). EC-CCM1 KO 
KLF4 KO mice showed a macroscopic reduction in the number, size and extension of the 
CCM vascular malformations in the cerebellum (Figure 39 A-C). Quantification of the 
number of cavernomas of any size revealed a 70% reduction in EC-CCM1 KO KLF4 KO 
in comparison to EC-CCM1 mice (Figure 39 C). Very interestingly, abrogation of Klf4 
also reduced by 75% mouse mortality observed in Ccm1 deficient pups (Figure 40). 
Notably, in EC-CCM1 KO KLF4 HET mice Klf4 expression was almost comparable to 
WT mice as assessed by qRT-PCR while immunofluorescence analysis revealed that 
endothelial cells lining vascular lesions of EC-CCM1 KO KLF4 HET mice showed a 
marked KLF4 positivity comparable to the one observed in EC-CCM1 KO mice (Figure 38 
and Figure 39 B). EC-CCM1 KO KLF4 HET animals display a milder phenotype 
characterized by both a partial reduction in lesion burden (that anyway lacked a proper 
quantification) and a 33% increase in overall mice survival, thus suggesting that the effect 
of KLF4 activity was gene dosage dependent (Figure 39 A-B and Figure 40). 
Since EC-CCM1 KO animals developed vascular malformations also at the 
periphery of the retinal vascular plexus 69, 291 (Figure 13 A and B), we then analyze the 
morphology of the retinal vessels by isolectin B4 staining upon Klf4 gene deletion. Loss of 
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either one or both Klf4 alleles significantly reduced both the area and the vascular density 
at the front of malformed Ccm1 deficient retinal vessels (Figure 41 C and D), while the 
advancing of the vasculature across the vitreal surface (vascular progression) was not 
modified by the absence of KLF4 (Figure 41 E). To date no studies in literature analyzed 
the retinal vascular plexus upon endothelial-specific Klf4 gene deletion. To this purpose we 
generated inducible endothelial-specific KLF4 KO (EC-KLF4 KO) mice by crossing 
tamoxifen-inducible Cdh5(PAC)-CreERT2 and Klf4 floxed/floxed transgenic mice. The 
newborn mice were tamoxifen-injected at P1 and then analyzed at P6, a stage during which 
endothelial cells are actively expanding across the superficial layer of the retina 292. As 
shown in Figure 42, abrogation of Klf4 expression per se did not significantly alter the 
vasculature in term of vascular progression, number of branching points and tip cells at the 
leading edge of the plexus. 
In conclusion, our data indicate that KLF4 was strongly required for the 
development and progression of brain and retina cavernomas in the absence of Ccm1.  
 
 
 
 
 
 
 
 
Figure 38 - Recombination efficiency of Ccm1 and Klf4 in the brain vasculature of EC-CCM1 KO, EC-
CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 KO mice.  
qRT-PCR of both Ccm1 and Klf4 performed in freshly isolated brain ECs derived by WT, EC-CCM1 KO, 
EC-CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 KO pups at P12. Data are mean ± SD (n=3 for each 
genotype). Fold difference in gene expression are relative to WT mice. *P<0.05; ** P<0.01; ***P<0.001.  
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Figure 39 - KLF4 is determinant for CCM development and progression in vivo.  
A) Representative images of WT, EC-CCM1 KO, EC-CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 KO 
mouse brains at P12 (n=5 for each genotype). Scale bar: 500 µm. B) Representative confocal analysis of VE-
CADHERIN (green) and KLF4 (red) in vascular lesions (dotted area) and pseudo-normal cerebellar vessels 
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(white arrowheads) of WT, EC-CCM1 KO, EC-CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 KO (n=4 
in each group). VE-CADHERIN identifies ECs; DAPI visualizes nuclei. Scale bar: 50 µm. C) Quantification 
of number and size of vascular lesions in the cerebellum of  both EC-CCM1 KO and EC-CCM1 KO KLF4 
KO mice at P12. Columns represent means ± SD (n=4 for each genotype from 2 litters). *P<0.05; ** P<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 - Loss of Klf4 stringly increases survival in Ccm1 null mice.  
Kaplan–Meier survival curve of WT, EC-CCM1 KO, EC-CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 
KO mice (n=8 for each group). P<0.001. 
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Figure 41 - Klf4 is critical for cavernoma development in the retina in the absence of Ccm1.  
A) Isolectin B4 staining (IB4, used to identify vasculature) on WT, EC-CCM1 KO, EC-CCM1 KO KLF4 
HET and EC-CCM1 KO KLF4 KO retinae at P12. Dotted area highligths macroscopic differences in the 
extension of CCM lesion area between EC-CCM1 KO, EC-CCM1 KO KLF4 HET and EC-CCM1 KO KLF4 
KO mice. Images are representative of 5 mice for each genotype. B) Representative immunostaining (one out 
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of three performed) for KLF4 (light blue) in the retinae of WT, EC-CCM1 KO and EC-CCM1 KO KLF4 KO 
mice. Vasculature at the periphery of the retina is shown after isolectin B4 staining (red). C-E) Quantification 
of several vascular parameters in retinae from WT, EC-CCM1 KO, EC-CCM1 KO KLF4 HET and EC-
CCM1 KO KLF4 KO mice at P12. Data are mean ± SD (n=5 for each genotype from 3 different litters). C) 
Percentage of retinal area covered by vascular lesions. D) Vascular front density at the leading edge of the 
plexus. E) Average distance covered by the growing vessels measured as vascular progression. Scale bar: 500 
µm (A), 60 µm (B).**P<0.01, ***P<0.001 
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Figure 42 - The vasculature of the retina is not altered in the absence of KLF4. 
A) Isolectin B4 staining (IB4, used to identify vasculature) on WT and EC-KLF4 KO retinae at P6. Images 
are representative of 5 mice for each genotype. Scale bar: 300 µm. B-C) Quantification of several vascular 
parameters (vascular progression, number of tip cells and branching points) in the retinae from WT and EC-
KLF4 KO mice at P6. Data are mean ± SD (n=5 for each genotype from 3 different litters). B) Higher 
magnification pictures of the blue and red boxed areas shown in A and used as representative images for 
quantification of both number of tip cells (indicated by yellow asterisks) and branching points (indicated by 
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yellow circles) in the retinal vasculature of WT and EC-KLF4 KO animals. Scale bars: 30 µm (blue boxes) 
and 20 µm (red boxes). C) Quantification of the average distance covered by the growing vessels measured 
as vascular progression (left panel), number of tip cells in 100 µm at the leading edge of the plexus (middle 
panel) and number of branchings in 100 µm2 area (right panel). D) Representative immunostaining (one out 
of three performed) for KLF4 (red) in the retinae of WT and EC-KLF4 KO mice to show gene ablation. 
Vasculature of the retina is stained with IB4 (green). Scale bar: 40 µm. 
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6.9 KLF4 induces EndMT in CCM1 null ECs in vitro 
Endothelial-specific deletion of Ccm1 gene induces EndMT switch in ECs lining 
the cavernomas 291. To investigate whether KLF4 had a key role in this process we stably 
transduced lung derived WT and CCM1 KO ECs with either a lentiviral vector expressing 
a short hairpin RNA directed to Klf4 (shKLF4) or with a lentiviral vector expressing a non-
targeting shRNA as control (shCTRL). As depicted in Figure 43, we achieved a 65% 
knockdown, restoring Klf4 mRNA and protein level similar to WT ECs (Figure 43 A and 
B). Klf4 silencing strongly attenuates the expression of mesenchymal and stem cell 
markers upregulated in CCM1 KO ECs (Figure 43 A and B), but it was ineffective in 
restoring the expression of the endothelial junction molecules VE-Cadherin and Claudin5 
(Figure 43 A and B).  
 
Figure 43 - Klf4 silencing inhibits EndMT marker expression in CCM1 KO lung derived ECs.  
A-B) WT and CCM1 KO ECs were lentiviral transduced with shRNA directed to either Klf4 (shKLF4) or 
control sequence (shCTRL). A) qRT-PCR of mesenchymal (Fsp1, Id1), stem cell-like (Sca1) and endothelial 
markers (VE-cadherin and Claudin5) in WT shCTRL, WT shKLF4, CCM1 KO shCTRL and CCM1 KO 
shKLF4 ECs. Data are mean ± SD (n=3). Fold difference in gene expression are relative to WT shCTRL ECs. 
*P<0.05; **P<0.01; ***P<0.001 B) WB of EndMT markers in WT shCTRL, WT shKLF4, CCM1 KO 
shCTRL and CCM1 KO shKLF4 ECs. Vinculin was the loading control. These data are representative of 
three independent observations.  
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         As previously mentioned cell-transition to a mesenchymal phenotype in CCM1 KO 
ECs is accompanied by increased proliferation and migratory capacity 105, 291. Interestingly 
we found that Klf4 down-regulation in cultured CCM1 KO ECs inhibited ECs proliferation 
(Figure 44) and migration (Figure 45). Interestingly, in line with what previously reported 
by Hale et al. 232, Klf4 silencing impairs proliferation also in WT ECs (Figure 44). 
 
 
 
 
 
 
 
Figure 44 - Klf4 silencing decreases the proliferation rate of both lung derived WT and CCM1 KO 
ECs.  
Proliferation rate of WT shCTRL, WTshKLF4, CCM1 KO shCTRL and CCM1 KO shKLF4 ECs cultured 
for 5 days. Columns represent mean ± SD (n=8). *P<0.05, **P<0.01, ***P<0.001 
 
 
 
 
 
 
 
 
 
Figure 45 - KLF4 silencing affects lung derived CCM1 KO ECs migration.  
Migration rate, measured in a wound assay, of WT shCTRL, CCM1 KO shCTRL and CCM1 KO shKLF4 
ECs. Mean ± SD is graphed (n=6). Scale bar: 500 µm*P< 0.05, **P<0.01,***P<0.001 
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         To further confirm these data in a more reliable cellular model and to understand 
whether loss of Klf4 expression was able to prevent the EndMT process in CCM1 null ECs, 
we concomitantly deleted Ccm1 and Klf4 expression in primary brain derived ECs. Cells 
were isolated from brain of WT, Ccm1 floxed/floxed and double Ccm1-Klf4 floxed/floxed 
mice and treated with TAT Cre-recombinase in vitro to induce recombination of LoxP-site 
flanked genes (Figure 46 and 47). Ccm1 deletion was comparable between CCM1 KO and 
CCM1-KLF4 KO BMECs (Figure 46 A) while, as expected, KLF4 expression was 
increased in CCM1 KO BMECs and almost abrogated in the double CCM1-KLF4 KO 
BMECs. Loss of KLF4 prevented the increased expression of mesenchymal and stem cell 
markers observed in the absence of Ccm1 as verified by qRT-PCR (Figure 46 A), WB 
(Figure 46 B) and immunofluorescence analysis (Figure 46 C). Also in this experimental, 
VE-CADHERIN organization at junctions was not affected by KLF4 depletion (Figure 47), 
thus suggesting that KLF4 was not involved in junctional disorganization observed in 
CCM1 null ECs.  
To investigate whether KLF4 is sufficient to promote EndMT we infected WT ECs 
in culture with a lentiviral vector expressing Klf4 (LentiKLF4) or an empty vector (Mock) 
as control, achieving a 3-fold Klf4 induction (Figure 48), a level of upregulation 
comparable to that observed in CCM1 KO ECs. KLF4 upregulation in WT ECs increased 
EndMT markers at both mRNA (Figure 48, left panel) and protein level (Figure 48, right 
panel), whereas it did not affect the expression of the endothelial junction molecules as 
VE-cadherin and Claudin5 (Figure 48, left panel), confirming that KLF4 did not seem to 
be involved in junction organization.  
Taken together, loss and gain of function approaches showed that KLF4 was 
necessary to induce EndMT in CCM1 null ECs in vitro.  
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Figure 46 - Loss of KLF4 prevents the EndMT switch induced by the loss of Ccm1 in BMECs.  
A) qRT-PCR of Ccm1, Klf4  and several EndMT markers after in vitro TAT-Cre recombinase treatment of 
BMECs from WT, Ccm1 floxed/floxed and Ccm1-Klf4 floxed/floxed  mice to originate cultured WT, CCM1 
KO and CCM1-KLF4 KO primary brain ECs, respectively. Data are presented as mean ± SD (n=3). Fold 
changes are relative to WT BMECs. B) WB of KLF4 and EndMT markers in WT, CCM1 KO and CCM1-
KLF4 KO BMECs. Tubulin was the loading control. These data are representative of three independent 
observations. C) Representative confocal analysis (out of three performed) of KLF4, FSP1 and SCA1 (red) in 
WT, CCM1 KO and CCM1-KLF4 KO BMECs obtained as in A. DAPI visualizes nuclei. Scale bar: 30 µm. 
*P< 0.05, **P<0.01, ***P<0.001 
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Figure 47 - Klf4 gene ablation did not restore the proper VE-CADHERIN localization at the cell-to-cell 
contacts.  
Representative confocal analysis (out of three performed) of KLF4 (red) and VE-CADHERIN (green) in WT, 
CCM1 KO and CCM1-KLF4 KO primary brain ECs obtained as in A. DAPI visualizes nuclei. Scale bar: 30 
µm. 
 
 
 
 
 
 
 
Figure 48 - KLF4 overexpression induces EndMT marker expression in WT ECs.  
Cultured lung derived WT ECs were lentiviral transduced with a full length murine Klf4 (LentiKLF4) or 
empty vector (Mock). qRT-PCR (left panel) and WB (right panel) of EndMT markers in Mock and 
LentiKLF4 ECs. qRT-PCR data are mean ± SD (n=3) and the fold changes are relative to Mock ECs. WB 
results are representative of three independent observations. Tubulin was the loading control. *P<0.05, 
**P<0.01, ***P<0.001 
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6.10 KLF4 induces EndMT in CCM1 null ECs in vivo in a context dependent manner 
To investigate whether the absence of KLF4 was able to prevent EndMT switch 
ongoing in the absence of CCM1 in vivo 291, we analyzed the expression of a number of 
mesenchymal and stem-cell markers both in normal cerebellar vessels of WT mice and 
vascular lesions of EC-CCM1 KO and EC-CCM1 KO KLF4 KO animals. Unlike EC-
CCM1 KO mice, immunofluorescence analysis revealed that EC-CCM1 KO KLF4 KO 
animals developed a limited number of vascular lesions, which were smaller in size and 
weakly positive for the expression of FSP1, SCA1 and ID1 (Figure 49). A strong reduction 
in EndMT marker expression was also confirmed ex vivo in freshly isolated brain derived 
ECs from EC-CCM1 KO KLF4 KO mice compared to EC-CCM1 KO (Figure 50 A). 
Moreover qRT-PCR analysis of freshly isolated brain ECs from EC-KLF4 KO and WT 
mice showed that abrogation of Klf4 expression per se resulted in reduction of both Sca1 
and Id1 expression, thus suggesting that KLF4 could modulate the transcription of some of 
EndMT markers in vivo also in normal conditions when Ccm1 is not deleted (Figure 50 B). 
A residual amount of EndMT expression in the few small lesions developed in EC-CCM1 
KO KLF4 KO mice mice might be ascribable to an incomplete KLF4 recombination. 
Notably, preliminary immunofluorescence analysis revealed that ECs positive for EndMT 
markers staining still retained KLF4 (Figure 51 A and B). In this regard, to understand 
whether KLF4 incomplete recombination is responsible for the development of lesions in 
EC-CCM1 KO KLF4 KO, it would be important in the future to quantify how many 
lesions in EC-CCM1 KO KLF4 KO mice still retain Klf4 expression. 
Intriguingly, the role of KLF4 as inducer of EndMT appears strongly cell-context 
dependent. CCM malformations at the periphery of the retina vasculature are restricted to 
veins and the surrounding capillaries 69, 92, 291 . By measuring KLF4 intensity in retinal 
endothelial cell nuclei we observed that KLF4 amount was higher in veins than arteries in 
both WT and EC-CCM1 KO mice and was further increased at the level of lesion area 
(Figure 52 A-C). To test whether a higher KLF4 expression correlated with an increased 
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amount of EndMT markers, we performed immunofluorescence staining also for ID1, 
FSP1 and SCA1 in retinae of WT and EC-CCM1 KO mice at P12. Accordingly, ID1 
expression pattern in the retina correlated with KLF4 one (Figure 52 A, B and D), while 
FSP1 and SCA1 staining did not work properly in retina samples. However this analysis, 
even if partial, suggested that higher levels of KLF4 in veins may explain the venous 
origin of the cavernomas.  
Moreover, in order to understand the role of KLF4 in the brain vasculature 
specificity of the disease, we compared freshly isolated endothelial cells derived from 
brain, lung, heart and spleen of WT and EC-CCM1 KO after gene recombination. In the 
absence of CCM1, KLF4 expression was almost equally increased in ECs of different 
origins while among all the EndMT markers analysed only Sca1 expression was increased 
also in spleen and in lung of EC-CCM1 KO mice, even if not at comparable levels to brain 
microvasculature. Since a full EndMT marker upregulation was detected only in brain ECs 
(Figure 53), it is likely that KLF4 upregulation may require a specific environment in order 
to induce the acquisition of a mesenchymal phenotype.  
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Figure 49 - EndMT marker expression is reduced in ECs lining the cavernomas in the absence of Klf4.  
 A) Representative confocal analysis of PECAM1 (green) and FSP1 (red) in normal cerebellar vessels of WT 
mice and vascular lesions (dotted area) of both EC-CCM1 KO and EC-CCM1 KO KLF4 KO mice (n=4 in 
each group). PECAM1 identifies ECs; DAPI marks nuclei. B) Representative confocal analysis of GLUT1 
(green) and SCA1 (red) in normal cerebellar vessels of WT mice and vascular lesions (dotted area) of both 
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EC-CCM1 KO and EC-CCM1 KO KLF4 KO mice (n=4 in each group). GLUT1 identifies ECs; DAPI marks 
nuclei. C) Representative confocal analysis of PECAM (green) and ID1 (red) in normal cerebellar vessels of 
WT mice and vascular lesions (dotted area) of both EC-CCM1 KO and EC-CCM1 KO KLF4 KO mice. 
PECAM1 identifies ECs; DAPI visualizes nuclei. Scale bars: 50 µm (B, C, D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50 - EndMT markers gene expression analysis in freshly isolated brain ECs from mice WT or 
null for Ccm1, Klf4 or both genes  
A) qRT-PCR of some EndMT markers in freshly isolated brain ECs from WT, EC-CCM1 KO and EC-
CCM1 KO KLF4 KO mice analyzed at P12. Fold changes are relative to WT animals. Data are mean ± SD 
(n=3 for each genotype). ** P < 0.01, ***P<0.001. B) qRT-PCR of some EndMT markers in freshly isolated 
brain ECs from WT and EC-KLF4 KO mice analyzed at P12. Fold changes are relative to WT animals. Data 
are mean ± SD (n=3 for each genotype). * P < 0.05 
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Figure 51 - Incomplete Klf4 gene recombination in ECs lining the vascular lesions of EC-CCM1 KO 
KLF4 KO mice.  
A) Representative confocal analysis of KLF4 (white), SCA1 (red) and GLUT1 (green) in normal cerebellar 
vessels of WT mice and vascular lesions (dotted area) of both EC-CCM1 KO and EC-CCM1 KO KLF4 KO 
mice at p12 (n=4 for each genotype). B) Representative confocal analysis of KLF4 (white), ID1 (red) and 
GLUT1 (green) in normal cerebellar vessels of WT mice and vascular lesions (dotted area) of both EC-
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CCM1 KO and EC-CCM1 KO KLF4 KO mice at p12 (n=4 for each genotype). GLUT1 marks endothelial 
cells while DAPI visualized nuclei. Scale bar: 20µm  
 
 
 
Figure 52 - KLF4 amount is higher in veins than in arteries of the retinal vasculature in both WT and 
EC-CCM1 KO mice.  
A) Confocal analysis of isolectin B4 (IB4, white), KLF4 (green) and ID1 (red) in the retinae of WT and EC-
CCM1 KO mice at p12. A:artery; V:vein. IB4 identifies the vasculature; DAPI visualizes nuclei. Images are 
representative of three mice for each genotype. Scale bar: 30 µm. B) Higher magnification images of IB4 
(white), KLF4 (green) and ID1 (red) in artery, vein and lesion of WT and EC-CCM1 KO mice retinae at p12. 
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Scale bar: 30 µm. C) Quantification of the KLF4 pixel intensity per endothelial nucleus in retinal arteries, 
veins and lesions of WT and EC-CCM1 KO mice. Co-localization highlighter plug in of Image J has been 
used to identify KLF4 positive pixels co-localizing with DAPI (to exclude background). Mean intensity of 
co-localizing pixel per field has been calculated through Image J and normalized on the number of 
endothelial nuclei. Three different fields for three different samples for each group (arteries, veins and 
lesions) have been analysed. D) Quantification of the ID1 pixel intensity per endothelial nucleus in retinal 
arteries, veins and lesion of WT and EC-CCM1 KO mice performed as described in C. *P<0.05, **P<0.01, 
***P<0.001 
 
 
 
Figure 53 - EndMT occurs specifically in the brain vasculature of EC-CCM1 KO mice.  
qRT-PCR analysis of Ccm1, Klf4, Fsp1, Sca1, Id1 and Bmp6 in freshly isolated ECs from brain, lung, heart 
and spleen of WT and EC-CCM1 KO mice at P12. Fold changes are relative to matched WT animals. Data 
are expressed as fold change versus control WT animals and are means ± SD from at least three mice for 
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group. The SD of values obtained in control mice did not exceed 10% of the mean. *P<0.05, **P<0.01, 
***P<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54 - Phenotype of livers in EC-CCM1 KO mice.  
Representative images of WT and EC-CCM1 KO mouse livers at P12 (n=3 for each genotype).  
 
To note, while harvesting different organs to perform fresh EC isolation in EC-
CCM1 KO pups, we observed that all the organs appeared macroscopically normal with 
the exception of the liver which showed a pale colour with diffuse red spots on the surface 
(Figure 54). As liver angiomas were reported to be found in a low percentage of familial 
CCM patients 293, further experiments will be directed in the future to analyse this 
phenotype in CCM mouse model. 
Taken together, these results showed that KLF4 upregulation was critical to 
promote the EndMT switch induced by CCM1 abrogation in vivo. However, the strength of 
this effect was context dependent being observed preferentially in the brain 
microvasculature. 
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6.11 KLF4 regulates BMP6-mediated signalling  
TGF-β/BMP pathway is a major inducer of EndMT in CCM1 KO ECs 119. Upon 
loss of CCM1, endogenous Bmp6 up-regulation in ECs leads to an increased SMAD 
phosphorylation resulting in EndMT marker acquisition 291. We therefore asked whether 
KLF4 could promote the EndMT switch observed in CCM1 KO ECs by modulating TGF-
β/BMP signalling. As shown in Figure 55, Klf4 silencing decreased Bmp6 expression 
together with a significant reduction in phosphorylated SMAD1 (pSMAD1) (Figure 56), 
that, as expected are strongly increased in CCM1 KO ECs shCTRL. The same data was 
confirmed in BMECs since Bmp6 amount was reduced in CCM1-KLF4 KO in comparison 
to CCM1 KO ECs (Figure 57). Interestingly, immunohistochemical analysis of brain 
tissues confirmed BMP6 reduction in vivo in ECs lining the cavernomas of double EC-
CCM1 KO KLF4 KO mice compared to EC-CCM1 KO animals (Figure 58). 
 
 
 
 
 
 
 
 
Figure 55 - Klf4 silencing decreases Bmp6 expression in CCM1 KO lung ECs.  
qRT-PCR of Bmp6 expression in WT shCTRL, WT shKLF4, CCM1 KO shCTRL and CCM1 KO shKLF4 
cultured ECs. Data represent the mean ± SD (n=3). Fold changes are relative to CCM1 KO shCTRL ECs. 
***P<0.001 
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Figure 56 - Klf4 silencing decreases SMAD1 phosphorylation in CCM1 KO lung ECs.  
WB of pSMAD1 and SMAD1 in WT shCTRL, WT shKLF4, CCM1 KO shCTRL and CCM1 KO shKLF4 
ECs. pSMAD1/SMAD1 ratio normalized over tubulin was quantified by densitometry scan. These data are 
representative of three independent observations. 
 
 
 
 
 
 
 
 
 
 
Figure 57 - Klf4 increases Bmp6 in CCM1 KO BMECs.  
qRT-PCR of Bmp6 in WT, CCM1 KO and CCM1-KLF4 KO BMECs. Data are mean ± SD (n=3). Fold 
changes are relative to WT ECs. **P<0.01,  
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Figure 58 - Loss of endothelial Klf4 decreases BMP6 amount in vivo in ECs lining the cavernomas in 
EC-CCM1 KO mice.   
Immunohistochemical analysis of PECAM1 (left panels) and BMP6 (central panels) performed on serial 
sections of cerebellum derived from WT, EC-CCM1 KO and EC-CCM1 KO KLF4 KO mice at P12. Higher 
magnification images of the boxed regions are shown in the right panels. Black arrowheads mark ECs, dotted 
area indicates the Purkinje cell layer used as positive control of the staining. Scale bar: 100 µm. These data 
are representative of three independent observations (n=3 for each genotype). 
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To understand whether Bmp6 is a direct transcriptional target of KLF4, we 
performed chromatin immunoprecipitation assay (ChIP). Eight putative KLF4 binding 
sites were identified within the murine Bmp6 promoter region at -5.0KB and +1.0 KB from 
the transcription start site (tss). As depicted in Figure 59, KLF4 binding was enriched at 
the selected sites on Bmp6 promoter in CCM1 KO ECs but not in WT cells, thus 
suggesting Bmp6 as a KLF4 target gene in ECs. To demonstrate that the binding of KLF4 
to Bmp6 promoter is functionally active, we generated a Bmp6 reporter construct by 
cloning the promoter region enriched in KLF4 binding sites upstream of the Luciferase 
cDNA of the PGL3 basic cloning vector (Figure 60). A transcriptional reporter assay was 
performed by co-transfecting the Bmp6 reporter construct together with an expression 
plasmid of a full length KLF4 or a mutant KLF4 lacking the DNA-binding zinc finger 
domains (KLF4 ΔZnF). We found that KLF4 induced Bmp6 promoter activity and this 
effect was reduced when KLF4 binding to DNA was altered (Figure 60), thus suggesting 
that KLF4 actively regulated Bmp6 transcription. 
 
 
 
 
 
 
 
 
 
Figure 59 - KLF4 binds Bmp6 promoter in CCM1 null ECs.  
ChIP analysis of KLF4 binding to Bmp6 promoter. Putative KLF4 binding sites identified by MatInspector 
are indicated. The levels of DNA are normalized to input. Columns are mean ±SD of triplicates from a 
representative experiment out of three. 
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Figure 60 - KLF4 regulates Bmp6 promoter activity.  
Transcriptional reporter assay performed in HEK-293 cells transfected with Bmp6 reporter plasmid together 
with an empty vector, a full lenght KLF4 or a mutant KLF4 lacking the DNA binding zinc finger domain 
(KLF4 DZnF). Red boxes in the picture indicate KLF4 binding sites validated by ChIP. Fold change in the 
Bmp6 promoter activity are relative to empty vector transfected cells. Data are mean ± SD (n=3). 
***P<0.001 
 
Furthermore, we confirmed the same results through a gain of function approach. 
Both Bmp6 mRNA (Figure 61) and pSMAD1 amount (Figure 62) were upregulated in 
KLF4 overexpressing ECs (LENTIKLF4) in comparison to empty vector transduced cells 
(MOCK). Similarly ChIP analysis revealed enriched KLF4 binding to selected putative 
sites within Bmp6 promoter region in LENTIKLF4 ECs (Figure 63). To prove that 
increased SMAD1 phosphorylation and EndMT marker up-regulation were BMP6-
dependent, we infected Mock and LENTIKLF4 ECs with a lentiviral vector expressing a 
short hairpin directed to Bmp6 (shBMP6) or a control sequence (shCTRL) (Figure 64). 
Stable Bmp6 silencing prevented the increase of both pSMAD1 (Figure 65 A) and EndMT 
markers induced by KLF4 in LentiKLF4 ECs (Figure 65 B).  
Overall our results demonstrate that KLF4 was able to promote Bmp6 expression 
that, in turn, contributed to the EndMT program of CCM1 null ECs. 
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Figure 61 - KLF4 overexpression in WT ECs upregulates Bmp6.  
qRT-PCR of Bmp6 in Mock and LentiKLF4 cultured ECs. Data are mean ± SD (n=3). Fold changes are 
relative to Mock ECs. **P<0.01 
 
 
 
 
 
 
 
 
 
Figure 62 - KLF4 overexpression in WT ECs increases SMAD1 phosphorylation.  
WB analysis of pSMAD1 and SMAD1 in Mock and LentiKLF4 ECs. Vinculin was used as loading control. 
pSMAD1/SMAD1 ratio normalized over vinculin was quantified by densitometry scan. These data are 
representative of three independent experiments. 
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Figure 63 - KLF4 binds Bmp6 promoter in KLF4 overexpressing cells.  
ChIP of KLF4 interaction with Bmp6 promoter in Mock and LentiKLF4 ECs. Putative KLF4 binding sites 
identified by MatInspector are indicated. The levels of DNA are normalized to input. Columns are mean ±SD 
of triplicates from a representative experiment out of three.  
 
 
 
 
 
 
 
 
Figure 64 - Knockdown efficiency of Bmp6 in Mock and LentiKLF4 ECs transduced with a lentiviral 
vector expressing a shRNA directed to Bmp6.  
Mock and LentiKLF4 cultured ECs were lentiviral transduced with shRNA directed to either Bmp6 
(shBMP6) or control sequence (shCTRL). qRT-PCR analysis of Bmp6 in Mock shCTRL, Mock shBMP6, 
LentiKLF4 shCTRL and LentiKLF4 shBMP6 ECs. qRT-PCR data represent the mean ± SD (n=3) and the 
fold changes are relative to Mock shCTRL ECs. ***P<0.001, **P<0.01 
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Figure 65 - Silencing of Bmp6 in KLF4 overexpressing ECs decreases SMAD phosphorylation and 
EndMT marker expression.  
Mock and LentiKLF4 ECs were lentiviral transduced with shRNA directed to either Bmp6 (shBMP6) or 
control sequence (shCTRL). A) WB of pSMAD1 and SMAD1 in Mock shCTRL, Mock shBMP6, 
LentiKLF4 shCTRL and LentiKLF4 shBMP6 ECs. Vinculin was used as loading control. pSMAD1/SMAD1 
ratio normalized over vinculin was quantified by densitometry scan.. These WB data are representative of 
three independent observations. B) WB analysis of EndMT markers in Mock shCTRL, Mock shBMP6, 
LentiKLF4 shCTRL and LentiKLF4 shBMP6 ECs. Tubulin was the loading control. FSP1, SCA1 and ID1 
fold changes were normalized over tubulin and quantified by densitometry scan. These WB data are 
representative of three independent observations. 
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6.12 KLF4 directly regulates the expression of some EndMT markers  
We then investigated whether KLF4-induced EndMT was fully dependent on the 
upregulation of BMP6 or whether KLF4 could also have an independent and direct effect 
on EndMT marker expression. To this purpose we isolated ECs from lungs of KLF4 
floxed/floxed mice, we immortalized them PmT antigen and then we recombined the gene 
through a treatment with TAT-Cre in vitro (Figure 66). WT and KLF4 KO ECs were 
stimulated with 100ng/ml of recombinant BMP6 for 96 hours and a number of 
representative mesenchymal and stem-cells markers were analyzed. Although the 
induction of SMAD1 phosphorylation was comparable in both cell type (Figure 67), 
BMP6-induced expression of Fsp1 and Sca1, but not Id1, was reduced in the absence of 
KLF4 (Figure 68), thus suggesting a direct contribution of KLF4 to the upregulation of 
some EndMT markers. Consistently with this hypothesis several consensus sequences for 
KLF4 were identified in the promoter region of murine Fsp1, Sca1 and Id1. ChIP analysis 
revealed KLF4 binding to both Fsp1 (Figure 69 A) and Sca1 promoters (Figure 69 B), with 
the binding occuring mainly in the regions located at +0.1KB and +0.7 KB (Fsp1) and -0.1 
KB and +0.4KB (Sca1) from the tss, respectively. Conversely KLF4 binding to Id1 
promoter was barely detectable, suggesting that Id1, a bona fide BMP6 target gene 294 was 
not directly regulated by KLF4 (Figure 69 C). Moreover, both Fsp1 and Sca1 
transcriptional reporters (generated by cloning the promoter regions enriched in KLF4 
binding sites validated by ChIP upstream of the Luciferase cDNA into the PGL3 basic 
vector) were strongly induced by KLF4 in a DNA-binding dependent manner (Figure 70 A 
and B). Interestingly, regions bound by KLF4 in the Fsp1 and Sca1 promoters are 
surrounded by canonical SMAD binding elements. SMADs bind weakly to the promoter of 
target genes 295 and through the association with KLF4 this binding could be reinforced.  
In conclusion, our results demonstrated that Klf4, besides modulating TGFb/BMP 
signalling pathway, could also regulate EndMT marker expression by directly binding to 
promoter regions of specific EndMT markers. 
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Figure 66 - Establishment of lung derived endothelial cell line KO for KLF4.  
A) qRT-PCR (left panel) and WB (right panel) analysis of KLF4 in cultured lung WT and KLF4 KO ECs. 
qRT-PCR data represent the mean ± SD (n=3) and the fold changes are relative to WT ECs. A two-tailed 
unpaired t-test was performed. ***P<0.001. GAPDH was the loading control in WB. These WB data are 
representative of three independent observations. 
 
 
 
 
 
 
 
Figure 67 - Loss of KLF4 does not affect SMAD1 phosphorylation upon BMP6 stimulation.  
WB analysis of pSMAD1 and SMAD1 in WT and KLF4 KO ECs left untreated or treated with recombinant 
BMP6 for 4 h. GAPDH was the loading control in WB. pSMAD1/SMAD1 ratio normalized over GAPDH 
was quantified by densitometry scan. These data are representative of three independent observations. 
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Figure 68 - BMP6-dependent Fsp1 and Sca1 induction is strongly reduced in KLF4 KO lung ECs.  
qRT-PCR of Fsp1, Sca1 and Id1 in WT and KLF4 KO ECs stimulated with BMP6 for 96 h. qRT-PCR data 
are mean ± SD (n=3). Fold changes in gene expression in BMP6-treated versus untreated ECs. *P<0.05, 
***P<0.001 
 
Figure 69 - KLF4 directly binds to promoter regions of specific EndMT markers.  
ChIP analysis of KLF4 binding to the promoters of Fsp1(A), Sca1(B) and Id1(C) in WT and CCM1 KO ECs. 
The positions of the putative KLF4 binding sites identified with MatInspector in the promoters of the genes 
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analysed were indicated. The levels of DNA were normalized to input. Columns are mean ± SD of triplicates 
from a representative experiment out of three performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70 - KLF4 increases promoter activity of specific EndMT markers.  
Transcriptional reporter assays performed in HEK-293 cells transfected with either Fsp1 (A) or Sca1 (B) 
reporter plasmid together with an empty vector, full lenght KLF4 or KLF4 DZnF. In the pictures: red boxes 
indicate KLF4 binding sites validated by ChIP, while grey boxes indicate KLF4 binding sites not validated 
by ChIP. Fold change in the promoter activity are relative to empty vector transfected cells. Data are mean ± 
SD (n=3). ***P<0.001 
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6.13 KLF2 expression is dispensable for EndMT transition in CCM1 null ECs 
KLF2, another member of KLF family that shares a high level of structural and 
functional homology with KLF4, was recently reported to be increased upon loss of Ccm 
genes 107, 296. KLF2 was found to play a causative role in the cardiac abnormalities observed 
in the absence of CCM in both mouse and zebrafish embryos since it was responsible for 
both digestion of the cardiac jelly 296 and excessive angiogenesis 107. Moreover in vitro and 
in vivo studies showed that loss of KLF2 resulted in an increase of KLF4 and viceversa 
thus raising the possibility that these factors may compensate one another 228, 297. KLF2 was 
found to be present in the list of the most upregulated transcripts that we obtained by 
Affimetrix analysis (Appendix Table1) performed to compare the gene expression profile 
of WT and CCM1 KO BMECs. In order to validate microarray data we first evaluated Klf2 
expression ex vivo in freshly isolated PECAM+ brain ECs derived from WT, EC-CCM1 
KO and double EC-CCM1 KO KLF4 KO mice (Figure 71 A and B). Klf2 was found to be 
upregulated in the absence of Ccm1 in EC-CCM1 KO compared to WT matched controls. 
However Klf4 depletion did not alter Klf2 expression levels either in EC-CCM1 KO KLF4 
KO or in EC-KLF4 KO mice (Figure 71), thus suggesting a non redundant role of these 
two transcription factors in CCM1 null ECs ex vivo. To further confirm these data in vitro 
we evaluated Klf2 expression in WT. CCM1 KO and double CCM1-KLF4 KO BMECs. 
As shown in Figure 72, Klf2 was found to be induced in the absence of Ccm1 and its 
expression was not further increased upon Klf4 ablation in CCM1-KLF4 double KO 
BMECs and did not apparently compensate for the lack of Klf4 in inducing EndMT 
(Figure 37) . 
In conclusion, even if the relative contribution of KLF2 to CCM brain disease 
remains an open issue that requires future studies, our data might suggest that KLF2 
upregulation is apparently dispensable for the EndMT phenotype observed in the absence 
of Ccm1. 
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Figure 71 - Loss of Klf4 does not affect Klf2 expression in ECs in vivo.  
A) qRT-PCR of Klf2 in freshly isolated brain ECs from WT, EC-CCM1 KO and EC-CCM1 KO KLF4 KO 
mice analyzed at P12. Fold changes are relative to WT animals. Data are mean ± SD (n=3). ** P<0.01, B) 
qRT-PCR of Klf2 in freshly isolated brain ECs from WT and EC-KLF4 KO mice analyzed at P12. Fold 
changes are relative to WT animals. Data are mean ± SD (n=3).  
 
 
 
 
 
 
Figure 72 - Loss of Ccm1 induces Klf2 upregulation in vitro in BMECs.  
qRT-PCR of Klf2 after in vitro TAT-Cre recombinase treatment of primary brain ECs derived from WT, 
Ccm1 floxed/floxed and Ccm1-Klf4 floxed/floxed mice to originate cultured WT, CCM1 KO and CCM1-
KLF4 KO brain ECs, respectively. Data are presented as mean ± SD (n=3). Fold changes were relative to 
WT brain ECs. ***P<0.001 
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6.14 Erk5 activation mediates KLF4 upregulation and KLF4-dependent EndMT in 
the absence of Ccm1 
We then moved to investigate the molecular mechanism through which loss of Ccm 
lead to Klf4 upregulation. Previous studies extensively reported that ERK5 
phosphorylation and activation promotes Klf2 and Klf4 transcription upon shear stress in 
ECs 226, 298, 299. As both Klf2 and Klf4 were concomitantly upregulated upon loss of Ccm1, 
we hypothesized that ERK5 could be involved in the regulation of Klf4 expression also in 
our experimental models. We found that ERK5 phosphorylation was increased in freshly 
isolated brain ECs of EC-CCM1 KO mice in comparison to matched controls (Figure 73). 
Accordingly, ERK5 phosphorylation was higher in cultured BMECs upon Ccm1 ablation 
and was not further modified by KLF4 depletion (Figure 74). To investigate whether 
ERK5 activation was responsible for the upregulation of both KLF4 and EndMT marker 
expression in the absence of CCM1, we transfected WT ECs with siRNAs directed to Erk5 
and Ccm1. The downregulation of ERK5 strongly prevented KLF4 upregulation in Ccm1 
silenced ECs (Figure 75). Similarly, the treatment of WT and CCM1 KO ECs for 72 hours 
with 5 µm of XMD8-92, a specific ATP-competitive for ERK5 kinase 259, 299, strongly 
decreased ERK5 phosphorylation and KLF4 overexpression together with an inhibition of 
Bmp6 upregulation, SMAD1 phosphorylation and EndMT marker acquisition in CCM1 
null ECs (Figure 76 A-D). Comparable data where obtained when XMD8-92 treatment 
was performed in WT and CCM1 KO BMECs (Figure 77).  
Myocyte enhanced (MEF) family of transcription factors are the best characterized 
downstream targets of ERK5 and were previously reported to be directly involved in the 
regulation of Klf2 and Klf4 expression in ECs 255, 256, 300, 301. To investigate a possible role of 
MEF2 transcription factors in KLF4 upregulation in the absence of CCM1 we silenced 
anyone of Mef2a, Mef2c and Mef2d in WT and CCM1 KO ECs. Both Mef2a and Mef2c 
knockdown in CCM1 KO ECs led to a partial but significant decrease in Klf4 expression 
(Figure 78 A and B) while Mef2d silencing did not affected KLF4 upregulation at all 
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(Figure 78 C). 
 
 
 
 
 
 
 
Figure 73 - Loss of Ccm1 induce Erk5 phosphorylation in ECs in vivo.  
A) WB analysis of phoshorylated ERK5 (pERK5) and total ERK5 in freshly isolated brain ECs from WT 
(n=2) and EC-CCM1 KO (n=4) mice from 2 different litters at P12. VE-PTP measured the endothelial 
content and vinculin was the loading control. pERK5/ERK5 ratio normalized over vinculin and VE-PTP was 
quantified by densitometry scan.  
 
 
 
 
 
 
 
 
Figure 74 - Erk5 phosphorylation is increased upon loss of Ccm1 in BMECs in vitro.  
A) WB analysis of pERK5 and ERK5 protein levels after in vitro TAT-Cre recombinase treatment of primary 
brain ECs derived from WT, Ccm1 floxed/floxed and Ccm1-Klf4 floxed/floxed mice to originate cultured WT, 
CCM1 KO and CCM1-KLF4 KO BMECs. pERK5/ERK5 ratio normalized over the loading control tubulin 
was indicated. This WB data is representative of three independent experiments. 
 
 
 145 
 
 
 
 
 
 
Figure 75 - Erk5 activitation is responsible for KLF4 upregulation upon Ccm1 silencing in vitro.  
WB analysis of pERK5, ERK5 and KLF4 protein leves in cultured lung derived WT ECs either Ccm1 
(siCCM1) or control (siCTRL) siRNA-treated alone or in combination with two siRNA targeting Erk5 
(siERK5#1,2). pERK5/ERK5 ratio normalized over  the loading control vinculin was indicated. This WB 
data is representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 76 - In the absence of Ccm1 increased ERK5 phosphorylation is responsible for KLF4 
upregulation, Bmp6-dependent SMAD signalling and KLF4-dependent EndMT in vitro in CCM1 KO 
ECs. 
 A-D) Treatment of WT and CCM1 KO ECs with either 5 µM of XMD8-92 or the vehicle for 72 hours. A) 
WB analysis of pERK5, ERK5 and KLF4. pERK5/ERK5 ratio was quantified over  the loading control 
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vinculin. B) Evaluation of pSMAD1 and SMAD1 protein levels by immunoblot analysis. pSMAD1/SMAD1 
ratio normalized over the loading control vinculin was shown. C) qRT-PCR of Bmp6. The data represent the 
mean ± SD (n=3). Fold changes are relative to vehicle-treated CCM1 KO ECs. **P<0.001, *P<0.01. D) 
Representative WB analysis of EndMT markers expression. Tubulin was used as loading control. All WB 
data presented in this figure are representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
Figure 77 - In the absence of Ccm1 increased ERK5 phosphorylation is responsible for KLF4 
upregulation, Bmp6 overexpression and KLF4-dependent EndMT in vitro in CCM1 null BMECs. 
Treatment of WT and CCM1 KO BMECs with either 5 µM of XMD8-92 or the vehicle for 72 hours. Left 
panel: WB analysis of pERK5, ERK5, KLF4, FSP1, SCA1, ID1. Tubulin was the loading control. These WB 
data are representative of three independent experiments. Right panel: qRT-PCR of Bmp6. Data are shown as 
mean ± SD (n=3) and fold changes are relative to vehicle-treated WT ECs. ***P<0.001, **P<0.01 
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It has been reported in literature that MEF transcription factors show functional 
redundancy and can compensate one another 301. To exclude the possibility that the partial 
KLF4 downregulation that we observed upon the single knockdown of any of Mef2a, 
Mef2c and Mef2d was due to a functional compensation of the other MEF family members, 
we performed a simultaneous triple knockdown of Mef2a, Mef2c and Mef2d. The 
combined silencing of all the three members of this family of transcription factors resulted 
in a decreased expression of Klf4 in CCM1 KO ECs (Figure 79) that, however, was 
comparable to that obtained upon Mef2a or Mef2c single knockdown. Thus, it is 
coincevable that either other ERK5-downstream transcription factors or ERK5 alone 243 
could be involved in KLF4 upregulation upon loss of Ccm genes. 
Interestingly, to identify ERK5-mediated KLF4 upregulation and KLF4-dependent 
EndMT as common molecular nodes in CCM, we analyzed ERK5 activation, KLF4 
amount and EndMT marker expression in lung-derived WT, CCM2 KO or CCM3 KO ECs 
obtained as previously described for CCM1 null ECs. More in detail, ECs from the lung of 
WT, Ccm2 and Ccm3 floxed/floxed mice were isolated, immortalyzed and then in vitro 
treated with TAT-cre recombinase to induce gene ablation. Notably, we found that in ECs 
null for either Ccm2 or Ccm3 ERK5 phosphorylation was increased (Figure 80 A and 81 A, 
respectively). Furthermore the treatment of both CCM2 KO and CCM3 KO ECs with 5µm 
of XMD8-92 for 3 days strongly inhibited KLF4 overexpression and EndMT marker 
upregulation (Figure 80 B and 81 B, respectively). 
Taken toghether these results showed that ERK5-MEF2A/C signalling axis is a 
common molecular node responsible for KLF4 upregulation and KLF4-dependent EndMT 
in ECs null for any of the three Ccm genes. 
 
 
 
 
 148
 
Figure 78 - Mef2A and Mef2C contribute to KLF4 upregulation in CCM1 KO ECs.  
A) qRT-PCR analysis of Klf4 and Mef2A (left panel) and WB analysis of KLF4 (right panel) in WT and 
CCM1 KO ECs treated with either control siRNA (siCTRL) or siRNA directed to Mef2A. qRT-PCR data 
represent the mean ± SD (n=3) and the fold changes are relative to WT siCTRL ECs.  B) qRT-PCR analysis 
of Klf4 and Mef2C (left panel) and WB analysis of KLF4 (right panel) in WT and CCM1 KO lECs treated 
with either control siRNA (siCTRL) or siRNA directed to Mef2C. qRT-PCR data represent the mean ± SD 
(n=3) and the fold changes are relative to WT siCTRL ECs. C) qRT-PCR analysis of Klf4 and Mef2D (left 
panel) and WB analysis of KLF4 (right panel) in WT and CCM1 KO ECs treated with either control siRNA 
(siCTRL) or siRNA directed to Mef2D. qRT-PCR data represent the mean ± SD (n=3) and the fold changes 
are relative to WT siCTRL ECs. 
A 
B 
C 
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Figure 79 - Combined silencing of Mef2A, Mef2C and Mef2D leads to partial downregulation of Klf4 
expression in CCM1 KO ECs.  
A) Left panels: qRT-PCR analysis of Mef2A, Mef2C, Mef2D and Klf4 in WT and CCM1 KO lECs treated 
with either control siRNA (siCTRL) or a combination of siRNA directed to Mef2A, Mef2C and  Mef2D. 
qRT-PCR data represent the mean ± SD (n=3) and the fold changes are relative to WT siCTRL ECs.  Right 
panel: WB analysis of KLF4 (right panel) in WT and CCM1 KO ECs treated with either control siRNA 
(siCTRL) or siRNA directed to Mef2A, Mef2C, Mef2D. Vinculin was the loading control. These WB data are 
representative of three independent experiments. **P<0.01, ***P<0.001 
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Figure 80 - ERK5 activation in CCM2 null ECs is responsible for KLF4 upregulation and increased 
EndMT marker expression.  
A) WB analysis of pERK5, ERK5 and KLF4 in lung derived WT and CCM2 KO ECs treated with XMD8-92 
or vehicle for 72 h. Both pERK5/ERK5 ratio and KLF4 amount normalized over vinculin, the loading control, 
were quantified by densitometry scan. These data are representative of three independent experiments. B) 
qRT-PCR of Ccm2, Klf4, Bmp6 and some EndMT markers in WT and CCM2 KO ECs treated as in A. qRT-
PCR results are shown as mean ± SD (n=3) and fold changes are relative to vehicle-treated WT ECs. 
*P<0.05, **P<0.01, ***P<0.001 
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Figure 81 - ERK5 activation in CCM3 null ECs is responsible for KLF4 upregulation and increased 
EndMT marker expression.  
A) WB analysis of pERK5, ERK5 and KLF4 in lung derived WT and CCM3 KO ECs treated with XMD8-92 
or vehicle for 72 h. Both pERK5/ERK5 ratio and KLF4 amount normalized over vinculin, the loading control, 
were quantified by densitometry scan. These data are representative of three independent experiments. B) 
qRT-PCR of Ccm3, Klf4, Bmp6 and some EndMT markers in WT and CCM3 KO ECs treated as in A. qRT-
PCR results are shown as mean ± SD (n=3) and fold changes are relative to vehicle-treated WT ECs. 
**P<0.01, ***P<0.001 
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6.15 Mekk3-Mek5-dependent signalling cascade promotes ERK5 activation and 
KLF4  upregulation in CCM1 KO ECs 
The final goal of this study was to clarify the signalling cascade through which the 
disruption of CCM complex promotes ERK5 activation and ERK5-dependent KLF4 
upregulation. In order to clarify this molecular step we referred to previous publications in 
which the MAP3K MEKK3 was identified as a CCM2 and CCM1 binding partner 296, 302. 
Active MEKK3 phosphorylates the MAP2K MEK5 that, in turn, directly activates ERK5 
303, 304. We therefore explored the possibility that the lack of CCM might increase Klf4 
expression through the MEKK3-MEK5-ERK5 signalling axis. To this purpose we silenced 
Mekk3 in WT and CCM1 KO ECs using two different siRNA. Even if MEKK3 levels were 
reduced in CCM1 KO ECs, a further Mekk3 knockdown strongly reduced ERK5 
phosphorylation in the absence of CCM1 (Figure 82). Interestingly, this effect was 
accompanied by the inhibition of Klf4 mRNA (Figure 82) and protein (Figure 83) 
upregulation. These results strongly correlated with Mekk3 downregulation efficiency that 
we obtained with the two different siRNA, thus supporting the idea that Mekk3 activity is 
fundamental for activation of the ERK5-dependent KLF4 regulation.  
Then, to evaluate if MEK5 could be the molecular link between MEKK3 and 
ERK5, we silenced Mek5 in WT and CCM1 KO ECs. Knockdown of Mek5 led to a 
decrease in ERK5 phosphorylation (Figure 84) and KLF4 upregulation (Figure 84 and 85) 
observed in CCM1 KO ECs. Accordingly, the treatment of WT and CCM1 KO ECs with 
BIX-02189, a specific MEK5 inhibitor 258, resulted in the loss of ERK5 activation (Figure 
86) and KLF4 upregulation in CCM1 KO ECs (Figure 86 and Figure 87). 
Thus, Ccm1 gene ablation resulted in increased MEKK3-MEK5-dependent ERK5 
phosphorylation responsible for KLF4 upregulation and KLF4-dependent EndMT. These 
data suggest that future pharmacological approaches targeting the MEKK3-MEK5-ERK5-
KLF4 signalling could be very promising for the treatment of CCM. 
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Figure 82 - MEKK3 activity is required for ERK5-mediated KLF4 upregulation.  
WB analysis of pERK5, ERK5, KLF4 and MEKK3 in WT and CCM1 KO lung ECs treated with either two 
different siRNAs against Mekk3 (siMEKK3 #1 and siMEKK3 #2) or a control sequence (siCTRL). Both 
pERK5/ERK5 ratio and KLF4 amount normalized over vinculin were quantified by densitometry scan. These 
WB data are representative of three independent experiments. 
 
 
 
 
 
 
 
 
Figure 83 - Mekk3 silencing inhibits KLF4 upregulation in CCM1 KO ECs.  
qRT-PCR of Klf4 in WT and CCM1 KO lung ECs treated with two different siRNAs directed to Mekk3 
(siMEKK3 #1 and siMEKK3 #2) or a control sequence (siCTRL). qRT-PCR results are shown as mean ± SD 
(n=3) and fold changes are relative to siCTRL-treated WT ECs. **P<0.01, ***P<0.001 
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Figure 84 - MEK5 activity is required for ERK5-mediated KLF4 upregulation.  
WB analysis of pERK5, ERK5, MEK5 and KLF4 in WT and CCM1 KO lung ECs treated with either a 
siRNA against Mek5 or a control sequence (siCTRL). Quantification of pERK5/ERK5 and KLF4 protein 
levels over vinculin were performed. These WB data are representative of three independent experiments. 
 
 
 
 
 
 
 
 
Figure 85 - Mek5 silencing decreases Klf4 mRNA levels in CCM1 KO ECs.  
qRT-PCR of Klf4  in WT and CCM1 KO lung ECs treated with either siMEK5 or siCTRL. qRT-PCR results 
are shown as mean ± SD (n=3). Fold changes are relative to siCTRL treated WT ECs. **P<0.01, ***P<0.001 
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Figure 86 - Chemical inhibition of MEK5 activity is required for ERK5-mediated KLF4 upregulation.  
WB analysis of pERK5, ERK5, and KLF4 in WT and CCM1 KO lung ECs treated with 10 µM of BIX-
02189 or vehicle for 48 hours. pERK5/ERK5 and KLF4 protein quantification over vinculin were shown. 
These WB data are representative of three independent experiments. 
 
 
 
 
 
 
 
 
Figure 87 - Chemical MEK5 inhibition decreases Klf4 mRNA levels in CCM1 KO ECs. 
qRT-PCR of Klf4  in WT and CCM1 KO lung ECs after 48 hours of treatment with 10 µM of BIX-02189 or 
vehicle. Fold changes are relative to vehicle treated WT ECs. qRT-PCR results are shown as mean ± SD 
(n=3).  ***P<0.001 
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DISCUSSION 
 
In the present study we introduced the concept that CCM lesions are formed by 
ECs undergoing EndMT transition. In the attempt to understand the molecular mechanisms 
through which loss of Ccm genes led to the high susceptibility of ECs to acquire a 
mesenchymal/stem cell-like phenotype, we identified the transcription factor KLF4 as a 
master regulator of EndMT ongoing in Ccm null ECs. KLF4 promoted an endogenous 
production of Bmp6 in ECs that, in turn, activated the TGF-β/BMP signalling pathway. 
Klf4 genetic inactivation as well as the pharmacological TGF-β/BMP pathway inhibition 
blocked the development and progression of CCM vascular lesions. Importantly, loss of 
Klf4 almost abolished the 100% mortality observed in EC-CCM1 KO mice due to brain 
hemorrhage. 
 
7.1 Development of a new mouse model of CCM disease 
We developed a relevant mouse model for CCM disease with a complete 
penetrance and a rapid progression of the disease useful to study in detail the signalling 
pathways involved in the etiology of CCM disease. Endothelial cell-specific deletion of the 
Ccm1 gene at P1 in mice resulted in the development of several vascular lesions within the 
CNS and in retina that faithfully phenocopied the human malformations. Thus, vascular 
lesions presented a mulberry-like structure composed of dilated vessels with multiple 
lumens, hemosiderin accumulation and a marked inflammatory reaction due to immune 
cell infiltration. In the area of the cavernomas the neurovascular unit was compromised 
due to an impaired endothelial/astrocyte interaction and pericyte coverage and the 
architecture of the endothelial junctions was strongly affected. The lesions had a venous 
origin and the number and size of malformations did not regress but, instead, increased 
with time. Finally, the morphology of the malformations was similar in the three strains of 
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mutants (Ccm1, Ccm2 or Ccm3 loss-of-function mice), with the phenotype of mice with 
Ccm3 deficiency being the most severe 69, 92, 291. All these alterations were previously 
described in human CCM. Although every mouse model had always limitations and it 
would be unrealistic to assume that they could reproduce in all details what occurs in 
human patients, our murine CCM model was quite close to the human disease. The rapid 
onset of the disease in this model makes it suitable for deciphering the molecular 
mechanisms involved in the different phases of development of the disease and for the 
study of future therapeutic agents. This was particularly important since, so far, no 
pharmacological therapy is available for CCM patients. 
 
7.2 Molecular mechanisms associated to CCM disease: KLF4 upregulation and 
KLF4-dependent EndMT 
 The process of EndMT occurring in several physiological and pathological 
conditions is characterized by multiple EC functional changes that include altered junction 
organisation, loss of cell polarity, increased cell proliferation and migratory capacity and 
finally modifications in the cytoskeleton and in the ECM organization 114, 278. Thus, the 
EndMT switch could explain most of the previously reported changes in phenotype of 
CCM null ECs 69, 88, 100, 103. Here we demonstrated that the increased Klf4 expression 
promoted most of the cellular phenotypic transitions associated to EndMT in the absence 
of Ccm1. In agreement, inhibition of KLF4 in CCM null ECs resulted in decreased 
expression of mesenchymal and stem-cell markers together with a relevant inhibition of 
cell proliferation and migration while a correct junction organization was not restored. In 
this regard KLF4 has been reported to maintain the endothelial barrier integrity by 
regulating the expression of important endothelial junction molecules in vitro 227, 229, 230. In 
our cellular models neither KLF4 depletion nor KLF4 overexpression seemed to affect VE-
cadherin or Claudin5 expression and localization, thus suggesting that junction 
dismantiling described in the absence of Ccm1 is KLF4 independent and other molecular 
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mechanisms altered upon loss of Ccm1 could cause modifications in endothelial cell-to-
cell junction organization.   
The mechanism of action of KLF4 in inducing CCM malformations is complex and 
here we defined some of the molecular steps involved (Figure 88). Klf4 expression 
increased soon after Ccm ablation and it remained high in ECs lining CCM lesions and 
pseudo normal peri-lesion vessels. KLF4 induction led to a strong endogenous production 
of BMP6 in CCM null ECs. This growth factor was able to activate the TGF-β/BMP 
signalling pathway and to induce the EndMT switch 291. In agreement, chemical inhibition 
of the TGF-β/BMP signalling prevented the EndMT switch in CCM1 null ECs and the 
appearance of CCM lesions in vivo 291. Besides modulating Bmp6 expression and TGF-
β/BMP pathway activation, KLF4 binds to the promoters of some EndMT markers (Sca1 
and Fsp1) and directly promotes their transcription. Intriguingly, the promoter regions of 
these representantive mesenchymal and stem-cell markers with a higher KLF4 binding 
affinity were surrounded by putative SMAD binding sites. Since pSMADs bind weakly to 
their target gene promoters 295 it could be possible that their DNA binding is reinforced 
through the association with KLF4, adding a further level of regulation of SMAD activity 
by KLF4 305. Viceversa, we found that TGF-β/BMP signalling pathway was able to 
regulate Klf4 expression. Stimulation of ECs with different TGF-β/BMP family ligands 
induces KLF4 upregulation 306, 307. Moreover treatment with TGF-β/BMP pathway 
inhibitors as well as Bmp6 silencing decreased KLF4 expression in CCM1 null ECs both in 
vitro and in vivo 291, thus suggesting that TGF-β/BMP pathway, once activated, could 
sustain Klf4 expression in a positive feedback loop. 
KLF4 could regulate the expression of other genes whose activity is potentially 
relevant for both EndMT dependent or independent CCM development and progression. 
Among a large number of genes that were differentialy expressed upon loss of Ccm1 in our 
Affimetrix analysis performed using mRNA extracts derived from WT and CCM1 KO 
BMECs, we focused our attention on Lrg1, Edn1 and Ednrb. The leucine-rich alpha-2-
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glycoprotein 1 (Lrg1) is an angiogenic molecule that is able to promote TβRII-ALK1-
SMAD1/5/8 signalling pathway in ECs by binding to the accessory receptor ENG 308. Since 
Lrg1 expression increased upon loss of Ccm1 in the Affimetrix analysis, we performed 
preliminary experiments in order to validate this data. Silencing of any one of the three 
Ccm genes in lung WT ECs (Appendix Figure 1 A) as well as loss of Ccm1 in primary 
brain ECs (Appendix Figure 1 B) led to Lrg1 upregulation. Interestingly loss of Klf4 
abolished Lrg1 upregulation in the absence of Ccm1 both in vitro and in vivo (Appendix 
Figure 1B and C), thus suggesting Lrg1 as a putative KLF4 target gene. Since Lrg1 is a 
modulator of TGF-β signalling pathway 308, we will investigate the role of this molecule 
during EndMT and CCM lesion development.  
Both Edn1 and Ednrb expression has been previously linked to KLF4 
transcriptional activity 224. EDN1 fulfills complex fuctions in vascular biology, including 
cellular proliferation, apoptosis and angiogenesis 309. EDN1 has a dual role in blood 
vessels: 1) it induces potent and long lasting vasoconstrinction by binding to the endothelin 
receptor A (Ednra), a receptor expressed specifically in SMCs; 2) it promotes vasodilation 
by binding EDNRB on ECs and inducing nitric oxide (NO) synthesis. Endothelial KLF4 
modulates the EDN-dependent pathway by repressing Edn1 expression and increasing 
Ednrb transcription 224. In line with these data, qRT-PCR analysis in primary brain ECs in 
vitro revealed that Edn1 was reduced while Ednrb was strongly increased in CCM1 KO 
BMECs compared to WT (Appendix Figure 1D). Moreover, loss of klf4 increased Edn1 
levels while it abolished Ednrb upregulation in the absence of Ccm1 (Appendix Figure 
1D). Since abnormal vessel dilation is a hallmark of CCM vascular malformations, future 
studies will be directed to evaluate the relevance of EDN-dependent signalling 
dysregulation in CCM disease.  
Thus, since we report that KLF4 is a master regulator of EndMT in CCM, a 
tempting idea is to understand whether KLF4 could play a role also in tumor EndMT. ECs 
are prominent component of tumor microenvironment and during cancer progression they 
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can undergo EndMT. Recent studies showed that a significant number of cancer-associated 
fibroblasts (CAFs) derive from ECs undergoing EndMT 118, 310. CAFs are key component of 
the tumor stroma that facilitate tumor growth and metastasis by modifying tumor 
microenvironment 118, 310. Moreover, as EndMT leads to the loss of a correct function and 
organization of the endothelium, a number of other processes involved in tumor 
progression can be affected. For instance, by weakening endothelial barrier function, 
EndMT has been reported to enable metastatic dissemination by facilitating tumor cell 
intra and extravasation 311 As TGF-β/BMP signalling pathway has been suggested as major 
inducer of EndMT 284 in several physiological and pathological conditions including cancer 
118, it would be of particular interest to understand whether KLF4 might act as a critical 
molecular effector of TGF-β/BMP signalling in the induction of EndMT during 
tumorigenesis. 
 
 
 
 
 
 
 
 
 
 
Figure 88 - Schematic model of KLF4 activity and regulation during CCM pathogenesis.  
Loss of Ccm1 led to MEKK3-MEK5-dependent ERK5 phosphorylation that, in turn, induced a strong 
upregulation of Klf4 expression in brain ECs. The resulting increased KLF4 transcriptional activity was 
responsible for the EndMT switch observed in CCM1 null ECs, since it was able to: i) promote Bmp6 
expression and consequent SMAD signalling activation; ii) drive the transcription of a number of EndMT 
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markers involved in CCM pathogenesis. In vivo Klf4 genetic inactivation blocked the development and 
progression of cavernomas. 
7.3 MEKK3-MEK5-ERK5 signalling pathways induce KLF4 expression in Ccm null 
ECs  
In the present study we also investigated the mechanism through which loss of Ccm 
genes leads to an increased Klf4 expression with the final aim of identifying new targets 
for future pharmacological therapies. Laminar flow through ERK5 activation is a well- 
known inducer of Klf4 expression and activity 226, 236. CCM complex disruption in the 
endocardium modulates the MEKK3-MEK5-ERK5 axis to upregulate Klf4 and Klf2 
expression resulting in mid-gestation heart failure 296. MEKK3, identified as a CCM2 
binding partner in the osmosensing complex 302, activates MEK5 that, in turn, through 
ERK5 dual phosphorylation, induces transcription factors MEF2A, MEF2C and MEF2D to 
regulate their target genes 303, 304. In agreement with these reports we found that MEKK3-
MEK5 axis promoted ERK5 activation upon loss of Ccm1 and the inhibition of ERK5 
prevented KLF4 upregulation and EndMT induction in cultured CCM1 KO ECs (Figure 
88), thus supporting the concept that ERK5 is a key regulator of Klf4 expression after 
CCM complex disruption. Importantly, ERK5-dependent KLF4 upregulation is induced by 
inactivation of any one of the three Ccm genes consistent with the comparable phenotype 
observed in patients. Phosphorylated ERK5 promoted Klf4 expression largely through 
MEF2A and MEF2C transcriptional activity. However, since a complete KLF4 
downregulation was not observed when these two transcription factors were silenced, 
either ERK5 alone or other ERK5-downstream transcription factors could be responsible 
for KLF4 upregulation 241.  
A marked increase in ERK5 activity and Klf4 expression in CCM null ECs was 
described in the absence of flow, thus suggesting that CCM complex distruption could 
mimic a condition of permanent flow. In line with this hypothesis Jilkova et al 
demonstrated that Ccm depletion led ECs to acquire an elongated “shear stress-like” 
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phenotype even in the absence of flow 312. Since differentially from the arteries the venous 
capillary bed, in which CCM specifically arises, is characterized by low shear stress, a 
molecular condition that mimics a sustained flow could explain the venous manifestation 
of the disease. Moreover CCM complex is necessary for maintaining β1 integrin in a low 
activation state in vitro in condition of low blood flow 312. In the absence of Ccm genes β1 
integrin is hyperactivated by flow and could be responsible for the vessel dilation observed 
in CCM 312. Thus CCMs appeared as mechanotrasducers able to modulate the EC response 
to different conditions of blood flow.  
 
7.4 Possible crosstalk between KLF4 and other signalling pathway involved in CCM  
Several recent pubblications unveiled that beyond KLF4-dependent signalling other 
pathways may contribute to CCM 92, 96, 112, 313, 314.  
Ccm genes deletion promoted β-catenin nuclear translocation and transcriptional 
signaling 92, 101. The activation of β-catenin-mediated transcription is a very early event in 
lesion formation in EC-CCM3 KO mice and is critical for the acquisition of a 
mesenchymal phenotype in ECs lining the cavernomas 92. Accordingly, inhibition of β-
catenin signalling in CCM3 null ECs both by using a dominant-negative mutant of TCF4 
(dnTCF4) or by a treatment with Sulindac, a nonsteroidal anti-inflammatory drug reported 
to switch off β-catenin signalling, resulted in strong reduction in the number and size of 
lesions as well as associated EndMT 92. A possible link between β-catenin and KLF4 
emerged from this study 92. β-catenin signalling inhibition reduced KLF4 upregulation in 
CCM3 null ECs both in vitro and in vivo thus suggesting a possible contribution of β-
catenin transcriptional activity to the increase of Klf4 expression at least in the absence of 
Ccm3 92. β-catenin signalling was found to be increased also in CCM1 KO ECs opening 
the possibility of a β-catenin-dependent KLF4 upregulation as a common molecular node 
upon loss-of-function of any of the three Ccm genes. Since we demonstrated that ERK5 
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activity is critical for KLF4 upregulation in CCM null ECs, future studies will be directed 
to evaluate a possible crosstalk between β-catenin and the MEKK3-MEK5-ERK5 
signalling cascade. Differentially to what we observed upon Klf4 silencing in CCM1 null 
ECs, β-catenin signalling inhibition was able, at least in part, to restore a proper junction 
organization in CCM3 KO ECs.  Thus, β-catenin could promote multiple features of the 
EndMT switch through both KLF4-dependent and independent mechanisms. 
CCM1 deficiency promoted also RhoA activation 88, 96 and Rho-dependent 
cytoskeletal rearrangements. Pharmacological inhibition of the Rho effector ROCK 
through Fasudil reduced stress fibers in vitro in CCM null ECs and decreased the number 
and size of vascular lesions in vivo 91. Since Rho activation has been reported to occurr 
during TGF-β-dependent EMT 315, 316, we hypothesized that KLF4-depedent TGF-β/BMP 
pathway activation could result in RhoA-dependent cytoskeletal rearrangements and 
increased endothelial permeability observed in CCM. 
A recent report claimed that defective autophagy could play a role during CCM 
pathogenesis 317. Loss of Ccm1 induced mTOR hyperactivation that, in turn, was important 
for the EndMT transition 317. The inhibition of mTOR activity with rapamycin or Torin1 
reduced the expression of some mesenchymal markers (such as Cd44 and Id1) and 
increased the levels of junctional molecules such as VE-cadherin and Pecam1 in vitro, thus 
suggesting mTOR inhibitor, which are currently used in several clinical trials, as a 
promising therapy for CCM 317. Since KLF4 has been reported to control autophagy in 
cardiomyocite 318 and in ECs (M.Jain personal communication), future studies will evaluate 
a possible relantioship between KLF4 and Ccm defective autophagy.  
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7.5 KLF4 context-dependent functions: a possible explanation for the brain specificity 
of the CCM disease 
KLF4 fulfills pleiotropic functions in EC biology. It is widely considered a vascular 
protective factor due to its ability to activate specific transcriptional programs with anti-
inflammatory, anti-coagulant and anti-oxidant roles in the endothelium 224, 227, 228. However, 
recent publications have associated KLF4 also to endothelial pathologies, since it can 
promote sprouting angiogenesis by regulating the Notch signalling pathway and it is 
upregulated in several pathological conditions 225, 319, 320.  
A context-dependent function of KLF4 could explain its protective versus 
pathogenic role in different type of vessels. While it confers vascular protection to 
atherothrombosis and pulmonary arterial hypertension when is upregulated in arteries 224, 
228, it could play a causative role in the development of venous-derived CCM cavernomas 
69, 291. Albeit we still do not know the molecular basis of these discrepancies, it is 
conceivable that the interaction with cell-specific transcription factors or differences in 
kinetics and levels of expression may modulate the response of ECs to KLF4. In this 
direction, it is noticeable that the levels of KLF4 are higher in retinal veins than in arteries 
in both physiological condition and upon Ccm1 deletion. Since KLF4 can differentially 
regulate EC gene expression also through coactivator competition by interacting 
with/sequestering p300 acetylase 215, 228, different cell-type specific and context-dependent 
function KLF4 could be placed in a central position in promoting either vascular health or 
disease.  
A large debate on CCM is related to the tissue specificity of the pathology. The 
lesions develop mainly in CNS vasculature although the gene was inactivated in all ECs 69, 
92, 291. In this regard a comparable increase in KLF4 induced in ECs of different organs by 
loss of Ccm1 resulted in a full EndMT switch only in brain ECs. These data support the 
idea of a KLF4-dependent specific activation of brain ECs to undergo EndMT. The 
difference between the endothelium of the brain in comparison to other organs is due to the 
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surrounding environment that strongly influences EC function. ECs of the brain 
vasculature are enwrapped by pericyte, astrocytic end feet processes and neuronal synapses 
and the correct crosstalk between these multiple components has been found to be 
necessary for proper formation and function of BBB. This type of interaction is unique for 
the brain vessels and may explain why in other organs the appearance of vascular 
malformations is much less frequent.  
 
7.6 KLF4 constitutes a novel target for a future pharmacological therapy for the 
treatment of CCM 
Pharmacological treatment limiting CCM disease progression is dearly needed as 
available therapy is limited to surgical lesion eradication. Loss of Klf4 in vivo prevented 
the onset and progression of vascular lesion and almost abolished mouse mortality due to 
brain hemorrhage in EC-CCM1 KO mice. Since the upregulation in KLF4 observed in our 
murine model of CCM was confirmed both in familial and sporadic CCM patients, the use 
of inhibitors of KLF4 could constitute a common strategy for the treatment of the familial 
and sporadic forms of the disease. Sporadic patients, at variance with the familial ones, got 
a diagnosis frequently at late phases of the disease when established vascular lesion are 
already symptomatic. Thus, the treatment of these patients with KLF4 inhibitors will 
require further studies on the effects of KLF4 inhibition at later stages of the CCM disease. 
Transcription factors are considered, in general, “undruggable agents”. Indeed, 
KLF4 is a member of the large family of Kruppel-like factors that are highly homologous 
sharing a triple zinc finger DNA-binding domain 182. The functions of the KLF family 
members can be exclusive or in some cases overlapping and redundant, compensating for 
one another and this might impair the efficacy of a possible therapy based on specific 
chemical compounds 198. An alternative approach could be the use of inhibitor of the 
MEKK3-MEK5-ERK5 axis responsible for the upregulation of KLF4 upon loss of anyone 
of the Ccm genes. Since the specific ERK5 inhibitor XMD8-92 was very effective in 
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reducing KLF4-dependent EndMT in cultured CCM1 KO ECs and was previously used in 
vivo 259, we are going to test its efficacy in preventing lesion development and progression 
in EC-CCM1 KO mice. However, widespread inhibition of ERK5 kinase could lead to 
severe side effects since ERK5 activity was reported to be critical for endothelial cell 
physiology by preventing apoptosis, regulating tumor angiogenesis and mediating EC 
response to shear stress 241, 243. The use of KLF4 or ERK5 inhibitors bound to nano-
particles targeting specifically CCM vascular lesions may represent a more safe therapeutic 
approach.  
In the immediate future a high throughput screening of small molecule libraries will 
be performed in collaboration with the Uppsala University to identify new componds able 
to inhibit the MEK5-ERK5-KLF4 signalling axis. They will be tested in vivo in our mouse 
model for their efficacy in preventing, arresting or even reverting the growth of CCM 
lesions. 
A targeted therapy with KLF4 inhibitors could anyway promote inflammation in 
vascular lesions. A robust infiltration of immune cells in human CCM specimens had been 
reported in literature 272. In agreement, vascular lesions in EC-CCM1 KO mice were 
infiltrated by CD11b and CD3 positive cells and showed an increased expression of cell 
adhesion molecules (CAMs) such as ICAM1 and VCAM1 282. KLF4 was described as a 
modulator of EC inflammation by its ability to inhibit NF-kB activity and the expression of 
pro-adhesive (such as Vcam1) and pro-thrombotic genes (such as Pai-1) 227, 228. Since 
inflammatory cytokines produced by immune cell infiltrated in CCM could act in 
synergism with TGF-β/BMP signalling to promote EndMT 278, targeting KLF4 expression 
in an established CCM lesion with an inflammatory reaction ongoing could lead to 
unexpected side effects. 
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7.7 KLF2 and KLF4 do not have overlapping roles in CCM 
Two different research groups recently reported a causative role for KLF2 in the 
cardiac phenotype observed in the absence of CCM in both mouse and zebrafish embryos 
107, 296.  
In these studies KLF2 was responsible for both digestion of the cardiac jelly 296 and 
increased angiogenesis 107. In our CCM disease model we found that Klf2 was upregulated 
in freshly isolated brain derived CCM1 null ECs or in cultured CCM1 KO BMECs 
supporting the idea of a possible cooperation between KLF2 and KLF4. However, 
although these two transcription factors have many common targets, they still exhibit 
specificity due to individual differences in their affinities for jointly regulated promoters. 
The lack of a fully overlapping biological role of KLF2 and KLF4 is also demonstrated by 
the different phenotype of the respective null mice. While Klf2 null mice exhibit abnormal 
blood vessel formation resulting in embryonic hemorrhage and death 321, Klf4 null mice die 
within one day after birth due to loss of skin barrier function 218. The relative contribution 
of KLF2 to the development of CCM remains an open question and requires future studies, 
since Klf2 was not further upregulated upon Klf4 ablation in our CCM model and 
apparently did not compensate for the lack of KLF4 in inducing EndMT.  
 
7.8 Concluding remarks 
In conclusion, this study highlights the importance of KLF4 transcriptional activity 
for the onset and development of CCM pathology and identifies novel potential 
pharmacological targets to prevent the progression of this so far incurable disease.  
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APPENDIX 
 
List of upregulated genes (threshold =1.2, P<0.05) 
Gene name Fold change Gene ID 
SERPINB9B 3,324091282 10404439 
KLF4 3,148817186 10513008 
STMN2 3,131122603 10490818 
FBLN2 3,034081838 10540085 
EDNRB 2,951564768 10422164 
DLL1 2,941944438 10448034 
KLF2 2,790241509 10572800 
LMCD1 2,610977454 10540523 
NEURL2 2,556606278 10489566 
NPNT 2,450489559 10502240 
PLTP 2,426118469 10489569 
F5 2,404721801 10351224 
LRG1 2,396352264 10451953 
CYP1B1 2,375432151 10453057 
FNDC1 2,329047398 10447649 
RAMP3 2,321472193 10374197 
LTBP4 2,298734744 10561212 
TNFSF18 2,294468499 10351099 
CMKLR1 2,260794718 10532711 
FAM20A 2,24657932 10392464 
PGLYRP1 2,193401621 10550509 
FAM107A 2,101296871 10417561 
NMNAT2 1,992120616 10350697 
CEACAM1 1,930902074 10561008 
KCNB1 1,9282004 10489872 
PTHLH 1,926136571 10549388 
JAM2 1,904576187 10436666 
CD55 1,900916287 10357488 
RTP3 1,880380989 10597273 
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LSR 1,875324167 10562181 
SERPINB1A 1,865516344 10408557 
ADAMTS5 1,85637735 10440534 
SNCG 1,840400814 10418921 
SLCO2A1 1,838692212 10588263 
FAM189A2 1,83422421 10466735 
TSC22D3 1,823784159 10606989 
FMO1 1,818948883 10359571 
FAM55D 1,80884025 10585068 
OLFML2A 1,803982071 10471882 
DHRS3 1,77509963 10510129 
LBP 1,769553034 10478048 
SELP 1,765736419 10351206 
GBP4 1,757384653 10531987 
NR4A1 1,739273725 10427035 
ITGB4 1,706050084 10382713 
CD14 1,701638995 10458382 
NOV 1,700778188 10424119 
NQO1 1,687818767 10581538 
MGLL 1,687052652 10539894 
LFNG 1,67692132 10527012 
TRPV4 1,667625109 10532839 
GPR1 1,66470899 10355109 
1700020C07RIK 1,664512841 10489562 
PMP22 1,662783111 10376950 
C430048L16RIK 1,65900703 10503359 
2310046K01RIK 1,656725977 10477052 
PPAP2B 1,645972235 10506488 
CLIC5 1,644865933 10445347 
CXX1A 1,644672122 10604633 
SERPINB8 1,636189673 10349174 
EGFL8 1,634330772 10450212 
PKN3 1,630613653 10470913 
CADM3 1,624944 10360349 
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CXX1A 1,62113024 10604637 
TSPAN7 1,61505131 10598626 
TINAGL1 1,603417361 10516735 
ATP2B4 1,599099822 10357833 
CYSLTR1 1,593092459 10606355 
2200002K05RIK 1,574550468 10583291 
CBFA2T3 1,572309247 10582429 
CRIP1 1,570365083 10399005 
CAR7 1,570256237 10574480 
AFAP1L2 1,562065555 10468668 
XDH 1,55413303 10452815 
CKB 1,552189822 10402708 
RASSF1 1,54975483 10596671 
RET 1,547581084 10547227 
RIPPLY3 1,532572156 10437073 
ATP2A3 1,52136888 10378216 
SCGB3A1 1,521295065 10375608 
GPRC5A 1,520673048 10542335 
P2RY2 1,519292869 10565962 
ANPEP 1,513758436 10564818 
L1CAM 1,510148057 10605113 
DISP2 1,508751285 10474814 
APLNR 1,50703717 10473444 
PNKD 1,501214365 10347310 
NR4A2 1,494424487 10482772 
KLF10 1,483546349 10428302 
ARF2 1,481737616 10381744 
ZFP341 1,476503729 10488802 
SCD1 1,451430005 10467979 
CBFA2T3 1,448595702 10582427 
CDC42EP2 1,438385119 10465278 
SLC9A3R2 1,434452305 10448676 
PLVAP 1,430956683 10579525 
FMO2 1,427311276 10359582 
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4930578C19RIK 1,422225275 10603796 
ADAMTS1 1,422077411 10440522 
SLC46A3 1,421717672 10535841 
RAMP2 1,420550382 10381298 
MS4A6D 1,419079092 10466210 
TRIL 1,418641444 10544837 
CAPN5 1,415493378 10565689 
APOD 1,409564993 10439009 
SLCO1A4 1,409545452 10548996 
LY6C2 1,405662262 10429573 
DOK4 1,404464346 10580782 
PDLIM1 1,402163903 10467420 
MAL 1,401940382 10487441 
EZR 1,397332155 10447602 
NRGN 1,396852802 10592330 
JAG2 1,3934971 10402808 
SLCO2B1 1,389436594 10565819 
SPA17 1,387103077 10592336 
CAR5B 1,383545414 10607738 
EMP2 1,375923252 10437639 
TMEM44 1,371885427 10438942 
ACER3 1,366130212 10565712 
CD97 1,3649991 10580033 
CST6 1,363712949 10464999 
DNAJA1 1,359668546 10503995 
2210411K11RIK 1,359404685 10559673 
WFDC1 1,357121606 10575917 
PBK 1,353547015 10416037 
LCN2 1,349355042 10481627 
S1PR4 1,347415686 10371217 
LEPREL1 1,345059506 10438753 
ANKRD37 1,344155456 10578515 
FAM78B 1,338034208 10351400 
MN1 1,330718116 10524327 
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ZFYVE9 1,328750284 10515028 
MYBL1 1,327806574 10353010 
STC1 1,327121079 10416181 
UPP1 1,32317144 10374236 
ID1 1,32317144 10477169 
ZFP697 1,322447088 10494655 
AQP11 1,321146084 10565627 
NRM 1,318218936 10444927 
ABI3 1,317739321 10390186 
NCOA3 1,312374985 10478718 
NT5E 1,310897605 10587639 
LY6C1 1,308940937 10429568 
THBD 1,300304944 10488378 
RFK 1,299989526 10461898 
PODXL 1,295447007 10543791 
PROM1 1,294751294 10529824 
AI836003 1,29463463 10426581 
KLF7 1,294369932 10355141 
MUSTN1 1,293697215 10413609 
HSPH1 1,292751519 10535904 
PIK3R6 1,289221363 10377286 
TEAD4 1,28403542 10548146 
KCTD12 1,283021192 10422059 
BAIAP2L1 1,282598833 10535559 
APOLD1 1,281781187 10542319 
BANP 1,27980588 10576073 
ALS2CL 1,275882082 10589654 
IDH1 1,275444392 10355214 
GBP6 1,27525875 10531994 
KIF23 1,273721618 10594251 
PAQR5 1,272962571 10594277 
STARD8 1,272327437 10600921 
FAM20C 1,272274524 10526853 
BC020535 1,271428207 10477237 
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NUSAP1 1,269864884 10474984 
CALCRL 1,269666854 10484371 
8430408G22RIK 1,269037763 10541071 
NSG1 1,26791673 10529656 
PIR 1,267161142 10603087 
CHORDC1 1,266318226 10583347 
DGKA 1,262820862 10373542 
SH3BGRL2 1,261967713 10587503 
SDPR 1,261464844 10346164 
NEK7 1,259804614 10358259 
SHE 1,256272992 10493604 
GJA1 1,256229453 10363173 
PLAUR 1,254258748 10550906 
KRAS 1,253589499 10549256 
KIF11 1,253298444 10462796 
HLX 1,25103747 10360834 
CDC25B 1,248707001 10476252 
E2F8 1,248503616 10563780 
2810417H13RIK 1,244770694 10586448 
RNF125 1,243951295 10454198 
ADAMTS4 1,243882318 10351551 
OXA1L 1,240180405 10419744 
HIST1H1B 1,239974112 10408081 
GPR182 1,239565924 10373325 
STK10 1,23741978 10375083 
RYBP 1,237346876 10546706 
NOS3 1,236061049 10520126 
MEST 1,234121983 10537062 
EMP3 1,233920973 10563441 
SLC16A3 1,232984788 10383502 
KANK3 1,232681428 10444028 
CDA 1,232126174 10517609 
RNF167 1,228616787 10377927 
BST1 1,225945632 10521667 
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AZIN1 1,224455209 10428310 
2610034B18RIK 1,222229324 10564849 
ADAMTS9 1,221623737 10546432 
GPR31C 1,219787638 10447647 
RACGAP1 1,219141008 10432511 
EBP 1,218756573 10603485 
HIST1H1A 1,218570736 10404069 
ENTPD1 1,21828359 10463070 
SERPINB6B 1,218156929 10404422 
DPAGT1 1,217777025 10584700 
DHRS7 1,217363487 10400941 
PPDPF 1,216089997 10599576 
HES1 1,215955136 10434925 
PDGFA 1,215529578 10535043 
AVPI1 1,214607346 10467739 
TEK 1,214531577 10505954 
PALMD 1,213732084 10501734 
LAYN 1,212849046 10593449 
ACY3 1,212630488 10460263 
MMP15 1,212382556 10574350 
GPR146 1,211861645 10526943 
FUCA2 1,209214346 10361790 
ADAMTS9 1,209029964 10546450 
CASKIN2 1,208338782 10392998 
MARVELD1 1,206476655 10463224 
PPP1R11 1,206351222 10450814 
AURKB 1,205348224 10377405 
3110001D03RIK 1,205264679 10513952 
C2CD2L 1,203720131 10592802 
ERI1 1,203290515 10578193 
PIK3R3 1,202010918 10507273 
 
Appendix Table 1- List of upregulated genes in CCM1 KO BMECs obtained by Affymetrix analysis 
and ranked according to the fold change.  
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List of down regulated genes threshold =1.2, P<0.05 
Gene name Fold change Gene ID 
FAM163A 2,220246717 10359113 
STFA1 1,875376162 10435501 
ZFP462 1,748848117 10505073 
CCL2 1,673246504 10379511 
KDM4D 1,651824026 10590915 
SELE 1,597720445 10351182 
IRG1 1,576510742 10416837 
ANKRD1 1,56004214 10467191 
EPHA7 1,535533514 10503659 
CCRN4L 1,532758069 10491915 
PRSS23 1,527407486 10554814 
CLDN1 1,523025398 10438769 
CCL5 1,515811125 10389207 
THY1 1,48728899 10584628 
ARRDC4 1,45031874 10564507 
SNORD49B 1,42795449 10376885 
MYL9 1,423167036 10477920 
ADAMTS7 1,419098765 10587748 
ACPP 1,417235983 10596303 
TGFB2 1,398325279 10360920 
ITGAV 1,396001024 10473281 
F2RL2 1,3950579 10406736 
GPX3 1,3823903 10376201 
SRPX2 1,38148031 10601659 
CSF1 1,377115915 10501164 
HMCN1 1,351615687 10358577 
ZIC3 1,351503268 10599812 
PLXDC2 1,347051492 10469457 
APCDD1 1,346206754 10456184 
ST5 1,344551486 10566767 
SNCA 1,338191884 10545086 
ARHGAP28 1,337677185 10452613 
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GNAS 1,335675916 10490203 
ICAM1 1,327627115 10583519 
LCP2 1,326293436 10375145 
RASSF2 1,323905365 10487894 
TAGLN 1,321553655 10593123 
BC046404 1,317958552 10386916 
MT2 1,314077169 10574023 
VCAM1 1,313166636 10501608 
GM8979 1,312848098 10566578 
CHGA 1,307005308 10397882 
LPAR4 1,306493548 10601412 
TNS3 1,305972936 10384233 
NFKBIE 1,302149415 10445412 
H2-Q6 1,295626606 10444824 
JAG1 1,291815468 10488060 
ESM1 1,287604925 10407281 
PHF15 1,285567177 10385747 
KCNQ4 1,284133327 10515960 
RCAN2 1,281732322 10445325 
PTGS2 1,281470262 10350516 
GM8979 1,280493562 10566571 
KRIT1 1,27832529 10519392 
SLC39A4 1,277811475 10430006 
RND1 1,273809909 10432236 
EDN1 1,272927277 10404783 
RND3 1,26779809 10482500 
SERPINE1 1,265142594 10534667 
NCKAP5L 1,263381192 10432473 
GADD45B 1,261683458 10364950 
ITIH5 1,261591635 10469151 
RGS16 1,255620075 10350733 
ISM1 1,253858894 10476560 
ENC1 1,25078602 10406817 
RIPK2 1,250720999 10511703 
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ODC1 1,250668984 10394770 
2610008E11RIK 1,250582297 10370544 
HSPG2 1,24971576 10509280 
SLC40A1 1,23876283 10354374 
GNAI1 1,235508555 10528227 
F2R 1,232296994 10411229 
HIVEP1 1,227267722 10404774 
COL15A1 1,222004841 10504775 
LAMB1 1,221327405 10395163 
VWA1 1,219212839 10519196 
ERN1 1,219128332 10392183 
VWF 1,218748126 10541910 
TCFEC 1,218490497 10543239 
ODC1 1,218241368 10582295 
NLRC5 1,217295984 10574100 
MEOX1 1,216330256 10391504 
NUAK1 1,215550642 10371379 
GVIN1 1,213774149 10566574 
WBP5 1,208904265 10601854 
TBC1D1 1,208736687 10522024 
TXNDC5 1,206142195 10408741 
HBEGF 1,202427575 10458340 
ENPP2 1,202194229 10428619 
 
Appendix Table 2 - List of downregulated genes in CCM1 KO BMECs obtained by Affymetrix 
analysis and ranked according to the fold change.  
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Appendix Figure 1 – Analysis of Lrg1, Edn1 and Ednrb expression in WT, CCM1 KO and CCM1-
KLF4 BMECs KO.  
A) qRT-PCR of Lrg1 upon silencing of anyone of the three Ccm genes in lung WT ECs. Data are mean ± SD 
(n=3) and fold changes are relative to siCTRL-treated WT ECs. B) qRT-PCR of Lrg1 in WT, CCM1 KO and 
CCM1-KLF4 KO BMECs. Data are mean ± SD (n=3) and fold changes are relative to WT BMECs C) qRT-
PCR of Lrg1 in freshly isolated ECs from WT, EC-CCM1 KO and EC- CCM1 KO KLF4 KO. qRT-PCR 
results are shown as mean ± SD (n=3) and are relative to WT freschly isolated ECs  D) qRT-PCR of Edn1 
and Ednrb in WT, CCM1 KO and CCM1-KLF4 KO BMECs. Data are mean ± SD (n=3) and fold changes 
are relative to to WT BMECs. *P<0.05, ** P<0.01, ***P<0.001. 
 179 
REFERENCES 
1. Dvorak, A. M., Kohn, S., Morgan, E. S., Fox, P., Nagy, J. A., & Dvorak, H. F. 
(1996). The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure 
that provides a transcellular pathway for macromolecular extravasation. Journal of 
leukocyte biology, 59(1), 100-115.  
2. Stevens, T., Garcia, J. G., Shasby, D. M., Bhattacharya, J., & Malik, A. B. (2000). 
Mechanisms regulating endothelial cell barrier function. American Journal of 
Physiology-Lung Cellular and Molecular Physiology, 279(3), L419-L422. 
3. Dejana, E., Bazzoni, G., & Lampugnani, M. G. (1999). The role of endothelial cell-
to-cell junctions in vascular morphogenesis. Thromb Haemost, 82(2), 755-761. 
4. Bazzoni, G., & Dejana, E. (2004). Endothelial cell-to-cell junctions: molecular 
organization and role in vascular homeostasis. Physiological reviews, 84(3), 869-
901. 
5. Ikenouchi, J., Umeda, K., Tsukita, S., Furuse, M., & Tsukita, S. (2007). 
Requirement of ZO-1 for the formation of belt-like adherens junctions during 
epithelial cell polarization. The Journal of cell biology, 176(6), 779-786. 
6. Taddei, A., Giampietro, C., Conti, A., Orsenigo, F., Breviario, F., Pirazzoli, V., ... 
& Dejana, E. (2008). Endothelial adherens junctions control tight junctions by VE-
cadherin-mediated upregulation of claudin-5. Nature cell biology, 10(8), 923-934. 
7. Wolburg, H., & Lippoldt, A. (2002). Tight junctions of the blood–brain barrier: 
development, composition and regulation. Vascular pharmacology, 38(6), 323-337. 
8. Dejana, E., Orsenigo, F., & Lampugnani, M. G. (2008). The role of adherens 
junctions and VE-cadherin in the control of vascular permeability. Journal of cell 
science, 121(13), 2115-2122. 
9. Engelhardt, B. (2003). Development of the blood-brain barrier. Cell and tissue 
research, 314(1), 119-129. 
10. Lampugnani, M. G., Resnati, M., Raiteri, M., Pigott, R., Pisacane, A., Houen, G., ... 
& Dejana, E. (1992). A novel endothelial-specific membrane protein is a marker of 
cell-cell contacts. The Journal of cell biology, 118(6), 1511-1522. 
11. Navarro, P., Ruco, L., & Dejana, E. (1998). Differential localization of VE-and N-
cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for 
junctional localization. The Journal of cell biology, 140(6), 1475-1484. 
12. Giampietro, C., Taddei, A., Corada, M., Sarra-Ferraris, G. M., Alcalay, M., 
Cavallaro, U., ... & Dejana, E. (2012). Overlapping and divergent signaling 
pathways of N-cadherin and VE-cadherin in endothelial cells. Blood, 119(9), 2159-
2170. 
13. Carmeliet, P., Lampugnani, M. G., Moons, L., Breviario, F., Compernolle, V., 
Bono, F., ... & Dejana, E. (1999). Targeted deficiency or cytosolic truncation of the 
VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and 
angiogenesis. Cell, 98(2), 147-157. 
14. Luo, Y., & Radice, G. L. (2005). N-cadherin acts upstream of VE-cadherin in 
controlling vascular morphogenesis. The Journal of cell biology, 169(1), 29-34. 
15. Dejana, E., Tournier-Lasserve, E., & Weinstein, B. M. (2009). The control of 
vascular integrity by endothelial cell junctions: molecular basis and pathological 
implications. Developmental cell, 16(2), 209-221. 
16. Nyqvist, D., Giampietro, C., & Dejana, E. (2008). Deciphering the functional role 
of endothelial junctions by using in vivo models. EMBO reports, 9(8), 742-747.  
17. Yamada, S., Pokutta, S., Drees, F., Weis, W. I., & Nelson, W. J. (2005). 
Deconstructing the cadherin-catenin-actin complex. Cell, 123(5), 889-901. 
18. Lampugnani, M. G., Zanetti, A., Breviario, F., Balconi, G., Orsenigo, F., Corada, 
M., ... & Dejana, E. (2002). VE-cadherin regulates endothelial actin activating Rac 
 180
and increasing membrane association of Tiam. Molecular biology of the cell, 13(4), 
1175-1189. 
19. Wimmer, R., Cseh, B., Maier, B., Scherrer, K., & Baccarini, M. (2012). 
Angiogenic sprouting requires the fine tuning of endothelial cell cohesion by the 
Raf-1/Rok-α complex. Developmental cell, 22(1), 158-171. 
20. Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C., & Dejana, E. 
(2006). Vascular endothelial cadherin controls VEGFR-2 internalization and 
signaling from intracellular compartments. The Journal of cell biology, 174(4), 
593-604. 
21. Rudini, N., Felici, A., Giampietro, C., Lampugnani, M., Corada, M., Swirsding, K., 
... & Dejana, E. (2008). VE‐cadherin is a critical endothelial regulator of TGF‐β 
signalling. The EMBO journal, 27(7), 993-1004. 
22. Hou, W. H., Liu, I. H., Tsai, C. C., Johnson, F. E., Huang, S. S., & San Huang, J. 
(2011). CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by 
inducing tyrosine phosphorylation and internalization of VE-cadherin. Journal of 
cell science, 124(8), 1231-1244. 
23. Andriopoulou, P., Navarro, P., Zanetti, A., Lampugnani, M. G., & Dejana, E. 
(1999). Histamine induces tyrosine phosphorylation of endothelial cell-to-cell 
adherens junctions. Arteriosclerosis, thrombosis, and vascular biology, 19(10), 
2286-2297. 
24. Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998). 
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation 
in endothelial cells. Journal of cell science, 111(13), 1853-1865. 
25. Orsenigo, F., Giampietro, C., Ferrari, A., Corada, M., Galaup, A., Sigismund, S., ... 
& Dejana, E. (2012). Phosphorylation of VE-cadherin is modulated by 
haemodynamic forces and contributes to the regulation of vascular permeability in 
vivo. Nature communications, 3, 1208. 
26. Angelini, D. J., Hyun, S. W., Grigoryev, D. N., Garg, P., Gong, P., Singh, I. S., ... 
& Goldblum, S. E. (2006). TNF-α increases tyrosine phosphorylation of vascular 
endothelial cadherin and opens the paracellular pathway through fyn activation in 
human lung endothelia. American Journal of Physiology-Lung Cellular and 
Molecular Physiology, 291(6), L1232-L1245. 
27. Hudry-Clergeon, H., Stengel, D., Ninio, E., & Vilgrain, I. (2005). Platelet-
activating factor increases VE-cadherin tyrosine phosphorylation in mouse 
endothelial cells and its association with the PtdIns3′-kinase. The FASEB journal, 
19(6), 512-520. 
28. Weis, S., Shintani, S., Weber, A., Kirchmair, R., Wood, M., Cravens, A., ... & 
Cheresh, D. (2004). Src blockade stabilizes a Flk/cadherin complex, reducing 
edema and tissue injury following myocardial infarction. Journal of Clinical 
Investigation, 113(6), 885. 
29. Nawroth, R., Poell, G., Ranft, A., Kloep, S., Samulowitz, U., Fachinger, G., ... & 
Vestweber, D. (2002). VE‐PTP and VE‐cadherin ectodomains interact to facilitate 
regulation of phosphorylation and cell contacts. The EMBO journal, 21(18), 4885-
4895. 
30. Lampugnani, M. G., Zanetti, A., Corada, M., Takahashi, T., Balconi, G., Breviario, 
F., ... & Dejana, E. (2003). Contact inhibition of VEGF-induced proliferation 
requires vascular endothelial cadherin, β-catenin, and the phosphatase DEP-
1/CD148. The Journal of cell biology, 161(4), 793-804. 
31. Sui, X. F., Kiser, T. D., Hyun, S. W., Angelini, D. J., Del Vecchio, R. L., Young, B. 
A., ... & Goldblum, S. E. (2005). Receptor protein tyrosine phosphatase μ regulates 
the paracellular pathway in human lung microvascular endothelia. The American 
journal of pathology, 166(4), 1247-1258. 
 181 
32. Ukropec, J. A., Hollinger, M. K., Salva, S. M., & Woolkalis, M. J. (2000). SHP2 
association with VE-cadherin complexes in human endothelial cells is regulated by 
thrombin. Journal of Biological Chemistry, 275(8), 5983-5986. 
33. Gavard, J., & Gutkind, J. S. (2006). VEGF controls endothelial-cell permeability by 
promoting the β-arrestin-dependent endocytosis of VE-cadherin. Nature cell 
biology, 8(11), 1223-1234. 
34. Hermant, B., Bibert, S., Concord, E., Dublet, B., Weidenhaupt, M., Vernet, T., & 
Gulino-Debrac, D. (2003). Identification of proteases involved in the proteolysis of 
vascular endothelium cadherin during neutrophil transmigration. Journal of 
Biological Chemistry, 278(16), 14002-14012. 
35. Furuse, M. (2010). Molecular basis of the core structure of tight junctions. Cold 
Spring Harbor perspectives in biology, 2(1), a002907. 
36. Steed, E., Balda, M. S., & Matter, K. (2010). Dynamics and functions of tight 
junctions. Trends in cell biology, 20(3), 142-149. 
37. Morita, K., Sasaki, H., Furuse, M., & Tsukita, S. (1999). Endothelial Claudin 
Claudin-5/Tmvcf Constitutes Tight Junction Strands in Endothelial Cells. The 
Journal of cell biology, 147(1), 185-194. 
38. Ebnet, K., Suzuki, A., Ohno, S., & Vestweber, D. (2004). Junctional adhesion 
molecules (JAMs): more molecules with dual functions?. Journal of Cell Science, 
117(1), 19-29. 
39. Ebnet, K., Suzuki, A., Horikoshi, Y., Hirose, T., zu Brickwedde, M. K. M., Ohno, 
S., & Vestweber, D. (2001). The cell polarity protein ASIP/PAR‐3 directly 
associates with junctional adhesion molecule (JAM). The EMBO journal, 20(14), 
3738-3748. 
40. Lamagna, C., Hodivala-Dilke, K. M., Imhof, B. A., & Aurrand-Lions, M. (2005). 
Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor 
growth. Cancer Research, 65(13), 5703-5710. 
41. Katsuno, T., Umeda, K., Matsui, T., Hata, M., Tamura, A., Itoh, M., ... & Tsukita, 
S. (2008). Deficiency of zonula occludens-1 causes embryonic lethal phenotype 
associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. 
Molecular biology of the cell, 19(6), 2465-2475. 
42. Gottardi, C. J., Arpin, M., Fanning, A. S., & Louvard, D. (1996). The junction-
associated protein, zonula occludens-1, localizes to the nucleus before the 
maturation and during the remodeling of cell-cell contacts. Proceedings of the 
National Academy of Sciences, 93(20), 10779-10784. 
43. Traweger, A., Lehner, C., Farkas, A., Krizbai, I. A., Tempfer, H., Klement, E., ... & 
Bauer, H. (2008). Nuclear Zonula occludens‐2 alters gene expression and 
junctional stability in epithelial and endothelial cells. Differentiation, 76(1), 99-
106. 
44. McCrea, P. D., Gu, D., & Balda, M. S. (2009). Junctional music that the nucleus 
hears: cell–cell contact signaling and the modulation of gene activity. Cold Spring 
Harbor perspectives in biology, 1(4), a002923. 
45. Balda, M. S., Garrett, M. D., & Matter, K. (2003). The ZO-1–associated Y-box 
factor ZONAB regulates epithelial cell proliferation and cell density. The Journal 
of cell biology, 160(3), 423-432. 
46. Aird, W. C. (2007). Phenotypic heterogeneity of the endothelium I. Structure, 
function, and mechanisms. Circulation research, 100(2), 158-173. 
47. Atkins, G. B., Jain, M. K., & Hamik, A. (2011). Endothelial Differentiation 
Molecular Mechanisms of Specification and Heterogeneity. Arteriosclerosis, 
thrombosis, and vascular biology, 31(7), 1476-1484. 
48. Clementi, F. R. A. N. C. E. S. C. O., & Palade, G. E. (1969). Intestinal capillaries I. 
Permeability to peroxidase and ferritin. The Journal of cell biology, 41(1), 33-58. 
49. Wisse, E. An electron microscopic study of the fenestrated endothelial lining of rat 
 182
liver sinusoids. Journal of ultrastructure research 31, 125-150 (1970).  
50. Warren, M. S., Zerangue, N., Woodford, K., Roberts, L. M., Tate, E. H., Feng, 
B., ... & Koller, K. J. (2009). Comparative gene expression profiles of ABC 
transporters in brain microvessel endothelial cells and brain in five species 
including human. Pharmacological research, 59(6), 404-413. 
51. Aird, W. C. (2006). Mechanisms of endothelial cell heterogeneity in health and 
disease. Circulation research, 98(2), 159-162. 
52. Augustin, H. G., Kozian, D. H., & Johnson, R. C. (1994). Differentiation of 
endothelial cells: analysis of the constitutive and activated endothelial cell 
phenotypes. Bioessays, 16(12), 901-906. 
53. Engelhardt, B., & Sorokin, L. (2009, November). The blood–brain and the blood–
cerebrospinal fluid barriers: function and dysfunction. In Seminars in 
immunopathology (Vol. 31, No. 4, pp. 497-511). Springer-Verlag. 
54. Paolinelli, R., Corada, M., Orsenigo, F., & Dejana, E. (2011). The molecular basis 
of the blood brain barrier differentiation and maintenance. Is it still a mystery?. 
Pharmacological Research, 63(3), 165-171. 
55. Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R., & Begley, D. J. 
(2010). Structure and function of the blood–brain barrier. Neurobiology of disease, 
37(1), 13-25. 
56. Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013). Development, 
maintenance and disruption of the blood-brain barrier. Nature medicine, 19(12), 
1584-1596.  
57. Daneman, R., & Prat, A. (2015). The Blood–Brain Barrier. Cold Spring Harbor 
perspectives in biology, 7(1), a020412. 
58. Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., ... & Tsukita, S. 
(2003). Size-selective loosening of the blood-brain barrier in claudin-5–deficient 
mice. The Journal of cell biology, 161(3), 653-660. 
59. Saitou, M., Furuse, M., Sasaki, H., Schulzke, J. D., Fromm, M., Takano, H., ... & 
Tsukita, S. (2000). Complex phenotype of mice lacking occludin, a component of 
tight junction strands. Molecular biology of the cell, 11(12), 4131-4142. 
60. Ha, S. N., Hochman, J., & Sheridan, R. P. (2007). Mini review on molecular 
modeling of P-glycoprotein (Pgp). Current topics in medicinal chemistry, 7(15), 
1525-1529. 
61. Oldendorf, W. H., Cornford, M. E., & Brown, W. J. (1977). The large apparent 
work capability of the blood‐brain barrier: A study of the mitochondrial content of 
capillary endothelial cells in brain and other tissues of the rat. Annals of neurology, 
1(5), 409-417. 
62. Zlokovic, B. V. (2008). The blood-brain barrier in health and chronic 
neurodegenerative disorders. Neuron, 57(2), 178-201. 
63. Daneman, R., Zhou, L., Agalliu, D., Cahoy, J. D., Kaushal, A., & Barres, B. A. 
(2010). The mouse blood-brain barrier transcriptome: a new resource for 
understanding the development and function of brain endothelial cells. PloS one, 
5(10), e13741-e13741. 
64. Shue, E. H., Carson-Walter, E. B., Liu, Y., Winans, B. N., Ali, Z. S., Chen, J., & 
Walter, K. A. (2008). Plasmalemmal vesicle associated protein-1 (PV-1) is a 
marker of blood-brain barrier disruption in rodent models. BMC neuroscience, 9(1), 
29. 
65. Keuschnigg, J., Henttinen, T., Auvinen, K., Karikoski, M., Salmi, M., & Jalkanen, 
S. (2009). The prototype endothelial marker PAL-E is a leukocyte trafficking 
molecule. Blood, 114(2), 478-484. 
66. Huang, J., Upadhyay, U. M., & Tamargo, R. J. (2006). Inflammation in stroke and 
focal cerebral ischemia. Surgical neurology, 66(3), 232-245. 
67. Davies, P. F., Civelek, M., Fang, Y., Guerraty, M. A., & Passerini, A. G. (2010, 
 183 
April). Endothelial heterogeneity associated with regional athero-susceptibility and 
adaptation to disturbed blood flow in vivo. In Seminars in thrombosis and 
hemostasis (Vol. 36, No. 3). NIH Public Access. 
68. Cavalcanti, D. D., Kalani, M. Y. S., Martirosyan, N. L., Eales, J., Spetzler, R. F., & 
Preul, M. C. (2012). Cerebral cavernous malformations: from genes to proteins to 
disease: Clinical article. Journal of neurosurgery, 116(1), 122-132. 
69. Boulday, G., Rudini, N., Maddaluno, L., Blécon, A., Arnould, M., Gaudric, A., ... 
& Tournier-Lasserve, E. (2011). Developmental timing of CCM2 loss influences 
cerebral cavernous malformations in mice. The Journal of experimental medicine, 
208(9), 1835-1847. 
70. Clatterbuck, R. E., Eberhart, C. G., Crain, B. J., & Rigamonti, D. (2001). 
Ultrastructural and immunocytochemical evidence that an incompetent blood-brain 
barrier is related to the pathophysiology of cavernous malformations. Journal of 
Neurology, Neurosurgery & Psychiatry, 71(2), 188-192. 
71. Batra, S., Lin, D., Recinos, P. F., Zhang, J., & Rigamonti, D. (2009). Cavernous 
malformations: natural history, diagnosis and treatment. Nature Reviews Neurology, 
5(12), 659-670. 
72. Rigamonti, D., Hadley, M. N., Drayer, B. P., Johnson, P. C., Hoenig-Rigamonti, K., 
Knight, J. T., & Spetzler, R. F. (1988). Cerebral cavernous malformations. New 
England Journal of Medicine, 319(6), 343-347. 
73. Labauge, P., Denier, C., Bergametti, F., & Tournier-Lasserve, E. (2007). Genetics 
of cavernous angiomas. The Lancet Neurology, 6(3), 237-244. 
74. Riant, F., Bergametti, F., Ayrignac, X., Boulday, G., & Tournier‐Lasserve, E. 
(2010). Recent insights into cerebral cavernous malformations: the molecular 
genetics of CCM. FEBS journal, 277(5), 1070-1075. 
75. Verlaan, D. J., Roussel, J., Laurent, S. B., Elger, C. E., Siegel, A. M., & Rouleau, G. 
A. (2005). CCM3 mutations are uncommon in cerebral cavernous malformations. 
Neurology, 65(12), 1982-1983. 
76. Gianfrancesco, F., Esposito, T., Penco, S., Maglione, V., Liquori, C. L., Patrosso, 
M. C., ... & Squitieri, F. (2008). ZPLD1 gene is disrupted in a patient with balanced 
translocation that exhibits cerebral cavernous malformations. Neuroscience, 155(2), 
345-349. 
77. Shenkar, R., Shi, C., Rebeiz, T., Stockton, R. A., McDonald, D. A., Mikati, A. 
G., ... & Awad, I. A. (2014). Exceptional aggressiveness of cerebral cavernous 
malformation disease associated with PDCD10 mutations. Genetics in Medicine, 
17(3), 188-196. 
78. Bacigaluppi, S., Retta, S. F., Pileggi, S., Fontanella, M., Goitre, L., Tassi, L., ... & 
Penco, S. (2013). Genetic and cellular basis of cerebral cavernous malformations: 
implications for clinical management. Clinical genetics, 83(1), 7-14. 
79. Akers, A. L., Johnson, E., Steinberg, G. K., Zabramski, J. M., & Marchuk, D. A. 
(2009). Biallelic somatic and germline mutations in cerebral cavernous 
malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. 
Human molecular genetics, 18(5), 919-930. 
80. Chan, A. C., Li, D. Y., Berg, M. J., & Whitehead, K. J. (2010). Recent insights into 
cerebral cavernous malformations: animal models of CCM and the human 
phenotype. FEBS journal, 277(5), 1076-1083. 
81. Gore, A. V., Lampugnani, M. G., Dye, L., Dejana, E., & Weinstein, B. M. (2008). 
Combinatorial interaction between CCM pathway genes precipitates hemorrhagic 
stroke. Disease models & mechanisms, 1(4-5), 275-281. 
82. Mably, J. D., Chuang, L. P., Serluca, F. C., Mohideen, M. A. P., Chen, J. N., & 
Fishman, M. C. (2006). Santa and valentine pattern concentric growth of cardiac 
myocardium in the zebrafish. Development, 133(16), 3139-3146. 
83. Zheng, X., Xu, C., Di Lorenzo, A., Kleaveland, B., Zou, Z., Seiler, C., ... & Kahn, 
 184
M. L. (2010). CCM3 signaling through sterile 20–like kinases plays an essential 
role during zebrafish cardiovascular development and cerebral cavernous 
malformations. The Journal of clinical investigation, 120(8), 2795. 
84. Hogan, B. M., Bussmann, J., Wolburg, H., & Schulte-Merker, S. (2008). ccm1 cell 
autonomously regulates endothelial cellular morphogenesis and vascular 
tubulogenesis in zebrafish. Human molecular genetics, 17(16), 2424-2432. 
85. Kleaveland, B., Zheng, X., Liu, J. J., Blum, Y., Tung, J. J., Zou, Z., ... & Kahn, M. 
L. (2009). Regulation of cardiovascular development and integrity by the heart of 
glass–cerebral cavernous malformation protein pathway. Nature medicine, 15(2), 
169-176. 
86. Mably, J. D., Burns, C. G., Chen, J. N., Fishman, M. C., & Mohideen, M. A. P. 
(2003). Heart of glass regulates the concentric growth of the heart in zebrafish. 
Current biology, 13(24), 2138-2147. 
87. Zheng, X., Riant, F., Bergametti, F., Myers, C. D., Tang, A. T., Kleaveland, B., ... 
& Kahn, M. L. (2014). Cerebral Cavernous Malformations Arise Independent of 
the Heart of Glass Receptor. Stroke, 45(5), 1505-1509. 
88. Whitehead, K. J., Chan, A. C., Navankasattusas, S., Koh, W., London, N. R., Ling, 
J., ... & Li, D. Y. (2009). The cerebral cavernous malformation signaling pathway 
promotes vascular integrity via Rho GTPases. Nature medicine, 15(2), 177-184. 
89. He, Y., Zhang, H., Yu, L., Gunel, M., Boggon, T. J., Chen, H., & Min, W. (2010). 
Cerebral cavernous malformation gene CCM3 is critical for vascular development 
by regulating VEGFR2 signaling. Science signaling, 3(116), ra26. 
90. Plummer, N. W., Gallione, C. J., Srinivasan, S., Zawistowski, J. S., Louis, D. N., & 
Marchuk, D. A. (2004). Loss of p53 sensitizes mice with a mutation in Ccm1 
(KRIT1) to development of cerebral vascular malformations. The American journal 
of pathology, 165(5), 1509-1518. 
91. McDonald, D. A., Shenkar, R., Shi, C., Stockton, R. A., Akers, A. L., Kucherlapati, 
M. H., ... & Marchuk, D. A. (2011). A novel mouse model of cerebral cavernous 
malformations based on the two-hit mutation hypothesis recapitulates the human 
disease. Human molecular genetics, 20(2), 211-222. 
92. Bravi, L., Rudini, N., Cuttano, R., Giampietro, C., Maddaluno, L., Ferrarini, L., ... 
& Lampugnani, M. G. (2015). Sulindac metabolites decrease cerebrovascular 
malformations in CCM3-knockout mice. Proceedings of the National Academy of 
Sciences, 112(27), 8421-8426. 
93. Louvi, A., Chen, L., Two, A. M., Zhang, H., Min, W., & Günel, M. (2011). Loss of 
cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular 
pathology. Proceedings of the National Academy of Sciences, 108(9), 3737-3742. 
94. Hilder, T. L., Malone, M. H., Bencharit, S., Colicelli, J., Haystead, T. A., Johnson, 
G. L., & Wu, C. C. (2007). Proteomic identification of the cerebral cavernous 
malformation signaling complex. Journal of proteome research, 6(11), 4343-4355. 
95. Li, X., Zhang, R., Zhang, H., He, Y., Ji, W., Min, W., & Boggon, T. J. (2010). 
Crystal structure of CCM3, a cerebral cavernous malformation protein critical for 
vascular integrity. Journal of Biological Chemistry, 285(31), 24099-24107. 
96. Stockton, R. A., Shenkar, R., Awad, I. A., & Ginsberg, M. H. (2010). Cerebral 
cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. 
The Journal of experimental medicine, 207(4), 881-896. 
97. Fisher, O. S., & Boggon, T. J. (2014). Signaling pathways and the cerebral 
cavernous malformations proteins: lessons from structural biology. Cellular and 
Molecular Life Sciences, 71(10), 1881-1892. 
98. Crose, L. E., Hilder, T. L., Sciaky, N., & Johnson, G. L. (2009). Cerebral cavernous 
malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated 
RhoA degradation in endothelial cells. Journal of Biological Chemistry, 284(20), 
13301-13305. 
 185 
99. Fidalgo, M., Guerrero, A., Fraile, M., Iglesias, C., Pombo, C. M., & Zalvide, J. 
(2012). Adaptor protein cerebral cavernous malformation 3 (CCM3) mediates 
phosphorylation of the cytoskeletal proteins ezrin/radixin/moesin by mammalian 
Ste20-4 to protect cells from oxidative stress. Journal of Biological Chemistry, 
287(14), 11556-11565. 
100. Glading, A., Han, J., Stockton, R. A., & Ginsberg, M. H. (2007). KRIT-1/CCM1 is    
     a Rap1 effector that regulates endothelial cell–cell junctions. The Journal of cell   
    biology, 179(2), 247-254. 
101. Glading, A. J., & Ginsberg, M. H. (2010). Rap1 and its effector KRIT1/CCM1 
regulate β-catenin signaling. Disease models & mechanisms, 3(1-2), 73-83. 
102. Iden, S., Rehder, D., August, B., Suzuki, A., Wolburg‐Buchholz, K., Wolburg, H., ... 
& Ebnet, K. (2006). A distinct PAR complex associates physically with VE‐cadherin 
in vertebrate endothelial cells. EMBO reports, 7(12), 1239-1246. 
103. Lampugnani, M. G., Orsenigo, F., Rudini, N., Maddaluno, L., Boulday, G., Chapon, 
F., & Dejana, E. (2010). CCM1 regulates vascular-lumen organization by inducing 
endothelial polarity. Journal of cell science, 123(7), 1073-1080. 
104. Fidalgo, M., Fraile, M., Pires, A., Force, T., Pombo, C., & Zalvide, J. (2010). 
CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell 
orientation. Journal of cell science, 123(8), 1274-1284. 
105. Wüstehube, J., Bartol, A., Liebler, S. S., Brütsch, R., Zhu, Y., Felbor, U., ... & 
Fischer, A. (2010). Cerebral cavernous malformation protein CCM1 inhibits 
sprouting angiogenesis by activating DELTA-NOTCH signaling. Proceedings of the 
National Academy of Sciences, 107(28), 12640-12645. 
106. Zawistowski, J. S., Stalheim, L., Uhlik, M. T., Abell, A. N., Ancrile, B. B., Johnson, 
G. L., & Marchuk, D. A. (2005). CCM1 and CCM2 protein interactions in cell 
signaling: implications for cerebral cavernous malformations pathogenesis. Human 
molecular genetics, 14(17), 2521-2531. 
107. Renz, M., Otten, C., Faurobert, E., Rudolph, F., Zhu, Y., Boulday, G., ... & 
Abdelilah-Seyfried, S. (2015). Regulation of β1 Integrin-Klf2-Mediated 
Angiogenesis by CCM Proteins. Developmental cell, 32(2), 181-190. 
108. Yoruk, B., Gillers, B. S., Chi, N. C., & Scott, I. C. (2012). Ccm3 functions in a 
manner distinct from Ccm1 and Ccm2 in a zebrafish model of CCM vascular 
disease. Developmental biology, 362(2), 121-131. 
109. Morrison, L., & Akers, A. (2011). Cerebral cavernous malformation, familial. 
110. Mouchtouris, N., Chalouhi, N., Chitale, A., Starke, R. M., Tjoumakaris, S. I., 
Rosenwasser, R. H., & Jabbour, P. M. (2015). Management of cerebral cavernous 
malformations: From diagnosis to treatment. The Scientific World Journal, 2015. 
111. Li, D. Y., & Whitehead, K. J. (2010). Evaluating strategies for the treatment of 
cerebral cavernous malformations. Stroke, 41(10 suppl 1), S92-S94. 
112. Gibson, C. C., Zhu, W., Davis, C. T., Bowman-Kirigin, J. A., Chan, A. C., Ling, J., 
... & Li, D. Y. (2015). Strategy for identifying repurposed drugs for the treatment of 
cerebral cavernous malformation. Circulation, 131(3), 289-299. 
113. McDonald, D. A., Shi, C., Shenkar, R., Stockton, R. A., Liu, F., Ginsberg, M. H., ... 
& Awad, I. A. (2012). Fasudil decreases lesion burden in a murine model of cerebral 
cavernous malformation disease. Stroke, 43(2), 571-574. 
114. Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal 
transition. The Journal of clinical investigation, 119(6), 1420. 
115. Markwald, R. R., Fitzharris, T. P., & Manasek, F. J. (1977). Structural development 
of endocardial cushions. American Journal of Anatomy, 148(1), 85-119. 
116. Eisenberg, L. M., & Markwald, R. R. (1995). Molecular regulation of 
atrioventricular valvuloseptal morphogenesis. Circulation research, 77(1), 1-6. 
117. Armstrong, E. J., & Bischoff, J. (2004). Heart valve development endothelial cell 
 186
signaling and differentiation. Circulation research, 95(5), 459-470. 
118. Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007). Discovery 
of endothelial to mesenchymal transition as a source for carcinoma-associated 
fibroblasts. Cancer research, 67(21), 10123-10128. 
119. Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., 
Gustafsson, E., ... & Kalluri, R. (2007). Endothelial-to-mesenchymal transition 
contributes to cardiac fibrosis. Nature medicine, 13(8), 952-961. 
120. Rastaldi, M. P. (2006). Epithelial-mesenchymal transition and its implications for the 
development of renal tubulointerstitial fibrosis. Journal of nephrology, 19(4), 407. 
121. Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M., & Kalluri, R. (2008). 
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. 
Journal of the American Society of Nephrology, 19(12), 2282-2287. 
122. Piera-Velazquez, S., Li, Z., & Jimenez, S. A. (2011). Role of endothelial-
mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. The 
American journal of pathology, 179(3), 1074-1080. 
123. Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial–
mesenchymal transitions. Nature reviews Molecular cell biology, 7(2), 131-142. 
124. Kalluri, R., & Neilson, E. G. (2003). Epithelial-mesenchymal transition and its 
implications for fibrosis. Journal of Clinical Investigation, 112(12), 1776. 
125. Gonzalez, D. M., & Medici, D. (2014). Signaling mechanisms of the epithelial-
mesenchymal transition. Science signaling, 7(344), re8. 
126. van Meeteren, L. A., & Ten Dijke, P. (2012). Regulation of endothelial cell plasticity 
by TGF-β. Cell and tissue research, 347(1), 177-186. 
127. Galat, A. (2011). Common structural traits for cystine knot domain of the TGFβ 
superfamily of proteins and three-fingered ectodomain of their cellular receptors. 
Cellular and Molecular Life Sciences, 68(20), 3437-3451. 
128. Shi, Y., & Massagué, J. (2003). Mechanisms of TGF-β signaling from cell 
membrane to the nucleus. Cell, 113(6), 685-700. 
129. ten Dijke, P., & Arthur, H. M. (2007). Extracellular control of TGFβ signalling in 
vascular development and disease. Nature reviews Molecular cell biology, 8(11), 
857-869. 
130. Moustakas, A., & Heldin, C. H. (2009). The regulation of TGFβ signal transduction. 
Development, 136(22), 3699-3714. 
131. Ross, S., & Hill, C. S. (2008). How the Smads regulate transcription. The 
international journal of biochemistry & cell biology, 40(3), 383-408. 
132. Makkar, P., Metpally, R. P. R., Sangadala, S., & Reddy, B. V. B. (2009). Modeling 
and analysis of MH1 domain of Smads and their interaction with promoter DNA 
sequence motif. Journal of Molecular Graphics and Modelling, 27(7), 803-812. 
133. Heldin, C. H., Miyazono, K., & Ten Dijke, P. (1997). TGF-β signalling from cell 
membrane to nucleus through SMAD proteins. Nature, 390(6659), 465-471. 
134. Goumans, M. J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., & ten 
Dijke, P. (2002). Balancing the activation state of the endothelium via two distinct 
TGF‐β type I receptors. The EMBO journal, 21(7), 1743-1753. 
135. Itoh, S., & ten Dijke, P. (2007). Negative regulation of TGF-β receptor/Smad signal 
transduction. Current opinion in cell biology, 19(2), 176-184. 
136. Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., ... & 
ten Dijke, P. (1997). Identification of Smad7, a TGFβ-inducible antagonist of TGF-β 
signalling. Nature, 389(6651), 631-635. 
137. Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., 
& Wrana, J. L. (2000). Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that 
targets the TGFβ receptor for degradation. Molecular cell, 6(6), 1365-1375 
138. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., & Gauthier, J. M. (1998). 
Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the 
 187 
promoter of human plasminogen activator inhibitor‐type 1 gene. The EMBO journal, 
17(11), 3091-3100. 
139. Jonk, L. J., Itoh, S., Heldin, C. H., ten Dijke, P., & Kruijer, W. (1998). Identification 
and functional characterization of a Smad binding element (SBE) in the JunB 
promoter that acts as a transforming growth factor-β, activin, and bone 
morphogenetic protein-inducible enhancer. Journal of Biological Chemistry, 
273(33), 21145-21152. 
140. Gomis, R. R., Alarcón, C., He, W., Wang, Q., Seoane, J., Lash, A., & Massagué, J. 
(2006). A FoxO–Smad synexpression group in human keratinocytes. Proceedings of 
the National Academy of Sciences, 103(34), 12747-12752. 
141. Verrecchia, F., Vindevoghel, L., Lechleider, R. J., Uitto, J., Roberts, A. B., & 
Mauviel, A. (2001). Smad3/AP-1 interactions control transcriptional responses to 
TGF-beta in a promoter-specific manner. Oncogene, 20(26), 3332-3340. 
142. Selvamurugan, N., Kwok, S., & Partridge, N. C. (2004). Smad3 interacts with JunB 
and Cbfa1/Runx2 for transforming growth factor-β1-stimulated collagenase-3 
expression in human breast cancer cells. Journal of Biological Chemistry, 279(26), 
27764-27773. 
143. López-Rovira, T., Chalaux, E., Rosa, J. L., Bartrons, R., & Ventura, F. (2000). 
Interaction and Functional Cooperation of NF-κB with Smads 
TRANSCRIPTIONAL REGULATION OF THE junBPROMOTER. Journal of 
Biological Chemistry, 275(37), 28937-28946. 
144. López-Rovira, T., Chalaux, E., Massagué, J., Rosa, J. L., & Ventura, F. (2002). 
Direct Binding of Smad1 and Smad4 to Two Distinct Motifs Mediates Bone 
Morphogenetic Protein-specific Transcriptional Activation ofId1 Gene. Journal of 
Biological Chemistry, 277(5), 3176-3185. 
145. Brugger, S. M., Merrill, A. E., Torres-Vazquez, J., Wu, N., Ting, M. C., Cho, J. Y. 
M., ... & Maxson, R. (2004). A phylogenetically conserved cis-regulatory module in 
the Msx2 promoter is sufficient for BMP-dependent transcription in murine and 
Drosophila embryos. Development, 131(20), 5153-5165. 
146. López-Casillas, F., Wrana, J. L., & Massagué, J. (1993). Betaglycan presents ligand 
to the TGFβ signaling receptor. Cell, 73(7), 1435-1444. 
147. Sankar, S., Mahooti-Brooks, N., Centrella, M., McCarthy, T. L., & Madri, J. A. 
(1995). Expression of transforming growth factor type III receptor in vascular 
endothelial cells increases their responsiveness to transforming growth factor β2. 
Journal of Biological Chemistry, 270(22), 13567-13572. 
148. Lebrin, F., Goumans, M. J., Jonker, L., Carvalho, R. L., Valdimarsdottir, G., 
Thorikay, M., ... & ten Dijke, P. (2004). Endoglin promotes endothelial cell 
proliferation and TGF‐β/ALK1 signal transduction. The EMBO journal, 23(20), 
4018-4028. 
149. Kirkbride, K. C., Townsend, T. A., Bruinsma, M. W., Barnett, J. V., & Blobe, G. C. 
(2008). Bone morphogenetic proteins signal through the transforming growth factor-
β type III receptor. Journal of Biological Chemistry, 283(12), 7628-7637. 
150. Zhang, Y. E. (2009). Non-Smad pathways in TGF-β signaling. Cell research, 19(1), 
128-139. 
151. Pardali, E., Goumans, M. J., & ten Dijke, P. (2010). Signaling by members of the 
TGF-β family in vascular morphogenesis and disease. Trends in cell biology, 20(9), 
556-567. 
152. A van Meeteren, L., Goumans, M. J., & ten Dijke, P. (2011). TGF-β receptor 
signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. 
Current pharmaceutical biotechnology, 12(12), 2108-2120.3 
153. Oh, S. P., Seki, T., Goss, K. A., Imamura, T., Yi, Y., Donahoe, P. K., ... & Li, E. 
(2000). Activin receptor-like kinase 1 modulates transforming growth factor-β1 
 188
signaling in the regulation of angiogenesis. Proceedings of the National Academy of 
Sciences, 97(6), 2626-2631. 
154. Lebrin, F., Deckers, M., Bertolino, P., & ten Dijke, P. (2005). TGF-β receptor 
function in the endothelium. Cardiovascular research, 65(3), 599-608 
155. Muñoz-Félix, J. M., González-Núñez, M., & López-Novoa, J. M. (2013). ALK1-
Smad1/5 signaling pathway in fibrosis development: friend or foe?. Cytokine & 
growth factor reviews, 24(6), 523-537. 
156. Watabe, T., Nishihara, A., Mishima, K., Yamashita, J., Shimizu, K., Miyazawa, K., 
... & Miyazono, K. (2003). TGF-β receptor kinase inhibitor enhances growth and 
integrity of embryonic stem cell–derived endothelial cells. The Journal of cell 
biology, 163(6), 1303-1311. 
157. Noel, A., Maillard, C., Rocks, N., Jost, M., Chabottaux, V., Sounni, N. E., ... & 
Foidart, J. M. (2004). Membrane associated proteases and their inhibitors in tumour 
angiogenesis. Journal of clinical pathology, 57(6), 577-584. 
158. Goumans, M. J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery, C., 
... & ten Dijke, P. (2003). Activin receptor-like kinase (ALK) 1 is an antagonistic 
mediator of lateral TGFβ/ALK5 signaling. Molecular cell, 12(4), 817-828.3 
159. Miyazono, K., & Miyazawa, K. (2002). Id: a target of BMP signaling. Science 
signaling, 2002(151), pe40-pe40. 
160. David, L., Feige, J. J., & Bailly, S. (2009). Emerging role of bone morphogenetic 
proteins in angiogenesis. Cytokine & growth factor reviews, 20(3), 203-212. 
161. Pardali, E., & Ten Dijke, P. (2012). TGFβ signaling and cardiovascular diseases. 
International journal of biological sciences, 8(2), 195. 
162. Valdimarsdottir, G., Goumans, M. J., Rosendahl, A., Brugman, M., Itoh, S., Lebrin, 
F., ... & Ten Dijke, P. (2002). Stimulation of Id1 expression by bone morphogenetic 
protein is sufficient and necessary for bone morphogenetic protein–induced 
activation of endothelial cells. Circulation, 106(17), 2263-2270. 
163. Suzuki, Y., Ohga, N., Morishita, Y., Hida, K., Miyazono, K., & Watabe, T. (2010). 
BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in 
vivo. Journal of cell science, 123(10), 1684-1692. 
164. Itoh, F., Itoh, S., Goumans, M. J., Valdimarsdottir, G., Iso, T., Dotto, G. P., ... & ten 
Dijke, P. (2004). Synergy and antagonism between Notch and BMP receptor 
signaling pathways in endothelial cells. The EMBO journal, 23(3), 541-551. 
165. Moya, I. M., Umans, L., Maas, E., Pereira, P. N., Beets, K., Francis, A., ... & 
Zwijsen, A. (2012). Stalk cell phenotype depends on integration of Notch and 
Smad1/5 signaling cascades. Developmental cell, 22(3), 501-514. 
166. Rivera-Feliciano, J., & Tabin, C. J. (2006). Bmp2 instructs cardiac progenitors to 
form the heart-valve-inducing field. Developmental biology, 295(2), 580-588. 
167. Camenisch, T. D., Molin, D. G., Person, A., Runyan, R. B., Gittenberger-de Groot, 
A. C., McDonald, J. A., & Klewer, S. E. (2002). Temporal and distinct TGFβ ligand 
requirements during mouse and avian endocardial cushion morphogenesis. 
Developmental biology, 248(1), 170-181. 
168. Bartram, U., Molin, D. G., Wisse, L. J., Mohamad, A., Sanford, L. P., Doetschman, 
T., ... & Gittenberger-de Groot, A. C. (2001). Double-outlet right ventricle and 
overriding tricuspid valve reflect disturbances of looping, myocardialization, 
endocardial cushion differentiation, and apoptosis in TGF-β2–knockout mice. 
Circulation, 103(22), 2745-2752. 
169. Liebner, S., Cattelino, A., Gallini, R., Rudini, N., Iurlaro, M., Piccolo, S., & Dejana, 
E. (2004). β-catenin is required for endothelial-mesenchymal transformation during 
heart cushion development in the mouse. The Journal of cell biology, 166(3), 359-
367. 
 189 
170. Niessen, K., Fu, Y., Chang, L., Hoodless, P. A., McFadden, D., & Karsan, A. (2008). 
Slug is a direct Notch target required for initiation of cardiac cushion cellularization. 
The Journal of cell biology, 182(2), 315-325.  
171. Mueller, M. M., & Fusenig, N. E. (2004). Friends or foes—bipolar effects of the 
tumour stroma in cancer. Nature Reviews Cancer, 4(11), 839-849.  
172. Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 
6(5), 392-401. 
173. Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R., & Olsen, B. R. 
(2010). Conversion of vascular endothelial cells into multipotent stem-like cells. 
Nature medicine, 16(12), 1400-1406. 
174. Lounev, V. Y., Ramachandran, R., Wosczyna, M. N., Yamamoto, M., Maidment, A. 
D., Shore, E. M., ... & Kaplan, F. S. (2009). Identification of progenitor cells that 
contribute to heterotopic skeletogenesis. The Journal of Bone & Joint Surgery, 91(3), 
652-663. 
175. Tabas, I., García-Cardeña, G., & Owens, G. K. (2015). Recent insights into the 
cellular biology of atherosclerosis. The Journal of cell biology, 209(1), 13-22. 
176. Hahn, C., & Schwartz, M. A. (2009). Mechanotransduction in vascular physiology 
and atherogenesis. Nature reviews Molecular cell biology, 10(1), 53-62. 
177. Libby, P., Lichtman, A. H., & Hansson, G. K. (2013). Immune effector mechanisms 
implicated in atherosclerosis: from mice to humans. Immunity, 38(6), 1092-1104. 
178. Chen, P. Y., Qin, L., Baeyens, N., Li, G., Afolabi, T., Budatha, M., ... & Simons, M. 
(2015). Endothelial-to-mesenchymal transition drives atherosclerosis progression. 
The Journal of Clinical Investigation, 125(12), 0-0. 
179. Chen, P. Y., Qin, L., Barnes, C., Charisse, K., Yi, T., Zhang, X., ... & Simons, M. 
(2012). FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition 
via control of let-7 miRNA expression. Cell reports, 2(6), 1684-1696. 
180. Feaver, R. E., Gelfand, B. D., Wang, C., Schwartz, M. A., & Blackman, B. R. 
(2010). Atheroprone hemodynamics regulate fibronectin deposition to create positive 
feedback that sustains endothelial inflammation. Circulation research, 106(11), 
1703-1711. 
181. Rohwedder, I., Montanez, E., Beckmann, K., Bengtsson, E., Dunér, P., Nilsson, J., ... 
& Fässler, R. (2012). Plasma fibronectin deficiency impedes atherosclerosis 
progression and fibrous cap formation. EMBO molecular medicine, 4(7), 564-576. 
182. McConnell, B. B., & Yang, V. W. (2010). Mammalian Krüppel-like factors in health 
and diseases. Physiological reviews, 90(4), 1337-1381. 
183. Schuh, R., Aicher, W., Gaul, U., Côte, S., Preiss, A., Maier, D., ... & Jäckle, H. 
(1986). A conserved family of nuclear proteins containing structural elements of the 
finger protein encoded by Krüppel, a Drosophila segmentation gene. Cell, 47(6), 
1025-1032. 
184. Miller, I. J., & Bieker, J. J. (1993). A novel, erythroid cell-specific murine 
transcription factor that binds to the CACCC element and is related to the Krüppel 
family of nuclear proteins. Molecular and cellular biology, 13(5), 2776-2786. 
185. Pearson, R., Fleetwood, J., Eaton, S., Crossley, M., & Bao, S. (2008). Krüppel-like 
transcription factors: a functional family. The international journal of biochemistry 
& cell biology, 40(10), 1996-2001. 
186. Suske, G., Bruford, E., & Philipsen, S. (2005). Mammalian SP/KLF transcription 
factors: bring in the family. Genomics, 85(5), 551-556. 
187. Presnell, J. S., Schnitzler, C. E., & Browne, W. E. (2015). KLF/SP transcription 
factor family evolution: expansion, diversification, and innovation in eukaryotes. 
Genome biology and evolution, 7(8), 2289-2309. 
188. Kaczynski, J., Cook, T., & Urrutia, R. (2003). Sp1-and Kruppel-like transcription 
factors. Genome Biol, 4(2), 206. 
 190
189. Nagai, R., Friedman, S. L., & Kasuga, M. (2009). The biology of Krüppel-like 
Factors (pp. 226-229). Springer. 
190. Dang, D. T., Pevsner, J., & Yang, V. W. (2000). The biology of the mammalian 
Krüppel-like family of transcription factors. The international journal of 
biochemistry & cell biology, 32(11), 1103-1121. 
191. Camacho-Vanegas, O., Till, J., Miranda-Lorenzo, I., Ozturk, B., Camacho, S. C., & 
Martignetti, J. A. (2013). Shaking the family tree: identification of novel and 
biologically active alternatively spliced isoforms across the KLF family of 
transcription factors. The FASEB Journal, 27(2), 432-436. 
192. Turner, J., & Crossley, M. (1998). Cloning and characterization of mCtBP2, a 
co‐repressor that associates with basic Krüppel‐like factor and other mammalian 
transcriptional regulators. The EMBO journal, 17(17), 5129-5140. 
193. van Vliet, J., Turner, J., & Crossley, M. (2000). Human Krüppel-like factor 8: a 
CACCC-box binding protein that associates with CtBP and represses transcription. 
Nucleic acids research, 28(9), 1955-1962. 
194. Chinnadurai, G. (2007). Transcriptional regulation by C-terminal binding proteins. 
The international journal of biochemistry & cell biology, 39(9), 1593-1607. 
195. Sewalt, R. G., Gunster, M. J., van der Vlag, J., Satijn, D. P., & Otte, A. P. (1999). C-
Terminal binding protein is a transcriptional repressor that interacts with a specific 
class of vertebrate Polycomb proteins. Molecular and cellular biology, 19(1), 777-
787. 
196. Knoepfler, P. S., & Eisenman, R. N. (1999). Sin meets NuRD and other tails of 
repression. Cell, 99(5), 447-450. 
197. Pei, J., & Grishin, N. V. (2013). A new family of predicted Krüppel-like factor genes 
and pseudogenes in placental mammals. 
198. Tetreault, M. P., Yang, Y., & Katz, J. P. (2013). Kruppel-like factors in cancer. 
Nature Reviews Cancer, 13(10), 701-713. 
199. Rowland, B. D., Bernards, R., & Peeper, D. S. (2005). The KLF4 tumour suppressor 
is a transcriptional repressor of p53 that acts as a context-dependent oncogene. 
Nature cell biology, 7(11), 1074-1082. 
200. Rowland, B. D., Bernards, R., & Peeper, D. S. (2005). The KLF4 tumour suppressor 
is a transcriptional repressor of p53 that acts as a context-dependent oncogene. 
Nature cell biology, 7(11), 1074-1082.  
201. Shields, J. M., Christy, R. J., & Yang, V. W. (1996). Identification and 
characterization of a gene encoding a gut-enriched Krüppel-like factor expressed 
during growth arrest. Journal of Biological Chemistry, 271(33), 20009-20017. 
202. Yet, S. F., McA’Nulty, M. M., Folta, S. C., Yen, H. W., Yoshizumi, M., Hsieh, C. 
M., ... & Lee, M. E. (1998). Human EZF, a Krüppel-like zinc finger protein, is 
expressed in vascular endothelial cells and contains transcriptional activation and 
repression domains. Journal of Biological Chemistry, 273(2), 1026-1031. 
203. Panigada, M., Porcellini, S., Sutti, F., Doneda, L., Pozzoli, O., Consalez, G. G., ... & 
Grassi, F. (1999). GKLF in thymus epithelium as a developmentally regulated 
element of thymocyte-stroma cross-talk. Mechanisms of development, 81(1), 103-
113. 
204. Chiambaretta, F., De Graeve, F., Turet, G., Marceau, G., Gain, P., Dastugue, B., ... & 
Sapin, V. (2004). Cell and tissue specific expression of human Kruppel-like 
transcription factors in human ocular surface. Mol Vis, 10, 901-909. 
205. Cullingford, T. E., Butler, M. J., Marshall, A. K., Sugden, P. H., & Clerk, A. (2008). 
Differential regulation of Krüppel-like factor family transcription factor expression 
in neonatal rat cardiac myocytes: effects of endothelin-1, oxidative stress and 
cytokines. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1783(6), 
1229-1236. 
 191 
206. Godmann, M., Kromberg, I., Mayer, J., & Behr, R. (2005). The mouse Krüppel-like 
Factor 4 (Klf4) gene: Four functional polyadenylation sites which are used in a cell-
specific manner as revealed by testicular transcript analysis and multiple processed 
pseudogenes. Gene, 361, 149-156. 
207. Evans, P. M., Zhang, W., Chen, X., Yang, J., Bhakat, K. K., & Liu, C. (2007). 
Krüppel-like factor 4 is acetylated by p300 and regulates gene transcription via 
modulation of histone acetylation. Journal of Biological Chemistry, 282(47), 33994-
34002. 
208. Dang, D. T., Zhao, W., Mahatan, C. S., Geiman, D. E., & Yang, V. W. (2002). 
Opposing effects of Krüppel-like factor 4 (gut-enriched Krüppel-like factor) and 
Krüppel-like factor 5 (intestinal-enriched Krüppel-like factor) on the promoter of the 
Krüppel-like factor 4 gene. Nucleic acids research, 30(13), 2736-2741. 
209. Chen, X., Xu, H., Yuan, P., Fang, F., Huss, M., Vega, V. B., ... & Ng, H. H. (2008). 
Integration of external signaling pathways with the core transcriptional network in 
embryonic stem cells. Cell, 133(6), 1106-1117. 
210. Shields, J. M., & Yang, V. W. (1998). Identification of the DNA sequence that 
interacts with the gut-enriched Krüppel-like factor. Nucleic acids research, 26(3), 
796-802. 
211. Liu, Y., Olanrewaju, Y. O., Zheng, Y., Hashimoto, H., Blumenthal, R. M., Zhang, 
X., & Cheng, X. (2014). Structural basis for Klf4 recognition of methylated DNA. 
Nucleic acids research, 42(8), 4859-4867. 
212. Vangapandu, H., & Ai, W. (2009). Kruppel like factor 4 (KLF4): a transcription 
factor with diverse context-dependent functions. Gene Ther Mol Biol, 13, 194-203. 
213. Shields, J. M., & Yang, V. W. (1997). Two potent nuclear localization signals in the 
gut-enriched Krüppel-like factor define a subfamily of closely related Krüppel 
proteins. Journal of Biological Chemistry, 272(29), 18504-18507. 
214. Feinberg, M. W., Cao, Z., Wara, A. K., Lebedeva, M. A., SenBanerjee, S., & Jain, 
M. K. (2005). Kruppel-like factor 4 is a mediator of proinflammatory signaling in 
macrophages. Journal of Biological Chemistry, 280(46), 38247-38258. 
215. Evans, P. M., Chen, X., Zhang, W., & Liu, C. (2010). KLF4 interacts with β-
catenin/TCF4 and blocks p300/CBP recruitment by β-catenin. Molecular and 
cellular biology, 30(2), 372-381. 
216. Noti, J. D., Johnson, A. K., & Dillon, J. D. (2005). The leukocyte integrin gene 
CD11d is repressed by gut-enriched Kruppel-like factor 4 in myeloid cells. Journal 
of Biological Chemistry, 280(5), 3449-3457. 
217. Ehlermann, J., Pfisterer, P., & Schorle, H. (2003). Dynamic expression of 
Krüppel‐like factor 4 (Klf4), a target of transcription factor AP‐2α during murine 
mid‐embryogenesis. The Anatomical Record Part A: Discoveries in Molecular, 
Cellular, and Evolutionary Biology, 273(2), 677-680. 
218. Segre, J. A., Bauer, C., & Fuchs, E. (1999). Klf4 is a transcription factor required for 
establishing the barrier function of the skin. Nature genetics, 22(4), 356-360. 
219. Katz, J. P., Perreault, N., Goldstein, B. G., Actman, L., McNally, S. R., Silberg, D. 
G., ... & Kaestner, K. H. (2005). Loss of Klf4 in mice causes altered proliferation and 
differentiation and precancerous changes in the adult stomach. Gastroenterology, 
128(4), 935-945. 
220. Swamynathan, S. K., Katz, J. P., Kaestner, K. H., Ashery-Padan, R., Crawford, M. 
A., & Piatigorsky, J. (2007). Conditional deletion of the mouse Klf4 gene results in 
corneal epithelial fragility, stromal edema, and loss of conjunctival goblet cells. 
Molecular and cellular biology, 27(1), 182-194. 
221. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & 
Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human 
fibroblasts by defined factors. cell, 131(5), 861-872. 
 192
222. Atkins, G. B., & Jain, M. K. (2007). Role of Krüppel-like transcription factors in 
endothelial biology. Circulation Research, 100(12), 1686-1695. 
223. Cowan, C. E., Kohler, E. E., Dugan, T. A., Mirza, M. K., Malik, A. B., & Wary, K. 
K. (2010). Krüppel-like factor-4 transcriptionally regulates VE-cadherin expression 
and endothelial barrier function. Circulation research, 107(8), 959-966. 
224. Shatat, M. A., Tian, H., Zhang, R., Tandon, G., Hale, A., Fritz, J. S., ... & Hamik, A. 
(2014). Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension. 
American journal of respiratory cell and molecular biology, 50(3), 647-653. 
225. Hale, A. T., Tian, H., Anih, E., Recio, F. O., Shatat, M. A., Johnson, T., ... & Hamik, 
A. (2014). Endothelial Krüppel-like Factor 4 Regulates Angiogenesis and the Notch 
Signaling Pathway. Journal of Biological Chemistry, 289(17), 12016-12028. 
226. Ohnesorge, N., Viemann, D., Schmidt, N., Czymai, T., Spiering, D., Schmolke, M., 
... & Schmidt, M. (2010). Erk5 activation elicits a vasoprotective endothelial 
phenotype via induction of Krüppel-like Factor 4 (KLF4). Journal of Biological 
Chemistry, 285(34), 26199-26210. 
227. Hamik, A., Lin, Z., Kumar, A., Balcells, M., Sinha, S., Katz, J., ... & Jain, M. K. 
(2007). Kruppel-like factor 4 regulates endothelial inflammation. Journal of 
Biological Chemistry, 282(18), 13769-13779. 
228. Zhou, G., Hamik, A., Nayak, L., Tian, H., Shi, H., Lu, Y., ... & Jain, M. K. (2012). 
Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. The 
Journal of clinical investigation, 122(12), 4727. 
229. Ma, J., Wang, P., Liu, Y., Zhao, L., Li, Z., & Xue, Y. (2014). Krüppel‐Like Factor 4 
Regulates Blood‐Tumor Barrier Permeability via ZO‐1, Occludin and Claudin‐5. 
Journal of cellular physiology, 229(7), 916-926. 
230. Zhao, Y. Y., Zhao, L. N., Wang, P., Miao, Y. S., Liu, Y. H., Wang, Z. H., ... & Xue, 
Y. X. (2015). Overexpression of miR‐18a negatively regulates myocyte enhancer 
factor 2D to increase the permeability of the blood–tumor barrier via Krüppel‐like 
factor 4‐mediated downregulation of zonula occluden‐1, claudin‐5, and occludin. 
Journal of neuroscience research. 
231. Palmer, R. M., Ferrige, A. G., & Moncada, S. (1987). Nitric oxide release accounts 
for the biological activity of endothelium-derived relaxing factor. 
232. Farber, H. W., & Loscalzo, J. (2004). Pulmonary arterial hypertension. New England 
Journal of Medicine, 351(16), 1655-1665. 
233. Sheikh, A. Q., Misra, A., Rosas, I. O., Adams, R. H., & Greif, D. M. (2015). Smooth 
muscle cell progenitors are primed to muscularize in pulmonary hypertension. 
Science translational medicine, 7(308), 308ra159-308ra159. 
234. Wang, Y., Yang, C., Gu, Q., Sims, M., Gu, W., Pfeffer, L. M., & Yue, J. (2015). 
KLF4 Promotes Angiogenesis by Activating VEGF Signaling in Human Retinal 
Microvascular Endothelial Cells. PloS one, 10(6), e0130341. 
235. Zheng, X., Li, A., Zhao, L., Zhou, T., Shen, Q., Cui, Q., & Qin, X. (2013). Key role 
of microRNA-15a in the KLF4 suppressions of proliferation and angiogenesis in 
endothelial and vascular smooth muscle cells. Biochemical and biophysical research 
communications, 437(4), 625-631. 
236. Clark, P. R., Jensen, T. J., Kluger, M. S., Morelock, M., Hanidu, A., Qi, Z., ... & 
Pober, J. S. (2011). MEK5 is activated by shear stress, activates ERK5 and induces 
KLF4 to modulate TNF responses in human dermal microvascular endothelial cells. 
Microcirculation, 18(2), 102-117. 
237. Zhou, G., Bao, Z. Q., & Dixon, J. E. (1995). Components of a new human protein 
kinase signal transduction pathway. Journal of Biological Chemistry, 270(21), 
12665-12669. 
238. Lee, J. D., Ulevitch, R. J., & Han, J. H. (1995). Primary structure of BMK1: a new 
mammalian map kinase. Biochemical and biophysical research communications, 
213(2), 715-724. 
 193 
239. Yan, C., Luo, H., Lee, J. D., Abe, J. I., & Berk, B. C. (2001). Molecular cloning of 
mouse ERK5/BMK1 splice variants and characterization of ERK5 functional 
domains. Journal of Biological Chemistry, 276(14), 10870-10878. 
240. Mody, N., CAMPBELL, D., Morrice, N., Peggie, M., & Cohen, P. (2003). An 
analysis of the phosphorylation and activation of extracellular-signal-regulated 
protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in 
vitro. Biochem. J, 372, 567-575. 
241. Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E., Müller, J., & Cross, M. J. 
(2012). ERK5: structure, regulation and function. Cellular signalling, 24(11), 2187-
2196. 
242. Nishimoto, S., & Nishida, E. (2006). MAPK signalling: ERK5 versus ERK1/2. 
EMBO reports, 7(8), 782-786. 
243. Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E., Mueller, J., & Cross, M. J. 
(2014). The role of ERK5 in endothelial cell function. Biochemical Society 
transactions, 42(6), 1584-1589. 
244. Chao, T. H., Hayashi, M., Tapping, R. I., Kato, Y., & Lee, J. D. (1999). MEKK3 
directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 
(BMK1) signaling pathway. Journal of Biological Chemistry, 274(51), 36035-36038. 
245. Sun, W., Kesavan, K., Schaefer, B. C., Garrington, T. P., Ware, M., Johnson, N. L., 
... & Johnson, G. L. (2001). MEKK2 associates with the adapter protein Lad/RIBP 
and regulates the MEK5-BMK1/ERK5 pathway. Journal of Biological Chemistry, 
276(7), 5093-5100. 
246. Morimoto, H., Kondoh, K., Nishimoto, S., Terasawa, K., & Nishida, E. (2007). 
Activation of a C-terminal transcriptional activation domain of ERK5 by 
autophosphorylation. Journal of Biological Chemistry, 282(49), 35449-35456 
247. Wang, X., & Tournier, C. (2006). Regulation of cellular functions by the ERK5 
signalling pathway. Cellular signalling, 18(6), 753-760. 
248. Hayashi, M., & Lee, J. D. (2004). Role of the BMK1/ERK5 signaling pathway: 
lessons from knockout mice. Journal of Molecular Medicine, 82(12), 800-808. 
249. Regan, C. P., Li, W., Boucher, D. M., Spatz, S., Su, M. S., & Kuida, K. (2002). Erk5 
null mice display multiple extraembryonic vascular and embryonic cardiovascular 
defects. Proceedings of the National Academy of Sciences, 99(14), 9248-9253. 
250. Yan, L., Carr, J., Ashby, P. R., Murry-Tait, V., Thompson, C., & Arthur, J. S. C. 
(2003). Knockout of ERK5 causes multiple defects in placental and embryonic 
development. BMC developmental biology, 3(1), 11. 
251. Hayashi, M., Kim, S. W., Imanaka-Yoshida, K., Yoshida, T., Abel, E. D., Eliceiri, 
B., ... & Lee, J. D. (2004). Targeted deletion of BMK1/ERK5 in adult mice perturbs 
vascular integrity and leads to endothelial failure. Journal of Clinical Investigation, 
113(8), 1138. 
252. Wang, X., Merritt, A. J., Seyfried, J., Guo, C., Papadakis, E. S., Finegan, K. G., ... & 
Tournier, C. (2005). Targeted deletion of mek5 causes early embryonic death and 
defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell 
survival pathway. Molecular and Cellular Biology, 25(1), 336-345. 
253. Yang, J., Boerm, M., McCarty, M., Bucana, C., Fidler, I. J., Yuan, Z. J., & Su, B. 
(2000). Mekk3 is essential for early embryonic cardiovascular development. Nature 
genetics, 24(3), 309-313. 
254. Roberts, O. L., Holmes, K., Müller, J., Cross, D. A., & Cross, M. J. (2010). ERK5 is 
required for VEGF-mediated survival and tubular morphogenesis of primary human 
microvascular endothelial cells. Journal of cell science, 123(18), 3189-3200. 
255. Parmar, K. M., Larman, H. B., Dai, G., Zhang, Y., Wang, E. T., Moorthy, S. N., ... & 
García-Cardeña, G. (2006). Integration of flow-dependent endothelial phenotypes by 
Kruppel-like factor 2. Journal of Clinical Investigation, 116(1), 4 
 194
256. Villarreal, G., Zhang, Y., Larman, H. B., Gracia-Sancho, J., Koo, A., & García-
Cardeña, G. (2010). Defining the regulation of KLF4 expression and its downstream 
transcriptional targets in vascular endothelial cells. Biochemical and biophysical 
research communications, 391(1), 984-989. 
257. Hayashi, M., Fearns, C., Eliceiri, B., Yang, Y., & Lee, J. D. (2005). Big mitogen-
activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway 
is essential for tumor-associated angiogenesis. Cancer research, 65(17), 7699-7706. 
258. Tatake, R. J., O’Neill, M. M., Kennedy, C. A., Wayne, A. L., Jakes, S., Wu, D., ... & 
Snow, R. J. (2008). Identification of pharmacological inhibitors of the MEK5/ERK5 
pathway. Biochemical and biophysical research communications, 377(1), 120-125. 
259. Yang, Q., Deng, X., Lu, B., Cameron, M., Fearns, C., Patricelli, M. P., ... & Lee, J. 
D. (2010). Pharmacological inhibition of BMK1 suppresses tumor growth through 
promyelocytic leukemia protein. Cancer cell, 18(3), 258-267. 
260. Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T. S., Bochenek, M. L., 
Sakakibara, A., ... & Adams, R. H. (2010). Ephrin-B2 controls VEGF-induced 
angiogenesis and lymphangiogenesis. Nature, 465(7297), 483-486. 
261. Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C. J., ... & 
Dejana, E. (2008). Wnt/β-catenin signaling controls development of the blood–brain 
barrier. The Journal of cell biology, 183(3), 409-417. 
262. Cattelino, A., Liebner, S., Gallini, R., Zanetti, A., Balconi, G., Corsi, A., ... & 
Dejana, E. (2003). The conditional inactivation of the β-catenin gene in endothelial 
cells causes a defective vascular pattern and increased vascular fragility. The Journal 
of cell biology, 162(6), 1111-1122. 
263. Weksler, B. B., Subileau, E. A., Perriere, N., Charneau, P., Holloway, K., Leveque, 
M., ... & Couraud, P. O. (2005). Blood-brain barrier-specific properties of a human 
adult brain endothelial cell line. The FASEB journal, 19(13), 1872-1874. 
 
264. Taulli, R., Accornero, P., Follenzi, A., Mangano, T., Morotti, A., Scuoppo, C., ... & 
Ponzetto, C. (2005). RNAi technology and lentiviral delivery as a powerful tool to 
suppress Tpr-Met-mediated tumorigenesis. Cancer gene therapy, 12(5), 456-463. 
265. Spagnuolo, R., Corada, M., Orsenigo, F., Zanetta, L., Deuschle, U., Sandy, P., ... & 
Dejana, E. (2004). Gas1 is induced by VE-cadherin and vascular endothelial growth 
factor and inhibits endothelial cell apoptosis. Blood, 103(8), 3005-3012. 
266. Korff, T., KIMMINA, S., MARTINY-BARON, G. E. O. R. G., & AUGUSTIN, H. 
G. (2001). Blood vessel maturation in a 3-dimensional spheroidal coculture model: 
direct contact with smooth muscle cells regulates endothelial cell quiescence and 
abrogates VEGF responsiveness. The FASEB Journal, 15(2), 447-457. 
267. Cartharius, K., Frech, K., Grote, K., Klocke, B., Haltmeier, M., Klingenhoff, A., ... & 
Werner, T. (2005). MatInspector and beyond: promoter analysis based on 
transcription factor binding sites. Bioinformatics, 21(13), 2933-2942. 
268. Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W. H., Arden, K. C., & Accili, D. 
(2003). The forkhead transcription factor Foxo1 regulates adipocyte differentiation. 
Developmental cell, 4(1), 119-129. 
269. Corada, M., Orsenigo, F., Morini, M. F., Pitulescu, M. E., Bhat, G., Nyqvist, D., ... & 
Dejana, E. (2013). Sox17 is indispensable for acquisition and maintenance of arterial 
identity. Nature communications, 4. 
270. Whitehead, K. J., Plummer, N. W., Adams, J. A., Marchuk, D. A., & Li, D. Y. 
(2004). Ccm1 is required for arterial morphogenesis: implications for the etiology of 
human cavernous malformations. Development, 131(6), 1437-1448. 
271. Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter 
strain. Nature genetics, 21(1), 70-71. 
 195 
272. Shenkar, R., Shi, C., Check, I. J., Lipton, H. L., & Awad, I. A. (2007). Concepts and 
hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous 
malformations. Neurosurgery, 61(4), 693-703. 
273. Reddy, S., Gorin, M. B., McCannel, T. A., Tsui, I., & Straatsma, B. R. (2010). Novel 
KRIT1/CCM1 mutation in a patient with retinal cavernous hemangioma and cerebral 
cavernous malformation. Graefe's Archive for Clinical and Experimental 
Ophthalmology, 248(9), 1359-1361. 
274. Corada, M., Nyqvist, D., Orsenigo, F., Caprini, A., Giampietro, C., Taketo, M. M., ... 
& Dejana, E. (2010). The Wnt/β-catenin pathway modulates vascular remodeling 
and specification by upregulating Dll4/Notch signaling. Developmental cell, 18(6), 
938-949. 
275. Pitulescu, M. E., Schmidt, I., Benedito, R., & Adams, R. H. (2010). Inducible gene 
targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. 
Nature protocols, 5(9), 1518-1534. 
276. López‐Novoa, J. M., & Nieto, M. A. (2009). Inflammation and EMT: an alliance 
towards organ fibrosis and cancer progression. EMBO molecular medicine, 1(6-7), 
303-314. 
277. Mariotti, A., Perotti, A., Sessa, C., & Rüegg, C. (2007). N-cadherin as a therapeutic 
target in cancer. 
278. Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-
mesenchymal transitions in development and disease. cell, 139(5), 871-890. 
279. Li, Y., Yang, J., Luo, J. H., Dedhar, S., & Liu, Y. (2007). Tubular epithelial cell 
dedifferentiation is driven by the helix-loop-helix transcriptional inhibitor Id1. 
Journal of the American Society of Nephrology, 18(2), 449-460. 
280. Welm, B. E., Tepera, S. B., Venezia, T., Graubert, T. A., Rosen, J. M., & Goodell, 
M. A. (2002). Sca-1 pos cells in the mouse mammary gland represent an enriched 
progenitor cell population. Developmental biology, 245(1), 42-56. 
281. Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., ... & Eaves, 
C. J. (2006). Purification and unique properties of mammary epithelial stem cells. 
Nature, 439(7079), 993-997. 
282. Shtutman, M., Levina, E., Ohouo, P., Baig, M., & Roninson, I. B. (2006). Cell 
adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and 
increases scattering and motility of MCF7 breast carcinoma cells. Cancer Research, 
66(23), 11370-11380. 
283. Gunia, S., Albrecht, K., Koch, S., Herrmann, T., Ecke, T., Loy, V., ... & May, M. 
(2008). Ki67 staining index and neuroendocrine differentiation aggravate adverse 
prognostic parameters in prostate cancer and are characterized by negligible inter-
observer variability. World journal of urology, 26(3), 243-250. 
284. Nakajima, Y., Yamagishi, T., Hokari, S., & Nakamura, H. (2000). Mechanisms 
involved in valvuloseptal endocardial cushion formation in early cardiogenesis: 
Roles of transforming growth factor (TGF)‐β and bone morphogenetic protein 
(BMP). The Anatomical Record, 258(2), 119-127. 
285. Gauger, K. J., Chenausky, K. L., Murray, M. E., & Schneider, S. S. (2011). SFRP1 
reduction results in an increased sensitivity to TGF-β signaling. BMC cancer, 11(1), 
59. 
286. Tanaka, H., Shinto, O., Yashiro, M., Yamazoe, S., Iwauchi, T., Muguruma, K., ... & 
Hirakawa, K. (2010). Transforming growth factor β signaling inhibitor, SB-431542, 
induces maturation of dendritic cells and enhances anti-tumor activity. Oncology 
reports, 24(6), 1637-1643. 
287. Yadla, S., Jabbour, P. M., Shenkar, R., Shi, C., Campbell, P. G., & Awad, I. A. 
(2010). Cerebral cavernous malformations as a disease of vascular permeability: 
from bench to bedside with caution. Neurosurgical focus, 29(3), E4. 
 196
288. Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., ... 
& Betsholtz, C. (2010). Pericytes regulate the blood-brain barrier. Nature, 
468(7323), 557-561. 
289. Cai, J., Pardali, E., Sánchez-Duffhues, G., & ten Dijke, P. (2012). BMP signaling in 
vascular diseases. FEBS letters, 586(14), 1993-2002. 
290. McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., ... & Buckanovich, R. 
J. (2011). Human ovarian carcinoma–associated mesenchymal stem cells regulate 
cancer stem cells and tumorigenesis via altered BMP production. The Journal of 
clinical investigation, 121(8), 3206. 
291. Maddaluno, L., Rudini, N., Cuttano, R., Bravi, L., Giampietro, C., Corada, M., ... & 
Dejana, E. (2013). EndMT contributes to the onset and progression of cerebral 
cavernous malformations. Nature, 498(7455), 492-496. 
292. Milde, F., Lauw, S., Koumoutsakos, P., & Iruela-Arispe, M. L. (2013). The mouse 
retina in 3D: quantification of vascular growth and remodeling. Integrative Biology, 
5(12), 1426-1438. 
293. Drigo, P., Mammi, I., Battistella, P. A., Ricchieri, G., & Carollo, C. (1994). Familial 
cerebral, hepatic, and retinal cavernous angiomas: a new syndrome. Child's Nervous 
System, 10(4), 205-209. 
294. Korchynskyi, O., & ten Dijke, P. (2002). Identification and functional 
characterization of distinct critically important bone morphogenetic protein-specific 
response elements in the Id1 promoter. Journal of Biological Chemistry, 277(7), 
4883-4891. 
295. Shi, Y., Wang, Y. F., Jayaraman, L., Yang, H., Massagué, J., & Pavletich, N. P. 
(1998). Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA 
binding in TGF-β signaling. Cell, 94(5), 585-594. 
296. Zhou, Z., Rawnsley, D. R., Goddard, L. M., Pan, W., Cao, X. J., Jakus, Z., ... & 
Kahn, M. L. (2015). The Cerebral Cavernous Malformation Pathway Controls 
Cardiac Development via Regulation of Endocardial MEKK3 Signaling and KLF 
Expression. Developmental cell, 32(2), 168-180. 
297. Atkins, G. B., Wang, Y., Mahabeleshwar, G. H., Shi, H., Gao, H., Kawanami, D., ... 
& Jain, M. K. (2008). Hemizygous deficiency of Krüppel-like factor 2 augments 
experimental atherosclerosis. Circulation research, 103(7), 690-693. 
298. Dekker, R. J., van Soest, S., Fontijn, R. D., Salamanca, S., de Groot, P. G., 
VanBavel, E., ... & Horrevoets, A. J. (2002). Prolonged fluid shear stress induces a 
distinct set of endothelial cell genes, most specifically lung Krüppel-like factor 
(KLF2). Blood, 100(5), 1689-1698. 
299. Komaravolu, R. K., Adam, C., Moonen, J. R. A., Harmsen, M. C., Goebeler, M., & 
Schmidt, M. (2014). Erk5 inhibits endothelial migration via KLF2-dependent down-
regulation of PAK1. Cardiovascular research, cvu236. 
300. Young, A., Wu, W., Sun, W., Larman, H. B., Wang, N., Li, Y. S., ... & García-
Cardeña, G. (2009). Flow activation of AMP-activated protein kinase in vascular 
endothelium leads to Krüppel-like factor 2 expression. Arteriosclerosis, thrombosis, 
and vascular biology, 29(11), 1902-1908. 
301. Maejima, T., Inoue, T., Kanki, Y., Kohro, T., Li, G., Ohta, Y., ... & Wada, Y. (2014). 
Direct Evidence for Pitavastatin Induced Chromatin Structure Change in the KLF4 
Gene in Endothelial Cells. 
302. Uhlik, M. T., Abell, A. N., Johnson, N. L., Sun, W., Cuevas, B. D., Lobel-Rice, K. 
E., ... & Johnson, G. L. (2003). Rac–MEKK3–MKK3 scaffolding for p38 MAPK 
activation during hyperosmotic shock. Nature cell biology, 5(12), 1104-1110. 
303. Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J., & Lee, J. D. 
(1997). BMK1/ERK5 regulates serum‐induced early gene expression through 
transcription factor MEF2C. The EMBO journal, 16(23), 7054-7066. 
 197 
304. Sohn, S. J., Li, D., Lee, L. K., & Winoto, A. (2005). Transcriptional regulation of 
tissue-specific genes by the ERK5 mitogen-activated protein kinase. Molecular and 
cellular biology, 25(19), 8553-8566. 
305. Li, H. X., Han, M., Bernier, M., Zheng, B., Sun, S. G., Su, M., ... & Wen, J. K. 
(2010). Krüppel-like factor 4 promotes differentiation by transforming growth factor-
β receptor-mediated Smad and p38 MAPK signaling in vascular smooth muscle 
cells. Journal of Biological Chemistry, 285(23), 17846-17856. 
306. Morikawa, M., Koinuma, D., Tsutsumi, S., Vasilaki, E., Kanki, Y., Heldin, C. H., ... 
& Miyazono, K. (2011). ChIP-seq reveals cell type-specific binding patterns of 
BMP-specific Smads and a novel binding motif. Nucleic acids research, gkr572. 
307. King, K. E., Iyemere, V. P., Weissberg, P. L., & Shanahan, C. M. (2003). Krüppel-
like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and TGFβ in 
the regulation of vascular smooth muscle cell phenotype. Journal of Biological 
Chemistry. 
308. Wang, X., Abraham, S., McKenzie, J. A., Jeffs, N., Swire, M., Tripathi, V. B., ... & 
Greenwood, J. (2013). LRG1 promotes angiogenesis by modulating endothelial 
TGF-[bgr] signalling. Nature, 499(7458), 306-311. 
309. Lüscher, T. F., & Barton, M. (2000). Endothelins and endothelin receptor antagonists 
therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 
102(19), 2434-2440. 
310. Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 
6(5), 392-401. 
311. Anderberg, C., Cunha, S. I., Zhai, Z., Cortez, E., Pardali, E., Johnson, J. R., ... & 
Pietras, K. (2013). Deficiency for endoglin in tumor vasculature weakens the 
endothelial barrier to metastatic dissemination. The Journal of experimental 
medicine, 210(3), 563-579. 
312. Jilkova, Z. M., Lisowska, J., Manet, S., Verdier, C., Deplano, V., Geindreau, C., ... & 
Duperray, A. (2014). CCM proteins control endothelial β1 integrin dependent 
response to shear stress. Biology open, 3(12), 1228-1235. 
313. Faurobert, E., Rome, C., Lisowska, J., Manet-Dupé, S., Boulday, G., Malbouyres, 
M., ... & Albiges-Rizo, C. (2013). CCM1–ICAP-1 complex controls β1 integrin–
dependent endothelial contractility and fibronectin remodeling. The Journal of cell 
biology, 202(3), 545-561. 
314. Goitre, L., Balzac, F., Degani, S., Degan, P., Marchi, S., Pinton, P., & Retta, S. F. 
(2010). KRIT1 regulates the homeostasis of intracellular reactive oxygen species. 
PLoS One, 5(7), e11786. 
315. Tavares, A. L. P., Mercado‐Pimentel, M. E., Runyan, R. B., & Kitten, G. T. (2006). 
TGFβ‐mediated RhoA expression is necessary for epithelial‐mesenchymal transition 
in the embryonic chick heart. Developmental dynamics, 235(6), 1589-1598. 
316. Tsapara, A., Luthert, P., Greenwood, J., Hill, C. S., Matter, K., & Balda, M. S. 
(2010). The RhoA activator GEF-H1/Lfc is a transforming growth factor-β target 
gene and effector that regulates α-smooth muscle actin expression and cell 
migration. Molecular biology of the cell, 21(6), 860-870. 
317. Marchi, S., Corricelli, M., Trapani, E., Bravi, L., Pittaro, A., Delle Monache, S., ... & 
Pinton, P. (2015). Defective autophagy is a key feature of cerebral cavernous 
malformations. EMBO molecular medicine, e201505316. 
318. Liao, X., Zhang, R., Lu, Y., Prosdocimo, D. A., Sangwung, P., Zhang, L., ... & Jain, 
M. K. (2015). Kruppel-like factor 4 is critical for transcriptional control of cardiac 
mitochondrial homeostasis. The Journal of clinical investigation, 125(9), 3461-3476. 
319. Magrini, E., Villa, A., Angiolini, F., Doni, A., Mazzarol, G., Rudini, N., ... & 
Cavallaro, U. (2014). Endothelial deficiency of L1 reduces tumor angiogenesis and 
promotes vessel normalization. The Journal of clinical investigation, 124(10), 4335. 
 198
320. Chen, P. Y., Qin, L., Tellides, G., & Simons, M. (2014). Fibroblast growth factor 
receptor 1 is a key inhibitor of TGFβ signaling in the endothelium. Science 
signaling, 7(344), ra90-ra90. 
321. Kuo, C. T., Veselits, M. L., Barton, K. P., Lu, M. M., Clendenin, C., & Leiden, J. M. 
(1997). The LKLF transcription factor is required for normal tunica media formation 
and blood vessel stabilization during murine embryogenesis. Genes & development, 
11(22), 2996-3006. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 199 
ACKNOWLEDGEMENTS 
 
I still remember well when I got the e-mail from the SEMM examination board 
notifying me that I was accepted in SEMM's PhD Program and assigned to the research 
group of Prof. Elisabetta Dejana”. It was something extraordinarily desired and exciting. 
Desired because the year before I failed to enter the same PhD program and I worked hard 
for one year in order to try again the exam; exciting because it was given to me the 
possibility to work on angiogenesis, the research topic of my interest since the beginning 
of my studies. For all of this reason I really took this long road like I was living a dream.  
I want to thank my boss, Elisabetta Dejana, to give me the opportunity to work in 
her group and to be involved in a so fascinating research project. Working for her it makes 
you fell as you are always at the edge of a new scientific discovery.  
A particular thank goes to Noemins “Etna” Rudini. She shared with me the every 
day lab life of these four years. Only we two (and our families) know how much efforts are 
beyond this project. Noemins, I am fully convinced that you are the PhD supervisor that 
every student would desire to have.   
I would like to give special thanks to Braves and Maria Grazia who shared with me 
the same scientific topic and provided me technical help and critical inspiriring comments 
respectively.  
I want to thank Monica Corada that since the first days of my PhD was always 
available to help me and to discuss with me. 
I am grateful to Federica Pisati who supported me with her big expertise in 
immunohistochemistry and for being really always available for me. 
I want to thank Prof. Mukesh Jain, Prof. Gary Owens and Prof. Martin Schwartz 
that provided me precious reagents and contributed to scientific discussion. 
I acknowledge my PhD supervisors, Ralph Adams and Gioacchino Natoli, for their 
very important and helpful feedback during these years.  
 200
These fours years would have been too much boring without the presence of special 
friends such as Benzocita, Frikkio, Giannottins, Jean Peter, Mari, Padellata, Papo Gaio 
Giacchè and Recchioman. Besides helping me everyday in the labwork, I really spent 
special time with each of you.  
I thank all the past and present members of the Vascular Biology Group, especially 
Gani, Cerri, il Caro Maderna, Cicilia and my PhD mates Butt, Valentina e Lara. 
I deeply thank my parents that always support me and give me the possibility to 
pursue my dreams. 
To Michela, all this would not make sense without you. 
 
 
 
 
 
 
 
